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ABSTRACT 
 
 
Peter J. Miller 
 
THE MECHANISMS OF pMHC RECOGNITION BY THE 
 AHIII T CELL RECEPTOR 
 
 
Cytotoxic T lymphocytes (CTL), or CD8+ T cells, are responsible for clearing 
infected or diseased cells from the body.  Diseased cells label themselves through 
presentation of non-self, or antigenic, peptides on the exterior of the cell.  Both healthy 
and infected cells present peptides on the surface.  These self and non-self peptides are 
presented by the class I major histompatibility complex molecule, or MHC.  The class I 
peptide-MHC (pMHC) complex is the ligand for the T cell receptor (TCR), which is 
expressed on the surface of CTLs.  TCR discrimination between self and non-self pMHC 
is the critical event in determining whether or not the CTL will be activated and lyse the 
antigen presenting cell.  It remains unclear through what mechanism(s) the recognition of 
different pMHC by the TCR translates into qualitatively different activation signals in the 
T cell. 
The AHIII12.2 (AHIII) TCR recognizes and is activated by its cognate pMHC, 
p1049 in HLA-A2(A2)  Activation of AHIII T cells is inhibited by the peptide p1058 
when presented by A2.  Through mutation of residues in both the peptides and MHC, we 
present here further support for the affinity model of T cell triggering, that AHIII T cell 
activation correlates with TCR-pMHC binding affinity.  Interestingly, mutations in the 
iv 
peptide seem to be more deleterious to binding than mutations in the MHC.  Crystal 
structures of A2 mutants bound to the AHIII TCR were determined, and showed that the 
K66A mutation in the MHC can influence the conformation of a TCR CDR3 loop, which 
is generally thought of as being restricted to peptide recognition.  Thermodynamic 
analysis of AHIII-p1049/A2(K66A) binding confirmed that the loop movement results in 
a loss of H-bonds.  Thermodynamic analysis of the AHIII TCR binding to wild-type 
p1049/A2 determined that binding occurs through favorable enthalpy and favor entropy, 
which contradicts the favored thermodynamic TCR-pMHC binding model of 
enthalpically driven and entropically apposed binding.  Finally, we present here a 
streamlined protocol to express and purify soluble TCR from singly isolated T cells 
directly ex vivo. 
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CHAPTER 1 
 
INTRODUCTION 
Section 1.2, Figure 1, and Table 1 are reprinted from Miller, P.J., Collins, E.J., Frelinger, 
J.A. (ed.): Immunodominance – The Choice of the Immune System. Pages 3-30. 2006. 
Copyright Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced with permission. 
 
1.1 Overview 
 Cytotoxic T lymphocytes (CTL), or CD8+ T cells, are a critical component of the 
adaptive immune response to infection.  They are required for the elimination of infected 
host cells, which are harboring virus or intracellular bacteria.  CTL are also responsible 
for the recognition and elimination of aberrant self-cells like cancers.  These infected or 
cancerous cells are labeled as such by self-presentation of non-self, or antigenic, peptides 
on the exterior of the cell.  Both healthy and uninfected cells present self-peptides on the 
surface.  These self and antigenic peptides are presented in the context of the class I 
major histompatibility complex molecule, or MHC.  The class I peptide-MHC (pMHC) 
complex is the ligand for the T cell receptor (TCR), which is expressed on the surface of 
CTLs.  If a TCR recognizes the peptide in the MHC as antigenic, the CTL will be  
activated, lysing the target cell and secreting immunostimulatory cytokines.  The 
interaction between the pMHC and the TCR is paramount; it determines whether or not 
the CTL will respond to a target cell.  Surprisingly, after almost two decades of research 
it is still unclear through which mechanism(s) of molecular recognition the TCR 
discriminates a self from a foreign pMHC.  The work presented here attempts to answer 
2 
what mechanism(s) are involved in the AHIII recognition of its cognate pMHC 
molecules.   
1.2 Presentation of Peptide in the Context of MHC 
1.2.1 Properties of Class I MHC  
Class I major histocompatibility complex (MHC) molecules are heterotrimeric 
complexes comprised of a ~44 kDa heavy chain, a non-covalently bound 12 kDa protein, 
β2-microglobulin (β2m), and peptide (Figure 1a).  Nomenclature for class I MHC is H-2 
in mice and Human Leukocyte Antigen (HLA) in humans.  The α1 and α2 α helices of 
the MHC along with the beta sheet floor create a peptide-binding cleft (Figure 1b).  Class 
I MHC molecules are constitutively expressed on the plasma membrane of all nucleated 
cells, and typically present endogenous self-peptides.  The presence of class I MHC 
molecules with those endogenous peptides on the surface of the cell is required for CD8+ 
T cell homeostasis (Kieper and Jameson, 1999).   
Class I MHC is polygenic, having three alleles A, B, and C in humans.  The MHC 
is also the most polymorphic gene family known in vertebrates.  Increasing diversity even 
more, MHC genes are co-dominantly expressed, meaning humans may have up to six 
different class I isoforms (Parham et al., 1995).  However, the crystallographic structures 
of class I MHC molecules are similar regardless of the isoform, allotype, or species of 
origin (Collins et al., 1995; Fremont et al., 1992; Garrett et al., 1989; Guo et al., 1992; 
Kjer-Nielsen et al., 2002; Madden et al., 1991; Meijers et al., 2005; Saper et al., 1991; 
Zhang et al., 1992; Zhao et al., 1999).  This is because the distribution of polymorphic 
residues is not randomly scattered through the molecule, but rather they are located in the  
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a. b. 
d. c. 
e. 
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peptide binding cleft (Figure 1c).  This allows the MHC to bind peptides with a diverse 
set of identities.   
Examination of peptide/MHC structures reveal that not all peptide side chains are 
solvent exposed for TCR recognition.  Some of these side chains bind in pockets, termed 
specificity pockets, down in the peptide-binding cleft of the MHC (Figure 1d).  Pocket A 
is composed of conserved residues that act as hydrogen bond acceptors for the amino 
terminus of the peptide backbone.  The entrance to the F pocket provides conserved  
hydrogen bond donors for the negatively charged carboxyl terminus of the peptide 
(Matsumura et al., 1992).  Pockets B-E and the base of pocket F are formed by a small set 
of conserved residues in conjunction with the polymorphic residues in the MHC.  These 
pockets are used to bind a variety of peptide side chains depending on the identity of the 
MHC molecule and the peptide.   
1.2.2 Properties of Peptides  
 
Peptides bound in class I MHC are typically eight to ten residues in length. This 
strict requirement in length led to early predictions of class I peptides bulging in order to 
fit into the binding pocket of the class I MHC molecule (Maryanski et al., 1990), which 
Figure 1.  Class I MHC molecule.  (a)  Heterotrimeric complex composed of MHC class I heavy 
chain, β2m, and peptide.  The peptide binding cleft created by the α1 and α2 α helices and the beta 
sheet floor is easily seen from the side.  (b)  A top view of the peptide binding cleft of the class I MHC 
molecule.  Bound peptide, p1049 (ALWGFFPYL), is colored black.  (c)  The polymorphic regions of 
the class I MHC molecule, shaded black, reside primarily within the α1 helix and beta sheet floor of the 
peptide binding cleft.  (d)  The chemical and spatial composition of the peptide binding cleft creates six 
binding pockets in HLA-A2, labeled A-F.  Pockets A, B, and F are especially prominent and 
accommodate the amino terminus, the side chain of P2, and the carboxyl-terminal leucine, respectively.  
(e)  The molecular surface of the peptide/MHC complex is dictated by the bound peptide and the 
conformation of the MHC heavy chain.  Peptide surface atoms are shaded black.  Elipses represent the 
binding regions of TCR domains that make contact with the MHC heavy chain based on crystal 
structures of pMHC-TCR complexes with the Vα binding on the α2 domain and the Vβ binding more 
diffusely on the α1 domain.  Figures were generated using PyMOL (DeLano, 2002). 
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has been confirmed by a number of peptide-MHC complex crystal structures (Collins et 
al., 1995; Fremont et al., 1992; Garrett et al., 1989; Guo et al., 1992; Kjer-Nielsen et al., 
2002; Madden et al., 1991; Meijers et al., 2005; Saper et al., 1991; Zhang et al., 1992; 
Zhao et al., 1999).  All peptides have a hydrophobic carboxyl-terminal end, with a 
predominance of leucine, isoleucine, or valine.  Each allelic peptide tends to have an 
additional anchor residue besides the one found at the carboxyl terminus (Falk et al., 
1991).  As a result of their specificity pockets, different MHC proteins bind different 
subsets of peptides.  The specificity pockets of HLA-A2 are shown in Figure 1e.  
Importantly, as it relates to the data presented in this body of work, in addition to primary 
anchors of position 2 (P2) and P9, positions 1, 3, and 7 have been identified as secondary 
anchors, as they bind into the specificity pockets A, C, and E, respectively.  Leucine or 
Methionine is preferred at P2 and a large bulky aromatic at P3 (Ruppert et al., 1993).  
This propensity for particular amino acids at particular positions allows one to predict the  
 
 Position  
Allele 1 2 3 4 5 6 7 8/9/10 Reference 
HLA-A1 - T,S D,E - - - - Y (Kubo et al., 1994) 
HLA-A2 - L,M - - - - - V,L (Falk et al., 1991) 
HLA-A3 - V,L,M - - - - - K (Kubo et al., 1994) 
HLA-A11 - T,V - - - - - K (Kubo et al., 1994; 
Zhang et al., 1993) 
HLA-A24 - Y - - - - - F,L (Kubo et al., 1994) 
HLA-B27 - R - - - - - K (Jardetzky et al., 
1991) 
H-2Kd - Y - - - - - L,I (Falk et al., 1991) 
H-2Db - - - - N - - M,I (Falk et al., 1991) 
H-2Kb - - - - F,Y - - L (Falk et al., 1991) 
H-2Ld - P - - - - - L,F,M (Corr et al., 1992) 
H-2Dd - G P - - - - L,I,F (Corr et al., 1993) 
 
 Table 1.  Peptide Binding Motifs of Common MHC Alleles 
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types of peptides that may bind to a particular MHC.  Table 1 lists a representative set of 
peptide-binding motifs.  A complete listing up thru 1994 was compiled by Rammensee et 
al. (Rammensee et al., 1995).  
1.2.3 Peptide-MHC Binding Affinity 
Peptides bind to class I MHC molecules with moderate to high affinity (Kd around 
10-8 to 10-7 M (Binz et al., 2003; Cerundolo et al., 1991)), and have extremely slow off-
rates (tens to hundreds of hours at 37 oC (Bjorkman et al., 1987; Buus et al., 1986; 
Cerundolo et al., 1991)).  However, this system cannot be described as a simple 
equilibrium.  The pMHC structure suggests that a conformational change would be 
required to bind or release peptide, which has been confirmed experimentally (Elliott et 
al., 1992; Neefjes et al., 1993a).  
Peptides play an important structural role in the class I MHC molecule.  They are 
essential in stabilizing the heavy chain during assembly of the MHC molecule in the 
endoplasmic reticulum (Townsend et al., 1990; Townsend et al., 1989).  In their absence 
class I MHC molecules can form, but are unstable at physiological temperatures 
(Ljunggren et al., 1990).  Generally, peptides that confer the greatest stability also have 
the highest affinity.  The fact that peptide-free MHC is extremely unstable and rapidly 
denatures is also a reason that it is not proper to discuss peptide binding to class I MHC 
as a standard equilibrium system.  If the system were in simple equilibrium, 
LeChatelier’s principle would govern.  Scheme 1 shows that peptide bound complex 
(pMHC) would be rapidly depleted due to the loss of peptide-free MHC to denaturation 
and free peptide to dilution.  
7 
 
1.2.4 Peptide Processing 
MHC-associated peptides are generated by cleavage of cellular proteins by the 
proteasome and other peptidases (Paradela et al., 2000; Serwold and Shastri, 1999).  
These peptides are derived from proteins that are degraded at the end of their useful 
lifespan as part of normal protein turnover.  Consistent with this thinking, the ubiquitin-
dependent proteolytic pathway plays a major role in the production of peptides for class I 
MHC restricted presentation (Michalek et al., 1993).  A key factor in selection of a 
peptide for MHC presentation is the peptide’s ability to be liberated from its precursor by 
proteolysis (Deng et al., 1997).  The peptide sequence must possess protease-recognition 
sites flanking its amino and carboxyl termini (Del Val et al., 1991; Eggers et al., 1995; 
Eisenlohr et al., 1992), and must lack internal cleavage sites in order to be processed 
successfully (Niedermann et al., 1995; Ossendorp et al., 1996).  
The proteasome is a multicatalytic proteinase complex consisting of five known 
proteolytic components that hydrolyze peptide bonds on the carboxyl side of basic, 
acidic, aromatic, branched chain, and small amino acids.  The proteasome contains only 
endoprotease activity, yielding peptides of discrete length and not single amino acids 
(Dick et al., 1991).  In a pathogen-infected cell, peptide generation is increased and the 
peptide sequences generated are different due to the expression of an altered proteasome, 
the immunoproteasome.  The immunoproteasome contains some of the constitutively 
Scheme 1 
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expressed subunits of the proteasome, as well as unique subunits, termed low molecular 
weight proteins (LMPs).  The LMP molecules are up-regulated by IFNγ during infection 
(Barton et al., 2002).  Incorporation of LMP2 reduces cleavage following acidic residues 
and increases cleavage after basic residues without affecting hydrophobic activity.  LMP7 
incorporation specifically increases cleavage after hydrophobic and basic residues 
without affecting acidic proteolysis (Gaczynska et al., 1994; Groettrup et al., 1995). 
The proteasome and immunoproteasome generate peptide lengths with a range of 
3-22 amino acids and less then 15% of those peptides are 8 or 9 residues in length 
(Kisselev et al., 1999).  Some peptides are further trimmed by aminopeptidases in the 
cytoplasm (Reits et al., 2003).  However, a great deal of amino-terminal trimming takes 
place in the endoplasmic reticulum (ER).  The primary aminopeptidase in the ER seems 
to be the ER aminopeptidase associated with antigen processing (ERAAP), or ERAP1, 
which is upregulated by IFNγ (Saric et al., 2002; Serwold et al., 2002).  ERAP1, unlike 
other aminopeptidases, seems to limit trimming to create peptides of no less than eight 
residues in length.  
1.2.5 Peptide Transport into the Endoplasmic Reticulum 
The loading of peptide onto folded class I MHC molecules occurs in the ER 
(Townsend et al., 1989).  Therefore, peptides generated in the cytosol via the constitutive 
proteasome, immunoproteasome, or other cytosolic proteases must be translocated into 
the ER for loading into a class I MHC molecule.  The most prevalent pathway is via the 
heterodimeric transporter associated with antigen presentation (TAP).  
TAP1 and TAP2, encoded within the MHC locus, are members of the ATP-
binding cassette (ABC) family of membrane transporters (Deverson et al., 1990; Monaco 
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et al., 1990; Spies et al., 1990; Trowsdale et al., 1990).  The TAP heterodimer spans the 
ER membrane allowing for movement of peptides from the cytoplasm to the lumen of the 
ER (Kleijmeer et al., 1992).  Like other ABC transporters, transport of peptides across the 
ER membrane via TAP requires ATP and/or possibly GTP (Androlewicz et al., 1993; 
Neefjes et al., 1993b; Saveanu et al., 2001; Shepherd et al., 1993; van Endert, 1999).  
Hydrolysis of the bound nucleotides by both TAP1 and 2 induces a conformational 
change in the transmembrane domains, which results in the transport of peptide across the 
membrane (Alberts et al., 2001; Gorbulev et al., 2001; Karttunen et al., 2001; Saveanu et 
al., 2001).  
TAP does not transport every peptide with the same efficiency.  The selectivity of 
TAP is dependent on the sequence and length of peptide, not just overall charge or 
hydrophobicity (Androlewicz et al., 1993; Neefjes et al., 1993b; Shepherd et al., 1993). 
The ideal length of peptides binding to TAP is 8-11 residues, which is also to the ideal 
length for binding to class I MHC molecules, and seems to be the most important factor 
in transport.  After length, the greatest determinant for TAP selectivity is the carboxyl-
terminal residue.  Peptides containing a basic or hydrophobic residues at the carboxyl 
terminus are translocated most effectively (Androlewicz and Cresswell, 1994; Momburg 
et al., 1994; Uebel et al., 1997).   
1.2.6 Class I MHC Peptide Loading 
TAP facilitates loading of peptides directly onto class I MHC molecules by its 
association in the ER lumen with a large complex of proteins, termed the peptide loading 
complex (PLC), which includes: nascently-formed class I MHC (with β2m) (Ortmann et 
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al., 1994; Suh et al., 1994), tapasin, calreticulin, and ERp57 (Reits et al., 2000).  Each of 
these peptide loading molecules are discussed briefly below. 
While not directly part of peptide loading, calnexin is a chaperone found in the 
ER that promotes the correct folding of glycosylated proteins including class I MHC 
heavy chain (Hammond et al., 1994; Hebert et al., 1996; Nauseef et al., 1995; Peterson et 
al., 1995; Wada et al., 1995; Zhang et al., 1995).  Tapasin is a 48 kDa type I 
transmembrane glycoprotein encoded within the MHCI locus, which is essential for 
peptide loading of class I MHC molecules.  Cells that lack expression of tapasin have no 
detectable class I molecules, calreticulin, or ERp57 associated with TAP (Grandea et al., 
1998; Li et al., 1999; Li et al., 1997; Ortmann et al., 1997; Sadasivan et al., 1996).  
ERp57 is responsible for facilitating disulfide bond formation in the α2 and α3 domains 
of the class I MHC heavy chain (Farmery et al., 2000; Lindquist et al., 1998).  After 
being recruited by calnexin to the class I heavy chain, ERp57 remains as part of the PLC 
until peptide is loaded (Lindquist et al., 2001).  Calreticulin, a 46 kDa soluble protein 
found in the ER, displays high sequence homology to the lumenal domain of calnexin 
(Michalak et al., 1992) and functions to keep the class I heavy chain-β2m complex in a 
peptide receptive state (Culina et al., 2004).  
 
1.3 The T cell Receptor 
1.3.1 T cell Receptor Structure 
The T cell receptor (TCR) was hypothesized to be structurally similar to an arm of 
an antibody based on sequence similarity (Claverie et al., 1989; Davis and Bjorkman, 
1988).  This was found to be the case in 1996 when the first two TCR structures were  
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Table 2.  Determined Structures of TCR-pMHC     
TCR Vα Vβ 
Bound 
pMHC(s) PDB Reference 
MHC Class I Restricted TCR         
A6 TRAV12-2*02 TRBV6-5*01 tax/A2 1AO7 
(Garboczi et al., 
1996) 
   tax(P6A)/A2 1QRN (Ding et al., 1999) 
   tax(V7R)/A2 1QSE (Ding et al., 1999) 
   HLA-A2-tax(Y8A) 1QSF (Ding et al., 1999) 
   tax(hapten)/A2 2GJ6 (Gagnon et al., 2006) 
      
B7 TRAV29/DV5*01 TRBV6-5*01 tax/A2 1BD2 (Ding et al., 1998) 
      
1G4 TRAV21*01 TRBV6-5*01 1G4 alone 2BNU (Chen et al., 2005) 
   NY-ESO-1(9C)/A2 2BNR (Chen et al., 2005) 
   NY-ESO-1(9V)/A2 2BNQ (Chen et al., 2005) 
      
JM22 TRAV27*01 TRBV19*01 flu/A2 1OGA 
(Stewart-Jones et al., 
2003) 
   JM22 alone 2VLM (Ishizuka et al., 2008) 
   flu/A2 2VLJ (Ishizuka et al., 2008) 
      
SB27 TRAV19*01 TRBV6-1*01 LPEP/B35 2AK4 (Tynan et al., 2005) 
      
LC13 TRAV26-2*01 TRBV7-8*01 EBV/B8 1MI5 
(Kjer-Nielsen et al., 
2003) 
      
ELS4 TRAV1-2*01 TRBV10-3*01 ELS4 alone 2NW2 (Tynan et al., 2007) 
   EBV/B35 2NX5 (Tynan et al., 2007) 
      
BM3.3 TRAV16D/DV11*01 TRBV1*01 pBM1/Kb 1FO0 (Reiser et al., 2000) 
   VSV8/Kb 1NAM (Reiser et al., 2003) 
   pBM8/Kbm8 2OL3 (Mazza et al., 2007) 
      
KB5-C20 TRAV14-1*01 TRBV1*01 pKB1/Kb 1KJ2 (Reiser et al., 2002) 
   Fab  1KB5 (Housset et al., 1997) 
      
AHIII12.2 TRAV12D-2*01 TRBV13-3*01 p1049/A2 1LP9 
(Buslepp et al., 
2003b) 
   p1049/A2(T163A) 2UWE (Miller et al., 2007) 
   p1049/A2(W167A) 2JCC (Miller et al., 2007) 
   p1049/A2(K66A) 2J8U (Miller et al., 2007) 
      
N15 TRAV12D-1*01 TRBV12-1*01 VSV8/Kb N/A (Teng et al., 1998) 
   H57 Fab 1FND (Wang et al., 1998) 
      
2C TRAV9-4*01 TRBV13-2*01 2C alone 1TCR (Garcia et al., 1996) 
   dEV8/Kb 2CKB (Garcia et al., 1998) 
   SIYR/Kb 1G6R (Degano et al., 2000) 
   dEV8/Kbm3 1MWA (Luz et al., 2002) 
2C(m6)   QL9/Ld 2E7L (Colf et al., 2007) 
   QL9/Ld 2OI9 (Colf et al., 2007) 
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(Table 2 continued)     
MHC Class II Restricted TCR         
HA1.7 TRAV8-4*05 TRBV28*01 HA/DR1 1FYT 
(Hennecke et al., 
2000) 
   HA/DR4 1J8H 
(Hennecke and 
Wiley, 2002) 
      
Ob.1A12 TRAV17*01 TRBV20*01 MBP/DR2 1YMM 
(Hahn et al., 
2005) 
      
3A6 TRAV9-2*01 TRBV5-1*01 MBP/DR2a 1ZGL (Li et al., 2005) 
      
E8 TRAV22*01 TRBV6-6*01 E8 alone 2IAL 
(Deng et al., 
2007) 
   TPI/DR1 2IAN 
(Deng et al., 
2007) 
   TPI-mut/DR1 2IAM 
(Deng et al., 
2007) 
      
D10 TRAV14D-2*01 TRBV13-2*01 CA/Ak 1D9K 
(Reinherz et al., 
1999) 
   D10 alone (NMR) 1BWM 
(Hare et al., 
1999) 
      
172.1 TRAV14-3*01 TRBV13-2*01 MBP/Au 1U3H 
(Maynard et al., 
2005) 
      
1.D9.B2 TRAV14-3*01 TRBV13-2*01 MBP/Au 2P1Y 
(McBeth et al., 
2008) 
      
B3K506   3K/Ab 3C5Z (Dai et al., 2008) 
      
2W20   3K/Ab 3C6O (Dai et al., 2008) 
      
YAe62   3K/Ab 3C6L (Dai et al., 2008) 
 
 
determined (Garboczi et al., 1996; Garcia et al., 1996).  Twelve years later, a total of 23 
unique class I or class II MHC restricted αβTCR have been studied structurally.  These 
TCR along with their respective co-crystal pMHC targets are listed in Table 2.  The TCR 
is a membrane bound heterodimeric molecule of approximately 60 kDa, which is 
comprised of an alpha and beta chain, and less frequently a gamma and delta chain.  Each 
chain contains a variable and constant immunoglobulin domain, a trans-membrane 
segment, and a short cytoplasmic tail.  The constant and variable domains each fold into 
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immunoglobulin (Ig) domains, composed entirely of β-sheets (Figure 2b).  Similar to an 
antibody-epitope interaction, the TCR contacts its ligand, pMHC, using the membrane 
distal variable domains; more specifically using the complementarity determining region 
(CDR) loops within the variable domains.  Generation of these CDR loops will be 
covered in greater detail in section 1.3.2.  The TCR molecule and its interaction with 
pMHC is diagramed in Figure 2.   
1.3.2  T cell Receptor Generation and T cell Maturation 
 
 T cell precursors are generated in the bone marrow and then migrate to the 
thymus for maturation (hence the name T cell).  It is in the thymus that the T cell receptor 
(TCR) is expressed.  Each T cell is clonotypic, meaning it expresses only one TCR.  Each 
unique TCR variable domain is generated through a recombination of three gene 
segments, the variable (V), diversity (D) (only in β-chain), and joining (J) segments, 
termed V(D)J recombination (Schatz and Spanopoulou, 2005; Spicuglia et al., 2006). 
The CDR1 and CDR2 loops are germ-line encoded within the variable gene segment.  
The diversity seen in the CDR1 and CDR2 loops is derived from the large number of Vα 
and Vβ TCR genes.  The gene for each CDR3 loop is unique and is located where the V, 
D, and J segments are joined.  V(D)J recombination utilizes non-homologous end-
joining, which is an imperfect process, often adding or deleting nucleotide bases in the 
process (Schatz and Spanopoulou, 2005; Spicuglia et al., 2006).  The process of V(D)J 
recombination in T cells can theoretically produce approximately 1015 unique TCR 
variable domains (Davis et al., 1998).  However, this number of T cells is pared down 
through the thymic selection leaving an estimated 108 different TCR. 
14 
 Thymic selection, thymic education, or T cell maturation are all names for the 
action of selecting T cells that can recognize antigen (Starr et al., 2003; von Boehmer et 
al., 2003).  The procedure has two distinct processes: positive and negative selection.  In 
positive selection the newly formed TCR must recognize self-peptide in the context of 
self-MHC presented on the surface of thymic epithelial cells.  This is essential because 
the TCR must be able to recognize the peptide/MHC complex once outside the thymus.  
The T cell must receive a signal from the TCR that it identifies self-pMHC, or it will die  
 
Cα 
Vα 
Vβ 
Cβ 
α3 
α1 
α2 
β2m 
(a) (b) 
Figure 2.  TCR-pMHC interaction is the keystone of the immunological synapse. (a) Diagram of 
interface between CTL and antigen presenting cell.  While discrimination between self and non-self 
peptides is determined TCR-pMHC interaction, T cell activation requires the recruitment of other 
molecules to the synapse.  ITAMs on the CD3 complex molecules are phosphorylated by Lck, which is 
recruited along with CD8.  Coreceptor CD8 and adhesion molecules LFA-1 and ICAM increase the 
avidity of the interaction between the cells.  (b) Ribbon diagram of AHIII TCR bound to p1049/A2 
(1LP9).  CDR loops of the Vα and Vβ domains contact the peptide (red) and the α1 and α2 domains of 
the class I MHC. 
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by neglect.  This is also where the CD4 or CD8 coreceptor lineage commitment of a T 
cell is determined as the coreceptors are involved in the TCR signaling into the cell 
(Germain, 2002; He and Kappes, 2006).  In negative selection, if TCR recognizes self-
pMHC too strongly, the T cell is deleted through apoptosis (Starr et al., 2003; von 
Boehmer et al., 2003).  Negative selection prevents self-reactive T cells from escaping 
the thymus, which could lead to potential autoimmune disorders. 
 
1.4  Molecular Recognition of pMHC by the T cell Receptor 
While the overall three-dimensional structure of the TCR resembles the epitope 
binding arm of an antibody (Fab), the key difference between them is the ligands to 
which they bind.  Antibodies can recognize a broad spectrum of linear and non-linear 
epitopes, but TCR only recognize self or foreign peptides presented in the context of the 
MHC molecule.  TCR binds to the molecular surface that is formed by a combination of 
atoms from the peptide and the class I MHC molecule, with the TCR α chain docking 
over the α2 α helix and the TCR β chain docking on the α1 α helix (Figures 1e and 2).  
Recognition of pMHC by the TCR heterodimer is accomplished using the three CDR 
loops from each chain of the TCR.  While recognition of the pMHC is carried out using 
all the CDR loops of each chain, generally the CDR3 makes more contacts with the 
bound peptide and the CDR1 and CDR2 loops contact the α1 and α2 α helices of the 
MHC (Rudolph et al., 2006).  Consequently, the TCR has the ability to recognize both 
the MHC and the peptide, allowing recognition of multiple peptides presented by one or 
more MHC molecules.   This ability, along with the diversity of CDR loop combinations 
produced by V(D)J recombination (section 1.3.2), provides the power of the adaptive 
immune response.  This diversity of recognition, or the ability of a TCR to recognize 
16 
multiple pMHC ligands, is termed polyspecificity (Wucherpfennig et al., 2007).  
Polyspecificity can be broken into parts: syngeneic, allogeneic, xenogeneic and cross-
reactivity.  Basically, syngeneic refers to TCR recognition of a self-MHC, allogeneic is 
recognition of genetically different MHC molecules within the same species, and 
xenogeneic is TCR recognition of MHC from different species.  Understanding and 
controlling allogeneic and xenogeneic responses is key to controlling organ transplant 
rejection.  Cross-reactivity is a general term that has been used to describe the ability of 
multiple pMHC to initiate a T cell response.  This is the basis of CTL response to 
antigenic peptide.  Early explanations of polyspecificity involved the model of molecular 
mimicry; or the idea that the molecular surfaces of the different pMHC that one TCR 
recognized would be almost identical regardless of sequence.  However, this has been 
shown not to be the case (Colf et al., 2007; Zhao et al., 1999).  Each pMHC has a unique 
surface and the TCR accommodates this in different manners. 
Compared to antibody-antigen interactions, the TCR binds pMHC with relatively 
low affinity (Kd = 1-100 µM) and fast off-rates.  However, this low affinity interaction is 
surprisingly selective.  To illustrate, a vesicular stomatitis virus (VSV) peptide 
(RGYVYQGL) presented in the context of mouse MHC Kb elicits a T cell response with 
clones of predominantly Vβ13.  A variant peptide E6 (RGYVYEGL) abrogates the 
response of Vβ13 expressing T cells.  The structures of these two peptides in Kb have 
been determined and the only difference is the side chain of position 6 (Q→E) (Thomson 
et al., 2001).  
Mutations in both the sequence of the peptide or the MHC molecule can have 
significant effects on recognition.  Often molecular recognition of the pMHC by the TCR 
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is dissected into peptide recognition and MHC recognition.  However, one cannot 
dissociate the two.  Peptide side chains bound into their complementary specificity 
pockets in the MHC can also influence the reactivity of cytotoxic T lymphocytes (Buxton 
et al., 1992; Matsui et al., 1993; Rohren et al., 1993; Santos-Aguado et al., 1989; 
Villadangos et al., 1992; Winter et al., 1991), even turning them from agonist to 
antagonist by mutating one residue (Dong et al., 1996).  Presumably, these mutations 
cause a slight conformational change in the peptide or in the MHC, altering the molecular 
surface of the pMHC complex, and hence, recognition by TCR.  This argument is 
especially lucid when considering that the buried surface area of the pMHC is generally 
greater than 900 Å2, while the peptide is buried so deeply in the groove that only 100-300 
Å2 is exposed outside the MHC to the TCR (Fremont et al., 1992).  
Understanding the paradox of TCR-pMHC recognition being promiscuous, or 
polyspecific, but yet highly specific at the same time has been the great challenge for 
structural immunologists. Interestingly, there are no significant differences in the way 
that TCR binds to syngeneic, allogeneic, or xenogeneic pMHC based on the determined 
co-crystal structures (Table 2). 
1.4.1 Induced Fit or Pre-Existing Equilibrium 
Induced fit is a general biophysical mechanism that describes plasticity in the 
binding site allowing for an initial weak association, following by an induced 
conformational change in the binding site, leading toward tight association in the active 
state (Goh et al., 2004).  This has been applied to TCR-pMHC binding.  After analyzing 
the association rate constants (kon) measured between the 2B4 TCR and class II MCC/I-
Ek mutants, Wu et al. proposed a two-step binding mechanism (Wu et al., 2002).  In this 
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model the CDR1 and CDR2 loops of the TCR first bind to the MHC prior to a binding 
transition state, followed by an induced fit of the CDR3 loops onto the peptide as the 
transition state moves to the bound state.  The two-step binding model has been 
challenged by data from other laboratories.  Davis-Harrison et al. have recently shown 
that the CDR3 loops of both A6 and B7 TCR do contribute to the initial formation of the 
TCR-pMHC complex when binding Tax/HLA-A2 (Davis-Harrison et al., 2007).  Lee et 
al. propose a variation of induced-fit involving a conformational change in the peptide 
following the TCR-pMHC transition state based on their thermodynamic data (Lee et al., 
2004).  The recently determined structures of the ELS4 TCR in non-ligand form and in 
complex with EPLP/HLA-B*3501 show limited movement of the CDR3α loop, as well 
as a large conformational change in the peptide upon binding (Tynan et al., 2007), similar 
to what had been seen by Lee et al. (Lee et al., 2004).  In contrast to the 2C (Degano et 
al., 2000; Garcia et al., 1998) and KB5-C20 TCR (Reiser et al., 2002) structural studies, 
where large conformational changes were limited to the CDR3 loops, upon binding its 
pMHC ligand the LC13 TCR undergoes dramatic changes in not just its CDR3s, but also 
the CDR1 and CDR2 alpha loops (Kjer-Nielsen et al., 2003).  Additionally, the CDR1α 
loop is critical in the LC13 system for peptide specificity, while the CDR3α loop 
interacts principally with the MHC.  Energetic studies of the LC13 TCR system, which 
demonstrate the CDR3 loops are key in initial pMHC recognition while the CDR1 and 
CDR2 loops only help stabilize the TCR-pMHC interaction, are also inconsistent with the 
two-step binding mechanism (Borg et al., 2005).  Crystal structures of the BM3.3 TCR 
bound to the H-2Kb MHC presenting two different peptides show that the CDR1 and 
CDR2 loops are flexible and make unique contacts with each pMHC surface, suggesting 
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that the cross-reactivity seen with TCR for various pMHC is not due to changes seen in 
the CDR3 loops alone (Reiser et al., 2003).  These examples suggest that the two-step 
model, dissecting TCR-MHC and TCR-peptide binding, is not general to TCR-pMHC 
binding.  The two-step model may better describe TCR binding to class II pMHC, where 
the peptide is buried deeper in the groove.   
Moreover, perhaps an induced fit model does not best describe TCR-pMHC 
binding.  The pre-existing equilibrium model theorizes that the protein binding site exists 
in a number of conformations, and that binding will occur once the ligand encounters the 
appropriate conformation (Goh et al., 2004).  A pre-existing equilibrium model still 
reconciles with the slower on-rates determined by surface plasmon resonance for many 
TCR binding to pMHC variants.  The TCR conformation necessary to bind a particular 
pMHC may be sparse in the overall population, taking longer for these TCR to find the 
pMHC and bind.  It has been suggested that TCR-pMHC binding may utilize pre-existing 
equilibrium and induced fit to allow both cross-reactivity and high specificity, 
respectively (Gakamsky et al., 2004).  Further supporting this idea, James et al. recently 
determined structures of two pre-existing conformations of the same antibody, as well as 
structures of each conformation bound to their respective antigens (James et al., 2003).  
Aside from the conformations of the CDR loops themselves the juxtaposition of 
the TRC α and β chains may play a role in pMHC recognition, especially when it comes 
to polyspecificity.  Analysis of the different TCR structures bound to their cognate 
pMHC has found that interdomain angles (between Vα and Vβ) vary among the different 
TCR.  Even more interesting, they were varied between structures of the same TCR 
bound to different pMHC ligands (McBeth et al., 2008). 
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1.4.2 The Thermodynamics of TCR-pMHC Recognition 
Isothermal titration calorimetry (ITC) provides a direct measure of enthalpy (ΔH) 
and is hence considered the most reliable determination of thermodynamic parameters.  
However, ITC has been rarely utilized for TCR-pMHC studies because of large amounts 
of protein required for the experiment.  More often, surface plasmon resonance (SPR) has 
been used to examine the thermodynamics of binding of many TCR to pMHC.  SPR can 
provide an indirect estimation of enthalpy based on the van’t Hoff equation using the 
affinity determined at various temperatures.  The caveats of van’t Hoff analysis have 
recently been discussed, including proton linkage (Armstrong et al., 2008) and the 
sensitivity of the analysis to errors in temperature or determined Kd  (Zhukov and 
Karlsson, 2007).  Whether using ITC or SPR, early thermodynamic experiments 
suggested that TCR-pMHC interactions seem to be dominated by large enthalpic 
contributions and with unfavorable entropy (Anikeeva et al., 2003; Boniface et al., 1999; 
Garcia et al., 2001; Krogsgaard et al., 2003; Lee et al., 2004; Willcox et al., 1999).  These 
results were satisfying considering polar interactions should provide the specificity seen 
with TCR-pMHC recognition, compared to relying on non-polar, or van der Waals 
contacts.  In addition, entropically unfavorable binding seems to correlate well with the 
idea that flexible CDR loops are being constricted upon TCR-pMHC binding.  However, 
more recent thermodynamic data of L13-FLR/B8 (Ely et al., 2006), A6-Tax/A2 (Davis-
Harrison et al., 2005), 2C-QL9/Ld  (Colf et al., 2007), and our AHIII-p1049/A2 presented 
in Chapter 2 (Miller et al., 2007) all show entropically favorable associations, or even 
completely entropically driven in the case of the A6 TCR (Davis-Harrison et al., 2005).  
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These data demonstrate that entropically unfavorable binding is not a signature of TCR-
pMHC recognition.  Furthermore, it has been shown that the same TCR can bind 
different ligands using varied thermodynamic mechanisms.  Examples include the A6 and 
B7 TCRs recognizing tax/A2 (Davis-Harrison et al., 2005), the 172.10 and 1934.4 TCRs 
binding the MBP peptide in the context of class II MHC I-Au (Garcia et al., 2001), and 
the 2C TCR recognition of two different MHC, H-2Ld and H-2Kb (Colf et al., 2007; 
Krogsgaard et al., 2003).   
Individual contributions to changes in binding entropy (ΔS) include changes in 
solvation, loss in translational and rotational degrees of freedom, and protein backbone 
and side chain conformational changes.  While a method exists to dissect these 
contributions from the overall DS (Spolar and Record, 1994), and has been employed on 
at least one TCR system to estimate conformational change in CDR loops upon TCR-
pMHC binding (Boniface et al., 1999), the accuracy of these calculated contributions is 
questionable.  A better thermodynamic parameter for estimating conformational changes 
is the heat capacity change (ΔCp).  A number of TCR-pMHC binding analyses have 
included ΔCp value in their analyses.  In general reported heat capacity changes for TCR-
pMHC binding have been large and negative (-400 to -800 cal/K/mol).  Since ΔCp is 
strongly influenced by changes in solvation, it is widely accepted in the field that these 
large negative values suggest that conformational changes are altering the solvent 
exposed surface area upon binding.  However, ΔCp measurements are not error free, 
including the fact that most for TCR-pMHC have been determined using SPR with van’t 
Hoff analysis (Armstrong et al., 2008; Zhukov and Karlsson, 2007).  Additionally, while 
a negative change in heat capacity suggests conformational change in a solvent exposed 
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surface upon binding, it can not tell you if that change is occurring in the TCR, the 
peptide, the MHC, or some distal surface of the proteins.  Therefore, the best 
investigation of conformation change in TCR or pMHC should include thermodynamic 
and structural analysis. 
 
1.5  T cell activation 
1.5.1 T cell signaling 
Full T cell activation requires the presence of two sets of signals.  The first is 
provided through the TCR upon engagement of an antigenic pMHC, the second is 
derived from co-stimulatory molecules.  The best-characterized co-stimulatory molecules 
are CD28 and LFA-1, which bind B7 and ICAM-1, respectively, on the surface of the 
antigen presenting cell (APC) (Schwartz, 2003).  Co-stimulation acts to increase the 
magnitude and/or duration of the TCR signal and is necessary for optimal IL-2 
production and proliferation.  More importantly, the first signal originating from the 
TCR-pMHC interaction ensures the specificity of the T cell response, and is hence, the 
focus of this work. 
The short cytoplasmic tail of the αβTCR is unable to propogate any signal inside 
the T cell upon TCR-pMHC binding.  Hence, the TCR relies on other cytotoxic T cell 
surface molecules for signaling, primarily the CD3 complex and the CD8 coreceptor 
(Figure 2a).  The CD3 complex is composed of γ, δ, ε, and ζ chains, which co-localize 
with the TCR on the surface of the CTL.  The cytoplasmic tails of all CD3 chains contain 
Immunological Tyrosine-based Activation Motifs (ITAMs), which are phosphorylated 
first by the Src family tyrosine kinase p56lck (Lck), followed by Syk family kinase Zap70 
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(van Oers, 1999).  Phosphorylation of the CD3 ITAMs initiates downstream signaling 
pathways that lead to T cell activation: T cell proliferation and cytokine secretion.   
The heterodimeric CD8 coreceptor serves two known roles in the immunological 
synapse.  First, like the TCR, the two Ig domain “heads” of the αβCD8 bind to MHC, but 
in a peptide independent manner on the α3 domain (Figure 2a).  This increases the 
avidity of the TCR-pMHC interaction, making it more stable (Luescher et al., 1995).  
Second, the cytoplasmic tail of the CD8α chain recruits Lck (Shaw et al., 1990; Turner et 
al., 1990).  This is the primary means of how Lck is brought into the immunological 
synapse where it can then phosphoryate the CD3 ITAMs.  In addition to binding the 
MHC, the glycolsylated CD8 β chain has been shown to interact with the TCR α chain 
(Backstrom et al., 1996; Naeher et al., 2002; Ulivieri et al., 2001; Werlen et al., 2000), 
providing a mechanism of CD8-TCR association and co-localization.  Of course 
complicating the issue, CD8-independent CTL responses have been documented for 
many T cell systems (Anel et al., 1997; Buslepp et al., 2003a; Cho et al., 2001; Curnow et 
al., 1994; Potter et al., 1989; Riddle et al., 2008).  The HLA-Aw68 MHC (Aw68) 
contains a naturally occurring mutation, which reduces CD8-MHC binding (Gao et al., 
1997; Hutchinson et al., 2003), resulting in CD8-independent Aw68 restricted CTL 
activation (Cerundolo et al., 1991).  It is unclear how the Lck is able to phosphorylate 
ITAMs in these CD8-independent systems.  One hypothesis is that CD8 still co-localizes 
with the TCR, bringing along with it Lck, but because the TCR-pMHC has a high enough 
affinity that CD8 is not required to bind the MHC to increase the avidity (Buslepp et al., 
2003a).  For T cells that are CD8-/-, suggestions include: that Lck is palmitylated and 
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already membrane associated, it is free and available in high enough concentrations in the 
cell, that other tyrosine kinases operate in the absence of Lck (Riddle et al., 2008). 
While the interaction between one TCR and one pMHC may last on the order of a 
second or less, full T cell activation requires a sustained TCR-pMHC interaction on the 
order of hours.  This long interaction between the T cell and the APC is accomplished 
through a supramolecular organization of the various molecules in the immunological 
synapse, termed supramolecular activation cluster (SMAC) (Bromley et al., 2001; 
Grakoui et al., 1999; Monks et al., 1998).  The SMAC is basically a “bull’s eye-like” 
capping of TCR-pMHC complexes and co-stimulatory molecules, LFA-1 and CD28 with 
their respective APC ligands.  Initial immunological synapse formation is initiated by 
TCR-pMHC ligation, and subsequent ITAM phosphorylation, results in Ca2+ flux, 
generation of inositol phospholipids, and arrest of T cell migration within approximately 
30 sec., followed by co-stimulatory signals.  Initially SMAC organization has co-
stimulatory molecule LFA-1 in the center of the bull’s eye and TCR around the 
periphery.  Between 5 minutes and 60 minutes the molecules reorganize and the TCR 
creates the bull’s eye and the co-stimulatory molecules surround them.  The density of 
TCR-pMHC molecules in SMAC reaches approximately 200 molecules per µm2 after 10 
minutes and maintains that density for more than 30 minutes (Grakoui et al., 1999).   
1.5.2 Levels of T cell Activation: Agonist, Partial Agonist, and Antagonist 
TCR triggering of T cell activation cannot be described as a binary system, i.e. on 
or off.  Instead, qualitatively different T cell signaling can lead to a range of responses 
from maximal activation to desensitization (reviewed in (Bongrand and Malissen, 1998; 
Uhlin et al., 2006)).  The cognate pMHC ligand of a TCR that leads to a full response is 
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generally referred to as an agonist.  Agonists elicit the full range of T cell responses, 
including cell proliferation, cytokine secretion, expression of activation markers, and 
cytotoxicity (for CTLs).  Variants of the cognate pMHC, often called altered peptide 
ligands (APLs), can result in various responses.  Partial agonists result in some, but not 
all, of these responses.  Null agonists elicit no response.  Other ligands, called 
antagonists, not only elicit no response, but actually seem to block T cell responses to 
agonist ligands, sometimes even resulting in T cell anergy (Sloan-Lancaster et al., 1993).  
Importantly, these antagonist peptides must be co-presented with agonists on the same 
antigen presenting cell (APC) to mediate their suppressive effects.   
The diverse range of T cell activation is critical not only for CTL cytoxicity, but 
also early during thymic selection (described in section 1.3.2) and later for survival in the 
secondary lymphoid organs.  Circulating mature T cells interact with self-pMHC after 
leaving the thymus.  These weak interactions do not activate the cell, but send small 
signals keeping them alive and ready to respond when necessary (Krogsgaard and Davis, 
2005; Stefanova et al., 2002).   
Antagonistic peptides do not follow a simple competitive model, occupying the 
TCR-pMHC binding and dampening T cell signaling in a dose dependent manner.  
Rather, the qualitative differences manifested above are the result of alternate patterns of 
phosphorylation in the signaling pathway for T cell activation.  Pull down experiments 
have shown that agonistic peptides result in full phosphorylation of Lck, ZAP-70, CD3ε, 
and both p21-CD3ζ and p23-CD3ζ chains, where as null or antagonistic peptides resulted 
in phosphorylation of only p21-CD3ζ and not p23-CD3ζ, CD3ε, or ZAP-70 (reviewed in 
(Madrenas and Germain, 1996)).  Importantly, this qualitative difference in 
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phosphorylation cannot be reproduced by just stimulating T cells with lower 
concentrations of weak or full agonists (Reis e Sousa et al., 1996).  It is theorized that this 
pattern is the result of incomplete activation, i.e. lack of the second activation signal from 
co-stimulatory receptors, primarily CD28 and LFA-1 (Schwartz, 2003).  Partial agonists 
and antagonists also affect the downstream patterns of Ca2+ flux compared to full 
agonists (Chen et al., 1998).  The formation of the supramolecular activation complex 
(SMAC), described above in 1.5.1, is also detrimentally affected by antagonist peptides, 
disabling MHC clustering and the signal to stop cell motility (Sumen et al., 2004). 
The most extreme effect of antagonism is T cell anergy, where the cell becomes 
functionally inactive following encounter with antagonist pMHC (reviewed in (Schwartz, 
2003)).  Anergic T cells have a similar phosphorylation pattern described above for 
antagonists.  Clonal anergy of CTLs often manifests itself in a somewhat normal 
secretion of IFNγ, but drastically reduced levels of IL-2 and an arrest in cell growth.  
These cells can sometimes be rescued from anergy with the addition of high levels of IL-
2 (Schwartz, 2003).  
The study of agonist, partial agonist, and antagonist peptides provides a means of 
deciphering the mechanisms of T cell activation.  Better understanding of these activation 
phenomena could also lead to be treatment of certain diseases.  Antagonist peptides have 
been encountered in viral infections and may aid in immune evasion.  Mutations in HIV, 
Hepatitis B and C, and LCMV have been reported to produce antagonistic peptides; and 
even self-peptides presented by MHC have been shown to enhance or suppress immune 
response to certain antigens (Vukmanovic et al., 2003).  Naturally processed antagonist 
peptides during a Listeria infection in mice were shown to suppress activation of naïve T 
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cells by agonist peptide, suppress memory response upon challenge, and alter the 
hierarchy of immunodominance (Lau et al., 2005).  These results suggest the need to 
study possible antagonistics associated with vaccine development.  A clearer 
understanding of T cell antagonism could potentially allow for the use of antagonistic 
peptides as therapeutics; potentially down-regulating a cytotoxic T cell response in 
autoimmune disorders or transplantation (Garcia-Peydro et al., 2000). 
1.5.3 Models of T cell activation 
The qualitatively different signals described above lead to a range of T cell 
responses, which stem from quantitative differences for TCR-pMHC molecular 
recognition.  However, it is still unclear how that quantitative difference is determined by 
the TCR.  As it has been discussed above in section 1.4, the structural and 
thermodynamic mechanisms of TCR-pMHC molecular recognition vary greatly.  It 
seems that each TCR finds a unique way in which to bind its respective pMHC targets.   
As the first TCR-pMHC co-crystal structures were determined (Garboczi et al., 
1996; Garcia et al., 1996) structural immunologists hypothesized that T cell activation 
would be mediated through some allosteric mechanism involving the TCR.  More 
specifically, upon binding an antigenic pMHC complex, the structure of the TCR would 
change and be distinct from the structure of the TCR bound to a self-pMHC, translating 
some quantitative difference into the T cell propagating the appropriate signal.  This was 
soon shown not to be the case when Ding et al. found that the structure of the A6 TCR in 
complex with four different pMHC ligands including an agonist, antagonist, and two 
weak antagonists was virtually unchanged between them (Ding et al., 1999).  This is true 
of many other TCR-pMHC structures determined since (Table 2).  The only other 
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structural hypothesis regarding T cell activation suggests that a small movement in a loop 
of the TCR Cα domain upon binding agonist pMHC allows for an interaction with CD3ε 
(Kjer-Nielsen et al., 2003); however, this has not been corroborated by any other TCR-
pMHC structure.  If a conformational change in the TCR structure does not relay the 
pMHC readout into the cell then some other biophysical mechanism must. 
A few biophysical models exist to explain differences in TCR triggering and 
downstream T cell outcome.  The kinetic model proposes that the level of T cell 
activation is dependent on the dissociation rate of the TCR-pMHC interaction; slower 
off-rate equals greater signal.  Due to the two sets of signals required for full T cell 
activation (discussed above in section 1.5.1) the kinetic model proposes that the TCR-
pMHC must be engaged long enough for both the first TCR initiated signal and the co-
stimulatory signal to occur (McKeithan, 1995; Rabinowitz et al., 1996).  This correlation 
has been supported by a number of experimental observations (Kersh et al., 1998; Lyons 
et al., 1996; Matsui et al., 1994; Rosette et al., 2001).  A more recent refinement of this 
basic off-rate model combines off-rate with a measure of conformational change upon 
binding (ΔCp) to predict T cell stimulation (Krogsgaard et al., 2003). 
Another popular model is the affinity model, which states that T cell activation 
relates to the concentration or number of pMHC ligands engaged.  The affinity model is 
also supported by an abundance of experimental data, which all show a correlation 
between determined TCR-pMHC affinities and activation (Alam et al., 1996; Baker et al., 
2000; Buslepp et al., 2001; Garcia et al., 2001; Holler and Kranz, 2003; Miller et al., 
2007; Schodin et al., 1996; Sykulev et al., 1994; Sykulev et al., 1998; Tian et al., 2007).  
The A6 T cell response to the pMHC structures referred to previously, that showed no 
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TCR conformational change (Ding et al., 1999), were ultimately shown to correlate with 
TCR-pMHC affinity (Baker et al., 2000).  Another case supporting a correlation with 
affinity involves activation of the P14 T cell.  Recently, two independent laboratories 
have determined the affinity to be consistent with other agonist pMHC interactions, but 
the shortest half-life of any other agonist TCR-pMHC interaction (koff   >1 s-1) (Boulter et 
al., 2007; Tian et al., 2007).   
The serial triggering model attempts to explain the paradox of high specificity 
with a low affinity interaction.  It does not compete with kinetic or affinity models, but 
rather incorporates them both.  Following ITAM phosphorylation the TCR-CD3 complex 
is downregulated, or internalized, in the T cell.  Lanzavecchia and colleagues measured 
this internalization following stimulation by agonist pMHC (Valitutti et al., 1995).  They 
determined that a single pMHC complex could serially trigger ~200 TCR, due to the fast 
off-rate of TCR-pMHC binding.  They also showed a correlated between IFNγ 
production and the number of TCRs downregulated.  Partial agonists were shown to 
downregulate fewer TCR, suggesting that there exists an optimum affinity and off-rate 
(or dwell time) that allows TCR triggering and pMHC complex recycling.  Without a full 
TCR trigger, antagonists would actually inhibit downregulation of TCR.  This model is 
able to account for the fact that antigenic peptides are presented in low-copy number 
compared to self-peptide.  Because of the fast serial triggering a small number of 
antigenic pMHC can trigger T cell activation.  Finally this model suggests that there is a 
threshold of “triggered” TCRs needed in order to fully activate the cell (Lanzavecchia et 
al., 1999; Valitutti et al., 1995). 
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The segregation model is the final model.  The bound TCR-pMHC and their 
accessory molecules create an immunological synapse of ~14 nm in distance between the 
cells.  The ectodomains of receptor protein tyrosine phosphatases known to inhibit TCR 
triggering, including CD45, are larger than 14 nm.  The segregation model suggests that 
large inhibitory molecules are segregated in a size-dependent manner from the 
immunological synapse, allowing for phosphorylation of the CD3 ITAMS (Choudhuri et 
al., 2005; van der Merwe and Davis, 2003). 
1.6 The AHIII12.2 T cell   
 
Many of the experiments performed within this body of work were done using the 
AHIII12.2 (AHIII) T cell system.  AHII is a murine T cell clone that was generated by 
injecting human lymphoblasts into a B6 (H-2b) mouse (Bernhard et al., 1987; Herman et 
al., 1983; Hogan et al., 1989).  The AHIII T cell is very interesting in that it recognizes a 
xenogenic human class I MHC, HLA-A2.1 (A2), when presenting the peptide p1049 
(ALFGFFPVL) (Henderson et al., 1993).  It was later discovered that AHIII also 
recognizes class I H-2Db (Db) in complex with the synthetic peptides p1027 
(FAPGVFPYM) and p1058 (FAPGFFPYL) and related variants (Loftus et al., 1997).  
That study included a careful analysis of p1049 in A2 and p1058 in Db, which concluded 
that the AHIII TCR must engage the surfaces of p1049/A2 and p1058/Db in a different 
manner due to the results of alanine scanning of the peptide.  Substitutions at P3 and P5 
were deleterious in p1049, while P5 and P8 were more important to p1058 (Loftus et al., 
1997).  They hypothesized that these were critical residues involved with TCR contacts.  
We now know that in the case of AHIII-p1049/A2 that the Phe at P5 is a critical contact, 
and Trp at P3 does not contact the TCR, but rather is a secondary anchor residue for the 
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peptide binding to A2 (Buslepp et al., 2003b).  So, p1058/Db and p1049/A2 both produce 
an agonistic response in AHIII.  Interestingly, it was found that when p1058 is bound and 
presented by A2 it becomes antagonistic.  Experiments using fluorescently labeled 
p1058/A2 tetramer also suggested that the AHIII TCR bound p1058/A2 with lower 
affinity than p1049/A2 (Buslepp et al., 2001).  However, this affinity has never been 
directly measured. 
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CHAPTER 2 
 
Single MHC Mutation Eliminates Enthalpy Associated with T Cell 
Receptor Binding 
 
Reprinted from Journal of Molecular Biology, Volume 373, Peter J. Miller, Yael Pazy, 
Brian Conti, David Riddle, Ettore Appella, and Edward J. Collins, Single MHC Mutation 
Eliminates Enthalpy Associated with T Cell Receptor Binding, pages 315-27, Copyright 
2007, with permission from Elsevier. 
 
2.1 ABSTRACT  
The keystone of the adaptive immune response is T cell receptor (TCR) 
recognition of peptide presented by Major Histocompatibility Complex (pMHC) 
molecules.  The co-crystal structure of AHIII TCR bound to the MHC, HLA-A2, showed 
a large interface with an atypical binding orientation.  MHC mutations in the interface of 
the proteins were tested for changes in TCR recognition.  From the range of responses 
observed, three representative HLA-A2 mutants, T163A, W167A, and K66A, was 
selected for further study.  Binding constants and co-crystal structures of the AHIII TCR 
and the three mutants were determined.  K66 in HLA-A2 makes contacts with both 
peptide and TCR and previously has been identified as a critical residue for recognition 
by numerous TCR.  The K66A mutation resulted in the lowest AHIII T cell response and 
the lowest binding affinity, which suggests T cell response may correlate with affinity. 
Importantly, the K66A mutation does not affect the conformation of the peptide.  The 
change in affinity appears to be due to a loss in hydrogen bonds in the interface as a result 
of a conformational change in the TCR complementarity-determining region 3 (CDR3) 
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loop.  Isothermal titration calorimetry confirmed the loss of hydrogen bonding by a large 
loss in enthalpy.  Our findings are inconsistent with the notion that the CDR1 and CDR2 
loops of the TCR are responsible for MHC restriction, while the CDR3 loops interact 
solely with the peptide.  Instead, we present here a MHC mutation that does not change 
the conformation of the peptide, yet results in an altered conformation of a CDR3.   
 
2.2 INTRODUCTION 
T cells are an integral part of the adaptive immune system’s ability to recognize 
virtually any pathogen that might attack the host.  A critical step required for T cell 
activation is the recognition of peptides derived from these pathogens when presented by 
the Major Histocompatibility Complex protein (MHC).  Recognition of foreign peptide 
bound to MHC is achieved through the clonotypic T cell receptor (TCR).  Upon TCR 
recognition of a peptide bound to MHC (pMHC) sets of T cells either kill the cell 
presenting the foreign peptide (cytotoxic T cells) or produce cytokines to “help” B cells 
and other T cells (helper T cells).  The pathogens are subsequently eliminated from the 
host by a combination of killing infected cells to remove reservoirs of replicating 
pathogen, and antibody-mediated neutralization of the pathogen outside of the cell.  
Although TCR binding to pMHC is paramount for T cell activation, there are still many 
unanswered questions regarding how TCR-pMHC interactions dictate T cell response. 
Recognition of pMHC by the TCR heterodimer is accomplished using the three 
complementarity determining region (CDR) loops from each chain.  The CDR1 and 
CDR2 loops are germ-line encoded within the variable gene segment of each TCRα and 
TCRβ chain.  The CDR3 loop of each chain is unique and arises through V(D)J 
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recombination (Schatz and Spanopoulou, 2005; Spicuglia et al., 2006).  While 
recognition of the pMHC is carried out using all the CDR loops of each chain, generally 
the CDR3 makes more contacts with the bound peptide than CDR1 and CDR2 (Rudolph 
et al., 2006). 
Engagement of TCR with pMHC may result in a variety of reactions from the T 
cell, and the mechanisms that generate these different responses are not understood 
(Rudolph et al., 2006).  The structures of TCR bound to partial agonist or antagonist 
pMHC complexes do not show changes in the TCR domains (Degano et al., 2000; Ding 
et al., 1999) that would suggest a way for the TCR to propagate a qualitatively different 
signal to the T cell through the plasma membrane.  It is generally accepted that there is 
great plasticity in the interaction between TCR and pMHC.  However, as seen in a variety 
of TCR-pMHC co-crystal structures the degree and location of this plasticity is not 
generalizable.  For example, the co-crystal structures of 2C-dEV8/Kb (Garcia et al., 
1998), 2C-SIYR/Kb (Degano et al., 2000), and KB5-C20-pKB1/Kb (Reiser et al., 2002) 
when compared to crystal structures of those TCRs alone show great flexibility in the 
CDR3 loops of the TCR.  The LC13 (Kjer-Nielsen et al., 2003) and BM3.3 (Reiser et al., 
2003) TCRs undergo changes in not just their CDR3s, but also their CDR1 and CDR2 
loops.  Conversely, the A6-Tax/A2 (Garboczi et al., 1996) and ELS4-EPLP/B*3501 
(Tynan et al., 2007) co-crystal structures exhibit conformational changes in the peptides 
upon TCR-pMHC binding.  Finally, the crystal structures of the 1G4 TCR alone and 
complexed with its pMHC ligands show no significant changes in either the TCR or the 
pMHC (Chen et al., 2005). 
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Similarly, there appear to be no general thermodynamic rules that describe TCR 
binding to pMHC.  Although surface plasmon resonance (SPR) has been used for more 
than a decade to examine binding of TCR to pMHC, it measures kinetic constants 
between TCR and pMHC and binding via Scatchard Analysis or mathematically using 
the kinetic constants.  Isothermal titration calorimetry (ITC) provides a direct measure of 
ΔH and is hence considered a more reliable determination of thermodynamic parameters.  
ITC has been rarely utilized for TCR-pMHC studies because of the much larger amounts 
of protein required for the studies.  Early experiments suggested that TCR-pMHC 
interactions seem to be governed by large enthalpically favorable and entropically 
unfavorable thermodynamics (Garcia et al., 2001; Krogsgaard et al., 2003; Lee et al., 
2004; Willcox et al., 1999).  However, more recent thermodynamic data of L13-FLR/B8 
(Ely et al., 2006), A6-Tax/A2 (Davis-Harrison et al., 2005), and 2C-QL9/Ld  (Colf et al., 
2007) all show entropically favorable associations.  
The human MHC, HLA-A2, is the most frequent MHC found in Caucasians and 
African Americans (Ellis et al., 2000).  A large panel of A2 mutants were created and 
tested against a panel of T cells.  Most interesting from that study, the K66A mutant was 
found to adversely affect recognition of 98% of the T cells examined (Baker et al., 2001).   
K66 has been shown to be a critical residue in TCR recognition of A2, regardless of the 
peptide presented (Baker et al., 2001; Baxter et al., 2004; Gagnon et al., 2005; Wang et 
al., 2002), resulting in K66 to be labeled a potential “hot spot” for TCR recognition of 
A2.  Importantly, even though K66 interacts with the peptide, the structure of 
Tax/A2(K66A) shows that the K66A mutation does not alter the structure of A2 or the 
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conformation of the Tax peptide (Gagnon et al., 2005).  However, the effect of the K66A 
mutation on the cognate TCR has never been determined structurally. 
AHIII12.2 (AHIII) is a murine T cell clone that recognizes human HLA-A2.1 
(Engelhard and Benjamin, 1982) when peptide 1049 (ALWGFFPVL) is presented 
(Henderson et al., 1993).  Reactivity towards p1049/A2 does not require binding of the 
TCR co-receptor CD8, (Buslepp et al., 2003a) which allows for the study of TCR-pMHC 
interactions without the additional complexity of the third protein.  We have previously 
described the crystal structure of the AHIII TCR complexed with p1049/A2 (Buslepp et 
al., 2003b).  From the AHIII-p1049/A2 co-crystal structure, we identified a number of A2 
surface residues that may be responsible for binding the AHIII TCR.  These residues 
were mutated in A2 and the changes in T cell cytolytic activity were examined as a 
function of the mutation.  Three mutants were then selected for kinetic, thermodynamic, 
and structural studies.  Most importantly, the K66A mutation causes substantial changes 
to cytotoxicity and the affinity.  This change in affinity appears to be due to a large 
reduction in hydrogen bonding that is a result of a large conformational change in the 
CDR3 loop.  This loss of hydrogen bonding is reflected in the almost complete loss of 
enthalpy in the binding reaction. 
 
2.3 RESULTS 
2.3.1 AHIII T Cell Reactivity 
Based on the co-crystal structure of AHIII bound to p1049/A2 (Buslepp et al., 
2003b), thirteen HLA-A2 mutations were selected to probe the interface.  The ability of 
AHIII T cells to lyse target cells expressing this panel of A2 variants was assessed by 
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loading the target cells with radioactive chromium (51Cr), incubating the T cells with the 
target cells for four hours and then measuring the radioactivity released to the media.  
Measured lysis was normalized to AHIII lysis of wild-type A2 expressing cells in each 
experiment.  A spectrum of responses to the mutations was seen (Figure 1).  Some of the 
mutants showed little affect on reactivity (E166A and T163A).  On the other end of the 
spectrum the K66A mutation almost completely abolished the response.  In addition to 
the K66 “hot spot” in A2 (Baker et al., 2001; Baxter et al., 2004; Gagnon et al., 2005; 
Wang et al., 2002), it has been suggested that positions 65, 69, and 155 could be critical 
to MHC-restriction due to the high frequency with which they are seen contacting TCRs  
 
Figure 1. CTL Killing as a Function of Substitutions in the p1049/A2 Complex.  Cytotoxic lysis 
assays (51Cr release assays) were performed with AHIII T cells against cells expressing mutant A2 
complexes.  Data was normalized such that lytic activity against native HLA-A2 is 100%.   
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in determined TCR-pMHC structures (Clements et al., 2006; Rudolph et al., 2006; Tynan 
et al., 2005).  Consistent with those data, mutations at positions 65, 69, and 155 all had 
deleterious effects on AHIII cytotoxicity. 
 Three A2 variants that represent the range of T cell reactivity were chosen for 
further study: T163A (high), W167A (medium), and K66A (low).  Mutant proteins were 
expressed recombinantly as inclusion bodies in E. coli and refolded in vitro with p1049  
 
Table 1. Equilibrium and kinetic binding parameters for AHIII TCR binding 
p1049/A2 mutants. 
pMHC Complex 
 
Kd Equilibrium  
(µM) 
Kd Kinetic  
(µM) 
kon  
(x104 M-1s-1) 
koff 
(s-1) 
p1049/A2 9.3 8.7 3.1 0.27 
p1049/A2(T163A) 4.7 4.6 3.3 0.16 
p1049/A2(W167A) 15.4 14.8 4.1 0.63 
p1049/A2(K66A) 31.8 34.0 0.47 0.15 
Parameters were obtained by fitting data with Scrubber 2.0 and CLAMP.  Kinetic dissociation constants (Kd) were 
obtained from kinetic data using the determined kon and koff values.  Equilibrium dissociation constants were obtained 
separately by fitting maximum binding responses for various concentrations of pMHC using Scrubber.  
 
peptide.  Binding to the recombinant AHIII TCR was measured using surface plasmon 
resonance (SPR).  Binding curves for these three complexes in addition to wild-type A2 
are shown in Figure 2.  The mutations in the MHC cause significant changes to the 
affinity for AHIII TCR (Table 1) with Kd values ranging from 4.7 µM 
(p1049/A2(T163A)) to 31.8 µM (p1049/A2(K66A)).  The kinetics were also dramatically 
affected.  The dissociation rates (koff) were both faster and slower than wild-type 
p1049/A2 (0.27 s-1).  Interestingly, even though the affinity of AHIII for 
p1049/A2(K66A) is significantly lower than for wild-type A2, the dissociation rate is 
significantly slower (Figure 2 and Table 1).  Association rates (kon) were generally less 
affected by the substitutions, except for p1049/A2(K66A) (4.7 X 103 M-1s-1), which has a 
much slower on-rate compared to wild-type A2 (3.1 X 104 M-1s-1).   
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2.3.2 Structural Analysis of A2 Variants 
 The physical manifestation of the 
differences found in T cell recognition 
and binding was examined using x-ray 
crystallography.  The three mutants 
described above (A2(K66A) A2(T163A) 
and A2(W167A)) were co-crystallized 
with AHIII TCR.  The locations of the 
mutations in the interface between the 
AHIII TCR and p1049/A2 are shown in 
Figure 3.  Based on previous work, (Ding 
et al., 1999) it seemed unlikely that  
these relatively small alterations would 
cause large changes in the overall 
structures of the TCR or pMHC, or the 
docking orientation of the TCR.  
Therefore, we hypothesized that the 
substitutions resulted in local alterations 
in the MHC or peptide, changing 
hydrogen bonds or van der Waals 
contacts present in our previously 
determined AHIII-p1049/A2 structure 
(Buslepp et al., 2003b).  Crystallographic 
Figure 2.  AHIII TCR binding to p1049/A2 
variants as measured by SPR.  Kinetic data 
between AHIII TCR and wild-type p1049/A2 as 
well as p1049/A2 mutants at various pMHC 
concentrations were obtained using SPR and 
globally fit to a reversible bimolecular reaction 
using Clamp (Myszka and Morton, 1998).  Model 
binding curves are drawn in black.  Curve fits are 
drawn in grey. 
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data were collected from three single co-crystals comprised of AHIII TCR complexed 
with p1049/A2(T163A), p1049/A2(W167A), or p1049/A2(K66A), to a resolution of 2.4 
Å, 2.5 Å, and 2.88 Å, respectively.  All the crystals were nearly isomorphous with AHIII-
p1049/A2 (Buslepp et al., 2003b).  Data collection and refinement statistics can be found 
in Table 2.  
 As might be expected because of the similar level of T cell activity, no gross 
structural changes were observed in the structure of p1049/A2(T163A) bound to AHIII  
 
TCR (Figure 4a). For all three structures superimposition was performed using the 
“align” feature in PyMol (Delano, 2002), restraining the alignment to the α-carbons of  
K66 
 
 
 
W167 
T163 
 CDR3α 
Figure 3.  Structure of AHIII TCR bound to p1049/A2.  The AHIII TCR alpha (green) and beta 
(blue) chains, interact with the p1049/A2 surface via CDR loops.  HLA-A2, consisting of a heavy 
chain (yellow) and β2m (magenta), present the peptide, p1049 (red).  (Inset) The surface of the 
p1049/A2 is contacted by the CDR loops of the AHIII TCR.  Residues that have been mutated to 
alanine for structural experiments (T163, W167, K66) are shown.  Figure generated using PDB 
coordinates 1LP9 and PyMol (Delano, 2002). 
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        Table 2.  Data Statistics 
 
AHIII- 
p1049/A2(T163A) 
AHIII- 
p1049/A2(W167A) 
AHIII- 
p1049/A2(K66A) 
Data Collection       
Space Group P21 P21 P21 
Cell Dimensions a=93.49 Å, 
b=84.18 Å, 
c=121.77 Å, 
β=92.05˚ 
a=94.28 Å,  
b=84.35 Å, 
c=122.47 Å, 
β=92.53˚ 
a=93.42 Å, 
b=83.89 Å, 
c=122.27 Å, 
β=92.21˚ 
Molecules/AU 2 2 2 
Resolution 50.0 - 2.10 Å 50.0 - 2.5 Å 50.0 - 2.88 Å 
Rmerge(%)a,b 5.9 (46.7) 6.6 (31.8) 7.8 (42.1) 
<I/σ>c 11.4 (1.6) 18.0 (1.8) 11.2 (1.3) 
Unique Reflections 76,682 61,781 40,707 
Avg. Redundancy 2.7 (1.7) 4 (2.5) 3.4 (2.3) 
Completeness (%) 70.0 (24.7) 92.8 (67.8) 95.7 (69.0) 
Solvent Content (%) 41.5 40.7 44.1 
    
Refinement    
Resolution Range 30.0 - 2.4 Å 30.0 - 2.5 Å 30.0 - 2.88 Å 
Number of Reflections 59,694 58,660 38,683 
Rfacd 24.0 25.3 26.8 
Rfree 28.9 29.9 29.3 
Number of non-H atoms 13,160 12,995 12,956 
Number of waters modeled 267 52 0 
<Rs fit>e 93% 93% 90% 
Coordinate errorf, (Murshudov et 
al., 1997; Reed, 1996) 0.25 0.32 0.46 
Deviations from ideality    
     Bond lengths 0.006 Å 0.006 Å 0.005 Å 
     Bond angles 1.040° 1.192° 0.750° 
<Temperature Factor>    
     Overall 37.6 49.7 47.2 
     TCR 37.8 49.6 47.5 
     MHC 37.6 50.1 47.1 
     Peptide 34.7 48.6 37.5 
Ramachandran    
     Most favored 1305 (91.4%) 1291 (90.7%) 1287 (90.4%) 
     Additional allowed 121 (8.5%) 131 (9.2%) 134 (9.4%) 
     Generously allowed  0 0 0  
     Disallowed 2 (0.1%) 2 (0.1%) 2 (0.1%) 
PDB Entry 2UWE 2JCC 2J8U 
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the TCR-pMHC interface (TCR Vα, Vβ; and MHC α1, α2 and peptide).  The AHIII-
p1049/A2(T163A) complex superimposed onto AHIII-p1049/A2 with an RMSD of 0.20 
Å2.  Difference electron density (Fobswild-type - Fobsmutant) maps show a large negative 
electron density peak in the position of the mutated residue that demonstrates the quality 
of the data and confirms the location of the mutation (Figure 4a).  One change in the TCR 
was observed.  The side chain of serine 99 in the TCR CDR3α has rotated into the cavity 
where the MHC threonine side chain is found in the wild-type structure.  Interestingly, 
the electron density maps show the location of the serine without ambiguity, but there are 
no contacts visible for the serine side chain.  This side chain orientation is not the most 
preferred rotamer (Lovell et al., 2003); that preferred conformation is found in the wild-
type structure.  Therefore, it may be that this position is taken to reduce undesired 
energetic contributions to the binding such as the fixation of solvent or the production of 
a cavity in the interface.   
In addition to its importance to this study concerning T cell reactivity, the A2(W167A) 
complex was also interesting because W167 forms a boundary of the peptide-binding 
cleft (Figure 3) and helps form the conserved pocket that binds the amino terminus of the 
peptide (Madden, 1995).  This tryptophan is highly conserved in not only HLA-A2 
subtypes (96%), but across all human class I MHC molecules (88.5%) (Robinson et al., 
2003).  Mutating tryptophan to alanine results in the loss of a hydrogen bond between the 
Trp indol nitrogen to the Tyr28 hydroxyl on the TCR CDR2 (Figure 4b).  Aside from the 
loss of the W167-Y28 hydrogen bond, the structure of AHIII bound 
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(a) T163A (b) W167A 
(c) K66A (d) K66A 
CDR3 
(f) K66A (e) WT-A2 
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to p1049/A2(W167A) shows no significant changes in the peptide amino terminus, the 
CDR2α or CDR3α of the AHIII TCR, or the MHC itself.  The mutant complex alpha 
carbons have an RMSD of 0.27 Å2 when superimposed onto the wild-type atoms.  The 
difference electron density (Fobswild-type - Fobsmutant) map once again shows a large 
negative peak in the position of the mutated residue demonstrating the quality of the data 
and confirming the loss of the Trp side chain.  Two side chains in A2 near the site of 
mutation do change conformation, but these differences do not alter binding to the TCR.  
The amino terminus of the peptide is still coordinated by hydrogen bonds to three 
tyrosine hydroxyl groups Tyr7, Tyr 159, and Tyr171 of the MHC, as in wild-type 
p1049/A2.  The AHIII-p1049/A2(W167A) structure shows weak positive difference 
density in the location where the nitrogen of the indole ring of wild-type Trp167 would 
be (data not shown).  This suggests that there may be a weakly associated water molecule 
replacing the amine, which could hydrogen bond to the hydroxyl group on Tyr28 of 
CDR2α. 
Figure 4.  Mutation of Lys66 to alanine results in large change in CDR3α  loop.  (a) Complex of 
AHIII TCR bound to p1049/A2(T163A) superimposed onto wild-type structure of AHIII-A2.  Mutant 
A2 (cyan) and peptide (blue) show little difference from wild-type A2 (yellow) and peptide (orange). 
Conformations of TCR CDR2 and CDR3 loops and side chains are no different between mutant 
(magenta) and wild-type (green) structures (coloring scheme same for all panels).  (b) Complex of 
AHIII TCR bound to p1049/A2(W167A) also shows no change in TCR structure and only minor 
alterations in local MHC side chains.  (c) Superimposition with of AHIII TCR bound to 
p1049/A2(K66A) onto wild-type shows a major rearrangement of the AHIII CDR3α loop, while the 
structure of pMHC remains unchanged.  (a, b, c) Mutations at T163A, W167A, and K66A are 
confirmed by difference electron density (Fobswild-type - Fobsmutant) contoured at -3σ surrounding the 
side chains.  (d) 2Fobs-Fcalc density map (blue), contoured at 1 σ, confirms placement of final 
modeled CDR3α loop at 2.88 Å.  (e) Five hydrogen bond interactions occur between AHIII TCR 
CDR3α and wild-type p1049/A2.  As shown above some or all of these bonds may be broken due to 
loop movement.  (f) The 2Fobs-Fcalc electron density suggests the presence of a water molecule in the 
AHIII-p1049/A2(K66A) structure, which would allow for a water-mediated hydrogen bond between 
Glu63 of A2 and Ser100 on CDR3α of AHIII (water shown for illustration, but not included in PDB).  
The only other possible hydrogen bond to CDR3α is from the Ser102 nitrogen to the Gly4 oxygen of 
the peptide. Figures generated using PyMol (Delano, 2002). 
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 The structure of AHIII bound to p1049/A2(K66A) is critical to this study because 
of the significantly different binding constants of A2(K66A) (Table 1).  Additionally, 
K66 on the α1 α helix of HLA-A2 has been identified as a “hot spot” for TCR 
recognition of HLA-A2 in a number of studies (Baker et al., 2001; Baxter et al., 2004; 
Gagnon et al., 2005; Wang et al., 2002).  Structures of A6-Tax/A2 (Ding et al., 1998; 
Garboczi et al., 1996) and AHIII-p1049/A2 (Buslepp et al., 2003b) also show that K66 is 
rare in that it makes critical contacts with both the TCR and the peptide.  K66A mutants 
have increased peptide dissociation rates; yet this is not likely to be responsible for the 
decrease in T cell function because T cell clones have also been identified that do not 
have altered recognition to the K66A mutation (Baker et al., 2001; Baxter et al., 2004).  
Furthermore, the K66A mutation does not alter the MHC structure or the conformation of 
the Tax peptide in Tax/A2(K66A) (Gagnon et al., 2005).  So, if increased peptide 
dissociation from A2(K66A) mutants does not influence T cell activation, and the pMHC 
molecular surface is not altered by the mutation, the next logical hypothesis would be that 
the K66A variation results in a change in the TCR that negatively affects T cell function. 
 The co-crystal structure of AHIII-p1049/A2(K66A) determined to 2.88 Å 
resolution shows an altered conformation of the CDR3α of the AHIII TCR (Figure 4c).  
The AHIII-p1049/A2(K66A) structure superimposes onto AHIII bound to wild-type A2 
with an RMSD of 0.37 Å2.  The 2Fo-Fc electron density maps show the new conformation 
of the loop (Figure 4d) and this location is confirmed by omit maps.  The conformational 
change in CDR3α is that the loop appears to fill the void left by the removal of the Lys66 
side chain.  The Cα atoms of the loop move, on average, 2.0 Å with Ala97 moving over 
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4.0 Å (Table 3).  This altered conformation of the loop likely disrupts the hydrogen 
bonding contacts found in the native structure (Buslepp et al., 2003b) between the  
Table 3.  CDR3α Movement 
Residue Distance (Å) 
Leu96 1.0 
Ala97 4.2 
Ser98 2.6 
Ser99 3.0 
Ser100 2.6 
Phe101 0.3 
Ser102 1.7 
Lys103 0.7 
  
Mean  2.0 
Distances limited to 2 significant figures due 
to low resolution of AHIII-p1049/A2(K66A). 
 
CDR3α and wild-type p1049/A2 (Figure 4e).  In a manner similar to the Tax/A2(K66A) 
structure (Gagnon et al., 2005), the K66A mutation does not change MHC or peptide 
conformation in this AHIII-p1049/A2(K66A) structure.  The CDR3 loop change also 
negatively affects the surface complementarity (SC).  The SC value for the wild-type 
AHIII-p1049/A2 structure is 0.71 and drops to 0.55 for AHIII-p1049/A2(K66A).   
The Tax/A2(K66A) structure showed a water molecule replacing the Lys66 side 
chain, mediating hydrogen bonds between Glu63 of A2 and the Tax peptide (Gagnon et 
al., 2005).  There is no electron density that would suggest a water replaces the Lys66 
side chain in our AHIII-p1049/A2(K66A) structure.  It appears that the new conformation 
of the CDR3α loop pushes further into the peptide binding cleft along the MHC α1 α 
helix where the Lys66 side chain would have been, displacing any water that might have 
filled the void before TCR binding.  The number of reflections associated with the 2.88 Å 
resolution data can not support the modeling of water molecules in the structure of 
AHIII-p1049/A2(K66A).  However, there is a small volume in the 2Fo-Fc electron 
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density map that suggests that there may be a weakly associated water molecule that 
would hydrogen bond with Glu63 of A2 and Ser100 on CDR3α of AHIII (Figure 4f).  
The only other plausible hydrogen bond between the AHIII CDR3α to p1049/A2(K66A) 
is from the Ser102 nitrogen to the Gly4 oxygen of the peptide (2.88 Å) (Figure 4f).  In 
summary, there is a large alteration in the AHIII CDR3α loop when bound to 
p1049/A2(K66A) as compared to the wild-type complex and this alteration appears to 
dramatically change the number of hydrogen bonds in the complex. 
 
 
2.3.3 Calorimetric measurement of AHIII TCR and HLA-A2 binding 
The altered hydrogen bonding pattern proposed here based on the crystal structure 
of AHIII-p1049/A2(K66A) suggests that there should be a large change in the enthalpy 
of binding.  To examine this directly, the heat of binding was measured using isothermal 
titration calorimetry (ITC).  Our data show that the wild-type complex binding has a 
relatively small enthalpic component (-3.9 kcal/mol) and that the binding is more 
entropically driven (Table 4 and Figure 5a).  As predicted, this small enthalpic 
contribution to binding is almost completely eliminated by mutation of K66 to alanine.  
This change is manifest clearly during the experiments because the K66A mutation 
changes the reaction from exothermic to endothermic (Figure 5b).  The enthalpy of 
binding (ΔH) goes from -3.9 kcal/mol for AHIII-p1049/A2 to almost zero (-0.6 kcal/mol) 
for AHIII-p1049/A2(K66A).  The free energy of binding (ΔG) measured for the two 
complexes is in agreement with those determined for other TCR-pMHC (Table 4).  The 
thermodynamic changes for AHIII-p1049/A2(K66A) correspond to a ΔΔG of only 1.4 
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kcal/mol, which highlights the tight range between activating and non-activating signals 
for TCR.    
Table 4.  Thermodynamic Parameters of TCR-pMHC Binding as Measured by ITC 
(a) error < 5%; (b) error < 20%; (c) van't Hoff calculation 
 
2.4 DISCUSSION 
The initial goal of this study was to determine how structural alterations in the 
TCR are responsible for the spectrum of T cell cytolysis by AHIII T cells.  Mutations in 
HLA-A2 were made and changes in cytolysis examined as a function of the mutation.  
Recombinant protein for three A2 variants was produced and binding constants were 
determined by surface plasmon resonance (SPR).  Surprisingly, A2(K66A) showed very 
different kinetic constants as compared to the wild-type complex.  Structural studies 
showed that most hydrogen bonds involving the CDR3α loop in the complex were lost 
upon mutation.  Isothermal titration calorimetry (ITC) confirmed a greatly decreased 
enthalpy of binding associated with the conformational change of the loop.   
Based on the AHIII-p1049/A2 co-crystal structure previously determined (Buslepp et al., 
2003b), A2 residues that were predicted to be involved in binding the 
Complex ΔH 
(kcal/mol) 
TΔS 
(kcal/mol) 
ΔG 
(kcal/mol) 
Kd (µM) Reference 
AHIII-p1049/A2  -3.9 a 4.4 -8.3 1 ± 5  
AHIII-
p1049/A2(K66A) 
 -0.6 b 6.3 -6.9 7 ± 20  
      
A6-Tax/A2 5.7 13.6 -7.9 2.2 (Davis-Harrison et 
al., 2005) 
JM22-flu/A2 -19.7  -12.6 c   -7.1 c   6.6 c (Willcox et al., 1999) 
2C-dEV8/Kb -22.7 -16.2 -6.3 84 (Ely et al., 2006) 
2C-QL9/Ld -4.19 3.4 -7.6 2 (Colf et al., 2007) 
LC13-FLR/B8 -3.6 3.4 -7.0 8.1 ± 2.7 (Ely et al., 2006) 
2B4-MCC/IEk -14.8 -8.2 -6.7 12.6 ± 7 (Krogs. et al., 2003) 
2B4-K5/IEk -13.5 -6.4 -7.2 6.2 ± 0.2 (Krogs. et al., 2003) 
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AHIIII TCR were mutated.  The AHIII T cells reacted with a full spectrum of 
outcomes from very low cytotoxicity to slightly improved cytotoxicity as a result of 
changing residues in the interface between the proteins.  Residues at positions 66 (Baker 
et al., 2001; Baxter et al., 2004; Gagnon et al., 2005; Wang et al., 2002) and 65, 69, and 
155 (Clements et al., 2006; Rudolph et al., 2006; Tynan et al., 2005) have all been 
previously identified as critical contacts in a number of TCR-pMHC systems.  Mutations 
Figure 5.  K66A mutation in p1049/A2 dramatically decreases the enthalpy of binding.  The 
binding enthalpy of AHIII TCR was measured directly with ITC for both wild-type p1049/A2, and 
p1049/A2(K66A).  (a) Power versus molar ratio plot for titration of 234 µM p1049/A2 into 19 µM of 
AHIII TCR (upper panel) and plot of integrated heat versus molar ratio after baseline correction (lower 
panel).  The baseline was generated by averaging heat measured for last 10 injections.  (b) Plot of 
power versus molar ratio for titration of 394 µM p1049/A2(K66A) into 40 µM of AHIII TCR (upper 
panel) and integrated heat versus molar ratio after baseline correction (lower panel). The baseline 
derived from titrating p1049/A2(K66A) into buffer alone.  All experiments performed at 25 °C. The 
fitted curves are from the model for single-site binding provided in Microcal Origin Software.  
Thermodynamic parameters determined are presented in Table 4. 
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at all of these four of these positions in A2 resulted in a reduction of AHIII T cell 
cytotoxicity of 30% to almost 100%.  Clearly, these residues are critical for AHIII TCR 
binding.  As an important control, it has been shown previously that peptide binding does 
not change significantly for the mutations studied except K66A (it has a faster peptide 
off-rate) (Baxter et al., 2004).  However, this faster peptide off-rate cannot account for 
the changes in activity because T cells can be found that are not affected by the K66A 
mutation (Baker et al., 2001; Baxter et al., 2004).  This implies that significant peptide 
bound to MHC remains on the cell surface even with the K66A mutation.  In addition, the 
expression levels of the various mutants studied here were confirmed to be similar by 
flow cytometry (data not shown).  Therefore, any observed changes in reactivity, binding, 
or structure should be due to changes in how the complexes interact.  A more thorough 
study of how those mutations resulted in a change of function was then initiated. 
A sub-set of the MHC mutants that represent dramatically reduced to full 
reactivity (K66A, W167A, and T163A, respectively) were chosen to study the physical 
manifestation of the differences.  TCR-pMHC binding studies were performed using 
SPR.  While all mutants showed some degree of change from wild-type A2, the K66A 
mutation resulted in remarkably slower on and off-rates than the wild-type complex.  The 
three mutant complexes were then co-crystallized with AHIII TCR.  The structures were 
determined and compared to the wild-type co-crystal structure.  Similar to the results seen 
for the altered peptide ligands for the Tax/A2 specific TCR (Ding et al., 1999), there were 
no gross differences in any of the structures examined.  Significantly, there were no 
changes in domain packing of the TCR that would suggest a mode to transmit 
information through the domains to the interior of the cell to confer different activities, as 
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previously suggested (Krogsgaard et al., 2003).  There is always the possibility that the 
domain movements are dynamic and/or weakly manifested and are overcome here by 
crystal packing forces that would make it impossible to view using protein 
crystallography.  Similarly, it has been suggested that upon TCR-pMHC interaction, a 
conformational change in the AB loop of the TCR Cα domain is required for signaling 
into the cell (Kjer-Nielsen et al., 2003).  Although the position of the AB loop for the 
non-liganded AHIII TCR is unknown, the loop in the AHIII TCR bound to all p1049/A2, 
even p1049/A2(K66A), is identical, and is the same conformation as seen in the liganded 
LC13 TCR (Kjer-Nielsen et al., 2003).  Importantly, the AB loop in the AHIII structures 
are not involved in any crystal contacts.  These data imply that the AB loop has no impact 
on the level of cytotoxicity seen in the AHIII system.   
There are no definitive structural explanations for the “improved” AHIII T cell 
reactivity for the A2(T163A) mutant.  With threonine being conserved in 98% of all 
known HLA-A2 subtypes (Robinson et al., 2003), we had expected a greater impact 
mutating it to alanine.  If anything, the rotation of the TCR CDR3α Ser99 into the cavity 
formed by the removal of the MHC threonine side chain would be expected to contribute 
negatively to the binding due to the less favorable rotamer that is chosen.  There are no 
hydrogen bonding partners near the new position of the serine hydroxyl.  There is no 
significant increase in the complementarity in the fit between the complexes.  The 
complementarity of fit of AHIII to p1049/A2(T163A) is 0.72 versus 0.71 for the wild-
type structure.  We conclude that the most likely explanation for the slightly increased 
binding affinity is that there is a set of very subtle changes that increase the 
complementarity of fit.   
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The A2(W167A) mutation results in a 20% loss in lysis by the AHIII T cells.  
There are no significant structural changes other than the loss of the W167-Y28 hydrogen 
bond.  Loss of the W167 indole also affects surface complementarity between AHIII-
p1049/A2(W167A) (SC = 0.68) compared to AHIII-p1049/A2 (SC = 0.71).  Therefore, 
the dramatic loss of affinity to the AHIII TCR is likely a result of the lost hydrogen bond 
and the concomitant loss of complementarity (ie van der Waals contacts).  The fact that 
the absence of the indole group from the end of the peptide binding cleft in the AHIII-
p1049/A2(W167A) structure did not significantly alter the conformation of the bound 
peptide is surprising.  Tryptophan is present at position 167 in 96% of all known HLA-
A2 subtypes and 88.5% conserved in all human class I MHC molecules (Robinson et al., 
2003).  It begs the question, why is this amino acid so highly conserved?  Unfortunately, 
the data provided in the AHIII-p1049/A2(W167A) structure are unable to address this. 
Of all the mutants tested, the K66A mutation caused the largest decrease in AHIII 
cytolysis.  The slow on-rate seen for AHIII-p1049/A2(K66A) and significant energy 
barriers measured for other TCR-pMHC (Davis-Harrison et al., 2007; Wu et al., 1996) 
imply that there are structural changes associated with binding, and in fact, a large change 
was seen in the CDR3α loop of the AHIII TCR.  This suggests that binding requires a 
conformational change in the TCR, but when exactly does this occur?   Does the AHIII 
TCR make initial contact with p1049/A2(K66A) and then the CDR3α loop moves 
(induced-fit) or does p1049/A2(K66A) associate with a minority member of the 
population of the AHIII TCRs in solution (pre-existing equilibrium).  The induced-fit or 
two-step model (Wu et al., 2002) has been a popular means of describing TCR-pMHC 
interaction.  However, the validity of the two-step model has been questioned by both 
72 
thermodynamic (Davis-Harrison et al., 2007) and structural (Chen et al., 2005; Kjer-
Nielsen et al., 2003; Reiser et al., 2003) data.  We propose that a pre-existing equilibrium 
model better describes TCR-pMHC association.  The idea that CDR loops exist in 
alternative pre-existing conformations in solution has been shown in antibody crystal 
structures (James et al., 2003).  Knowing the structural similarities between antibodies 
and TCR, it is easy to imagine this binding mechanism to exist for TCR and pMHC.  The 
total number of possible conformations that the CDR loops can adopt is finite and limited 
by the conserved framework regions of the TCR and/or antibody structure (Al-Lazikani 
et al., 1997; Chothia et al., 1992; Chothia et al., 1989; Morea et al., 1998).  The residues 
that constitute the loop will maintain phi and psi angles that allow for the lowest potential 
energy.  Loops in higher potential energy conformations would be found less often in the 
population (minority member).  Therefore, the pMHC surface that allows the TCR to 
have the greatest number of its CDR loops in conformations with the lowest energy 
would provide the most stable interaction, a higher affinity, and subsequent greater 
activation of the T cell.  The structural and thermodynamic data presented here for AHIII 
TCR-p1049/A2(K66A) demonstrates this relationship between energetics and activation.  
When the CDR3α loop is required to take a conformation with higher energy, the 
interactions between TCR and pMHC suffer, and T cell activation is adversely affected.  
As there is not currently a structure of the AHIII TCR alone, we cannot be sure where the 
CDR3α loop lies when it is free in solution.  However, the on-rate of AHIII-
p1049/A2(K66A) being an order of magnitude slower than wild-type AHII-p1049/A2 
binding, suggests the loop to undergo greater change in order to bind p1049/A2(K66A) 
than wild-type p1049/A2.  We propose the TCR conformations seen in our AHIII-
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p1049/A2(K66A) complex are minor in the population, so the longer kon is a reflection of 
the unfavorable equilibrium of the pMHC binding that minority member. 
The AHIII-p1049/A2(K66A) structure also suggested most of the hydrogen bonds 
found between AHIII CDR3α and wild-type p1049/A2 are not present in the mutant 
structure.  The conformational change in CDR3α potentially leaves only the Ser102 to 
Gly4 hydrogen bond.  This suggested that the enthalpy of binding is greatly diminished.  
The ITC data complement the structural data, as it shows there is a significant loss in 
binding enthalpy.  Due to the small amount of heat absorbed upon AHIII-
p1049/A2(K66A) binding, the titration curve generated is not satisfactory to allow for 
confident analysis of the entropy in the system.  However, the endothermic binding 
combined with the loss of enthalpy suggests that the binding of AHIII TCR to 
p1049/A2(K66A) is nearly entirely entropically driven.  For TCR-pMHC complexes 
where heats of binding have been measured directly (and inferred from van’t Hoff 
calculations), the enthalpic and entropic contributions are different for each TCR-pMHC 
system without any unifying thermodynamic properties.  Originally it was thought that 
TCR-pMHC interactions were governed by enthalpically favorable and entropically 
unfavorable thermodynamics features (Krogsgaard et al., 2003; Lee et al., 2004; Willcox 
et al., 1999); however, AHIII-p1049/A2 joins LC13-FLR/B8 (Ely et al., 2006), A6-
Tax/A2 (Davis-Harrison et al., 2005),  and 2C-QL9/Ld  (Colf et al., 2007) as TCR-pMHC 
systems that rely on entropically favorable binding.   
One of the difficulties associated with studying diverse receptor systems such as 
TCR recognition of pMHC is that it is difficult to extract general rules about the system.  
However, in the context of what has been done with other TCR-pMHC, there are some 
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general features that we can present from these data.  Previous structural studies have 
highlighted TCR recognition of altered peptide ligands (Chen et al., 2005; Ding et al., 
1999), different peptides presented by the same MHC (Degano et al., 2000; Garcia et al., 
1998; Reiser et al., 2003; Reiser et al., 2000), or the effects of mutation in the TCR to 
binding (Borg et al., 2005), but not the structural effects of MHC mutation on TCR-
pMHC binding.  The effects of mutations in the MHC through biological readout, co-
crystal structures, and thermodynamics suggest a correlation between T cell response and 
affinity.  As many as 32 hydrogen bonds determine specificity in BM3.3-pBM1/Kb 
(Reiser et al., 2000), but only 21 in AHIII-p1049/A2 (Buslepp et al., 2003b) and 
approximately 15 in the AHIII-p1049/A2(K66A) complex.  The recently determined 
structure of 2C-QL9/Ld (Colf et al., 2007) reveals an interface with less than 10 hydrogen 
bonds and entropically favorable binding.  What does this say about specificity?  If there 
are no hydrogen bonds determining specificity, the only way the TCR can be sure to only 
recognize the foreign complex must be complementarity of fit.  Not surprisingly perhaps, 
AHIII-p1049/A2 (Buslepp et al., 2003b) and 2C-QL9/Ld (Colf et al., 2007) have the 
greatest complementarity of fit of all TCR-pMHC structures determined to date.  In 
addition to other published results, our data suggest that the thermodynamics for each 
TCR-pMHC interaction is unique.  The large range of thermodynamic constants reveals 
that there are many ways to get to T cell activation.  This all suggests that the pathways to 
activation are not important, just the end point.  
Most importantly, the AHIII-p1049/A2(K66A) structure provides evidence that a 
variation in the MHC and not the peptide can directly affect a CDR3 loop.  The idea of 
CDR1 and CDR2 recognition of MHC followed by CDR3 binding to peptide works for a 
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select few TCR, but not for most.  In the case of K66, Lys is not conserved across all 
MHC (93% of HLA-A2 subtypes, but only 42.5% conserved in HLA-A overall, and only 
1.5% of HLA-B molecules (Robinson et al., 2003)).  Therefore, the presence of this 
charge is not required, but can be thought of as another piece of the antigen surface.  TCR 
recognition of the pMHC surface cannot be divorced into separate binding events of 
peptide and MHC. 
 
2.5 MATERIALS AND METHODS 
2.5.1 Cell Lines and Expression Plasmids 
The HLA-A2 mutants transfected into Hmy2.C1R cells have been described 
previously (Wang et al., 2002).  All cell lines showed cell surface expression of HLA-A2 
at similar levels as wild-type HLA-A2 as detected by the HLA-A2-specific Ab BB7.2 
(Brodsky et al., 1979). 
2.5.2 Protein Production and Purification 
Soluble AHIII12.2 TCR was produced as previously described (Buslepp et al., 
2003b).  Briefly, the ectodomains of AHIII TCR α and β chains were expressed as 
inclusion bodies in E. coli.  Purified inclusion bodies, previously dissolved in 8M urea, 
were rapidly injected into a folding buffer optimized for the AHIII TCR at a 
concentration of 50 µg/ml.  After incubation for 36 hours at 10 °C and extensive dialysis 
the native TCR was purified and concentrated by DE52 anion exchange (Whatman, 
Florham Park, NJ)) followed by gel filtration chromatography (Phenomenex, Torrance, 
CA) on HPLC.  The purified AHIII TCR was concentrated to 10 mg/ml and stored at -80 
°C.  Soluble AHIII TCR was tested for proper folding and activity through an ELISA 
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using HLA-A2 tetramer.  Typical yield for each 1 L refold is about 3-5 mg of active 
TCR.  
Similarly, soluble HLA-A2 variants were produced as inclusion bodies in E. coli 
and refolded in vitro (Garboczi et al., 1992).  Peptide p1049 (ALWGFFPVL), presented 
by A2, was synthesized by the UNC Peptide Synthesis Facility (Chapel Hill, NC).  
Briefly, peptide, β2m, and heavy chain were injected in that order into a folding buffer 
optimized for refolding class I MHC at a concentration of 50 µg/ml.  After incubation for 
24-36 hours at 10 °C the folded pMHC was concentrated in an Amicon ultrafiltration cell 
(Millipore, Billerica, MA) and purified using gel filtration chromatography 
(Phenomenex) on HPLC.  The purified wild-type and A2 variants were concentrated to 
10 mg/ml and stored at -80°C.  Typical yield for each 1 L refold is about 5 mg of pMHC.   
2.5.3 Cytotoxicity Assay 
Cytotoxicity was assayed using a standard 4 hour 51Cr release assay as described 
previously (Loftus et al., 1997). Briefly, between 5.0 × 103 and 5.0 × 104 AHIII 12.2 T 
cells were incubated with 5000 peptide-pulsed 51Cr-labeled A2 mutant-transfected cells.  
Since p1049 is a human self-antigen, the transfectants were recognized without the 
addition of p1049 to the cells.  Additional p1049 did not increase cytotoxicity (data not 
shown).   
2.5.4 Surface Plasmon Resonance Experiments 
Five-thousand resonance units (RUs) of H57-597 (capturing molecule, anti-TCR 
Cβ Ab) were covalently bound to a Biacore CM5 sensor chip (Uppsala, Sweden) using 
standard amine coupling.  Soluble AHIII12.2 TCR (ligand) was then added to the Ab at a 
concentration of 50-100 nM to generate 300–400 RU of bound TCR.  Soluble class I 
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MHC (analyte) was injected onto the surface at a flow rate of 100 µl/min in a 30-s pulse.  
TCR and MHC were removed from the surface with 0.1 M Glycine, 0.5 M NaCl, pH 2.5, 
and the procedure was repeated until at least three curves were obtained for the different 
concentrations of analyte.  Curves obtained at each concentration were subtracted from a 
reference surface that contained Ab alone without TCR or using recombinant P14 TCR as 
a negative control.  Data were processed using Scrubber (BioLogic Software, Campbell, 
Australia) and CLAMP (Myszka and Morton, 1998).  The suitability of the fit was 
measured based on χ2 values and the appearance of residuals.  In all cases, χ2 was below 
1, residuals were small and random, and the experimental curves visually matched the 
predicted curves. 
2.5.5 Protein Crystallization and Structure Determination 
The crystallization conditions for the co-crystal complexes were similar to those 
optimized for AHIII TCR with wild-type A2 (Buslepp et al., 2003b).  Briefly, crystals are 
grown by hanging drop, vapor diffusion, using AHIII TCR and A2 variants mixed at 
equal ratios at a concentration of 10 mg/ml.  Drops contain 1 µl of protein mixed with 1 
µl of a well solution containing Hepes, pH 7.5-8.0, 1 M NaCl, and 14%-18% PEG 8000.  
Small crystals formed within 3 days along with precipitate in drops.  Crystal size was 
improved by macro-seeding into identical conditions.  Crystals were transferred to 
mother liquor containing 25% glycerol as cryoprotectant.  Crystallographic data were 
collected at Southeast Regional Collaborative Access Team (SER-CAT) 22-ID and 22-
BM beamlines at the Advanced Photon Source, Argonne National Laboratory (Argonne, 
IL).  Data for AHIII-p1049/A2(T163A) was collected on the 22-BM beamline at 
12,398.42 eV for 360° at a distance of 200 mm using 1.0° oscillations.  Two datasets for 
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AHIII-p1049/A2(W167A) were collected on the 22-ID beamline at 12,759.89 eV at a 
distance of 300 mm using 1.0° oscillations.  180° were collected at an omega angle of 90° 
and an additional 45° was collected at an omega of 45°.  These data sets were indexed 
separately and then scaled together.  Data for AHIII-p1049/A2(K66A) was collected on 
the 22-ID beamline at 12,759.89 eV for 180° at a distance of 300 mm using 1.0° 
oscillations.  Data for all co-crystal complexes were indexed and scaled with HKL2000 
(Otwinowski, 1997).  The data for AHIII-p1049/A2(T163A) was originally collected out 
to 2.1 Å, but it was highly anisotropic.  As a result, the statistics in the highest shells were 
poor, so the data was truncate at 2.4 Å.  Molecular replacement solutions were 
determined using Rigid Body Refinement in Refmac 5.0 (1994) with AHIII-p1049/A2 
(1LP9) (Buslepp et al., 2003b) as the search model.  Temperature factors were set to 30.0 
using Moleman (Kleywegt, 1992-2004).  Positional refinement using noncrystallographic 
symmetry restraints for the first few cycles and TLS refinement (Winn et al., 2001) in 
Refmac 5.0 was performed iteratively with manual intervention with O (Jones et al., 
1991). When the statistics did not improve over two subsequent rounds of refinement and 
the Rfree was below 30%, waters were added using Arp within Refmac 5.0 to AHIII-
p1049/A2(T163A) and AHIII-p1049/A2(W167A) models.  All waters were examined to 
confirm the presence of hydrogen bond donors or acceptors at reasonable geometries.  
For the AHIII-p1049/A2(K66A) model, an omit map of the CDR3α loop was generated 
to verify the conformational change.  The refinement statistics for the final models are 
presented in Table 2.  Surface complementarity (SC) calculated using Sc (Lawrence and 
Colman, 1993) in CCP4 (1994). 
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2.5.6 Isothermal Titration Calorimetry 
ITC experiments on AHIII TCR with wild-type p1049/A2 and p1049/A2(K66A) 
were performed on a Microcal VP-ITC in the UNC Macromolecular Interactions Facility 
(Chapel Hill, NC).  Thermodynamic constants were obtained for AHIII TCR binding 
wild-type p1049/A2 as well as p1049/A2(K66A) by fitting the calorimetric data using a 
one-site binding model in Microcal Origin Version 5.0 Software (OriginLab Corporation, 
Northampton, MA).  Soluble AHIII TCR was placed in the mixing chamber.  p1049/A2 
or p1049/A2(K66A) was titrated into the AHIII TCR solution until binding reached 
saturation.  Titration of wild-type p1049/A2 into AHIII TCR was performed in duplicate, 
once in Phosphate buffer, pH 7.5, and then in Tris buffer, pH 7.5, to ensure that the 
determined enthalpy was not affected by ionization enthalpy of the buffer (Baker and 
Murphy, 1996).  Concentrations of AHIII TCR and p1049/A2 were 17 µM and 217 µM, 
respectively, in Phosphate and 19 µM and 234 µM, respectively in Tris.  For wild-type 
p1049/A2 experiments, a volume of 3 µL was used for the first four injections, and then 5 
µL for the remaining titrations.  The baseline, generated by averaging the heat measured 
for the last 10 injections, was subtracted from all peaks.  Titration of p1049/A2(K66A) in 
AHIII TCR was performed in triplicate in Phosphate buffer, pH 7.5.  Concentrations of 
AHIII TCR and p1049/A2(K66A) were 40 µM and 618 µM, 65 µM and 450 µM, and 43 
µM and 394 µM, respectively, for the three replicates.  For all p1049/A2(K66A) 
experiments, 5 µL was injected for the first four peaks, increasing to 10 µL for the 
remainder of the experiment.  Because of the relatively small amount of heat released 
upon AHIII-p1049/A2(K66A) binding, a more accurate baseline was determined by 
injecting p1049/A2(K66A) into Phosphate buffer to measure heat of dilution.  This 
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reference data set was then subtracted from the experimental data set in Origin Software.  
All concentrations were determined before the proteins were placed in the 
microcalorimeter using extinction coefficients.  ΔH and ΔS were calculated using the 
Origin software.  Gibbs free energy was calculated as ΔG = ΔH – TΔS, T = 298 K.   
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CHAPTER 3 
 
Biophysical Characterization of AHIII TCR Interaction with Agonist 
and Antagonist Peptide/MHC Complexes  
 
 
3.1 ABSTRACT 
 T cell receptor (TCR) recognition of peptide presented by MHC (pMHC) is the 
critical first step for T cell activation.  T cell activation is not binary, as a full range of T 
cell responses have been reported, which stem from the discriminatory ability of the TCR 
to recognize self from non-self pMHC ligands.  Altered peptide ligands (APL) can 
produce this range of responses, including antagonism, whereby the T cell response is 
actually inhibited by a particular pMHC.  It remains unclear through what mechanism 
this inhibition occurs.  The p1058 peptide, when presented by the class I MHC HLA-
A2.1 (A2), has been previous recorded as an antagonist peptide for the AHIII12.2 
(AHIII) T cell.  This p1058 peptide differs from the agonist p1049 peptide by only a few 
residues.  A panel of over 20 variants of these peptides presented in A2 was used in 
surface plasmon resonance experiments to determine binding constants to the AHIII 
TCR.  The data presented here suggest that the antagonism of p1058 correlates with a 
very weak binding affinity and this weak binding is due to the inability of the AHIII TCR 
to bind p1058/A2 without undergoing a conformational change.  These data also suggest 
that mutations made on the surface of the MHC molecule are better by the TCR tolerated 
than mutations in the peptide.  This biophysical data presented in this chapter will be 
combined with a full spectrum of biological assays on AHIII T cells including cytolysis, 
88 
combined with a full spectrum of biological assays on AHIII T cells including cytolysis, 
proliferation, and cytokine secretion, as a means to evaluate any correlation between 
TCR-pMHC recognition and T cell activation. 
 
3.2 INTRODUCTION 
 Cytotoxic T cells are a critical component of the adaptive immune response, 
responsible for clearing infected cells from the body.  Recognition of these infected cells 
is mediated through the T cell receptor (TCR), which recognizes and binds to peptides 
presented in the context of the class I major histocompatibility complex (MHC) 
molecules on the surface of nearly all nucleated cells.  While other T cell surface 
molecules are involved in cytotoxic T cell killing of antigen presenting cells, the TCR 
interaction with peptide/MHC ultimately determines if the cell is healthy or infected.   
TCR triggering of T cell activation cannot be described in as a binary system, i.e. 
on or off.  Instead, qualitatively different T cell signaling can lead to a range of responses 
from maximal activation to desensitization of the T cell (reviewed in (Bongrand and 
Malissen, 1998; Uhlin et al., 2006)).  The cognate pMHC ligand of a TCR that leads to a 
full response is generally referred to as an agonist.  Agonists elicit the full range of T cell 
responses, including cell proliferation, cytokine secretion, expression of activation 
markers, and cytotoxicity (for CTLs).  Variants of the cognate pMHC, often called 
altered peptide ligands (APLs), can result in various responses.  Partial agonists result in 
some, but not all, of these responses.  Null agonists elicit no response.  Other ligands, 
called antagonists, not only elicit no response, but actually seem to block T cell responses 
to agonist ligands, sometimes even resulting in T cell anergy (Sloan-Lancaster et al., 
89 
1993).  Importantly, these antagonist peptides must be co-presented with agonists on the 
same antigen presenting cell (APC) to mediate their suppressive effects.   
Antagonistic peptides do not follow a simple competitive model, occupying the 
TCR-pMHC binding and dampening T cell signaling in a dose dependent manner.  
Rather, the qualitative differences in T cell signaling are the result of alternate patterns of 
phosphorylation in the signaling pathway.  Pull down experiments have shown that 
agonistic peptides result in full phosphorylation of Lck, ZAP-70, CD3ε, and both p21-
CD3ζ and p23-CD3ζ chains, where as null or antagonistic peptides resulted in 
phosphorylation of only p21-CD3ζ and not p23-CD3ζ, CD3ε, or ZAP-70 (reviewed in 
(Madrenas and Germain, 1996)).  Importantly, this qualitative difference in 
phosphorylation cannot be reproduced by just stimulating T cells with lower 
concentrations of weak or full agonists (Reis e Sousa et al., 1996).  It is theorized that this 
pattern is the result of incomplete activation, i.e. lack of the secondary activation signal 
from co-stimulatory receptors, primarily CD28 and LFA-1 (Schwartz, 2003).  Partial 
agonists and antagonists also affect the downstream patterns of Ca2+ flux compared to 
full agonists (Chen et al., 1998).  
The most extreme effect of antagonism is T cell anergy, where the cell becomes 
functionally inactive following encounter with antagonist pMHC (reviewed in (Schwartz, 
2003)).  Anergic T cells have a similar phosphorylation pattern described above for 
antagonists.  Clonal anergy of CTLs often manifests itself in a somewhat normal 
secretion of IFNγ, but drastically reduced levels of IL-2 and an arrest in cell growth.  
These cells can sometimes be rescued from anergy with the addition of high levels of IL-
2 (Schwartz, 2003).  
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The study of agonist, partial agonist, and antagonist peptides provide a means of 
deciphering the mechanisms of T cell activation.  Better understanding of these activation 
phenomena could also lead to be treatment of certain diseases.  Antagonist peptides have 
been encountered in viral infections and may aid in immune evasion.  Mutations in HIV, 
Hepatitis B and C, and LCMV have been reported to produce antagonistic peptides; and 
even self-peptides presented by MHC have been shown to enhance or suppress immune 
response to certain antigens (Vukmanovic et al., 2003).  Naturally processed antagonist 
peptides during a Listeria infection in mice were shown to suppress activation of naïve T 
cells by agonist peptide, suppress memory response upon challenge, and alter the 
hierarchy of immunodominance (Lau et al., 2005).  These results suggest the need to 
study possible antagonistics associated with vaccine development.  A clearer 
understanding of T cell antagonism could potentially allow for the use of antagonistic 
peptides as therapeutics; potentially down-regulating a cytotoxic T cell response in 
autoimmune disorders or transplantation (Garcia-Peydro et al., 2000). 
The qualitatively different signals described above lead to a range of T cell 
responses.  These stem from quantitative differences for TCR-pMHC molecular 
recognition.  However, it is still unclear how that quantitative difference is determined by 
the TCR.  It was hypothesized that the overall structure of a TCR bound to an agonist 
would differ from the same TCR bound to antagonist, thus relaying a signal into the cell 
through some allosteric mechanism.  Unfortunately, it was found that the TCR-pMHC 
crystal structures of A6-tax/A2 (agonist) and A6-tax(P6A)/A2 (antagonist) are virtually 
identical, and another A6-tax(Y8A)/A2 (antagonist) structure showed only a small 
change in the CDR3β loop (Ding et al., 1999).  Consequently, the structural (Rudolph et 
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al., 2006) and thermodynamic (Armstrong et al., 2008) mechanisms of TCR-pMHC 
molecular recognition vary greatly.  It seems that each TCR finds a unique way in which 
to bind its respective pMHC targets.  If a conformational change in the TCR structure 
does not relay the pMHC readout into the cell than some other biophysical mechanism 
must. 
A few biophysical models exist to explain differences in TCR triggering and 
downstream T cell outcome.  The kinetic model proposes that the level of T cell 
activation is dependent on the dissociation rate of the TCR-pMHC interaction; slower 
off-rate equals greater signal.  Due to the two sets of signals required for full T cell 
activation the kinetic model proposes that the TCR-pMHC must be engaged long enough 
for both the first TCR initiated signal and the co-stimulatory signal to occur (McKeithan, 
1995; Rabinowitz et al., 1996).  This kinetic correlation has been supported by a number 
of experimental observations (Kersh et al., 1998; Lyons et al., 1996; Matsui et al., 1994; 
Rosette et al., 2001).  Experiments with the class II MHC restricted 2B4 TCR measured 
lower affinities and faster dissociation rates when the TCR bound antagonist ligands 
compared to the agonist 2B4 target (Lyons et al., 1996).  A more recent refinement of this 
basic off-rate model combines off-rate with a measure of conformational change upon 
binding (ΔCp) to predict T cell stimulation (Krogsgaard et al., 2003). 
Another popular model is the affinity model, which states that T cell activation 
relates to the concentration or number of pMHC ligands engaged.  The affinity model is 
also supported by an abundance of experimental data, which all show a correlation 
between determined TCR-pMHC affinities and activation (Alam et al., 1996; Baker et al., 
2000; Buslepp et al., 2001; Garcia et al., 2001; Holler and Kranz, 2003; Miller et al., 
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2007; Schodin et al., 1996; Sykulev et al., 1994; Sykulev et al., 1998; Tian et al., 2007). 
Agonist versus antagonist response of the class I MHC restricted A6 T cell correlates 
with the determined affinities (Baker et al., 2000; Ding et al., 1999).  Another case 
supporting a correlation with affinity involves activation of the P14 T cell.  Recently, two 
independent laboratories have determined the affinity to be consistent with other agonist 
pMHC interactions, but the shortest half-life of any other agonist TCR-pMHC interaction 
(koff   >1 s-1) (Boulter et al., 2007; Tian et al., 2007).   
The serial triggering model attempts to explain the paradox of high specificity of 
TCR-pMHC with a low affinity interaction.  It does not compete with kinetic or affinity 
models, but rather incorporates them both.  Following ITAM phosphorylation the TCR-
CD3 complex is downregulated, or internalized, in the T cell.  Lanzavecchia and 
colleagues measured this internalization following stimulation by agonist pMHC 
(Valitutti et al., 1995).  They determined that a single pMHC complex could serially 
trigger ~200 TCR, due to the fast off-rate of TCR-pMHC binding.  Partial agonists were 
shown to downregulate fewer TCR, suggesting that there exists an optimum affinity and 
off-rate (or dwell time) that allows TCR triggering and pMHC complex recycling.  
Without a full TCR trigger, antagonists could actually inhibit downregulation of TCR. 
Finally this model suggests that there is a threshold of “triggered” TCRs needed in order 
to fully activate the cell (Lanzavecchia et al., 1999; Valitutti et al., 1995). 
Differences in kinetics or affinity should be able define the differences in 
response between agonist and antagonist peptides.  However, there is still no concensus 
on which mechanisms connect TCR-pMHC molecular recognition to T cell activation.  In 
an effort to address this, we undertook most extensive analysis of TCR-pMHC binding to 
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date.  We have evaluated the affects of 24 variants of an agonist and antagonist peptides.  
Most studies of this nature have only evaluated a handful of pMHC ligands and a single 
readout of T cell activation, where we will have measured T cell proliferation, 
cytotoxicity, and cytokine secretion.   
The work presented here attempts to answer if TCR-pMHC binding affinity or 
kinetics can be correlated with the T cell response measured against an agonist versus an 
antagonist pMHC ligand.  To address this we relied on the AHIII12.2 (AHIII) T cell 
system.  AHII is a murine T cell clone that recognizes class I H-2Db (Db) in complex with 
the synthetic peptide p1058 (FAPGFFPYL) and its variants (Loftus et al., 1997).  AHIII 
is interesting in that it also recognizes a xenogenic human class I MHC, HLA-A2.1 (A2), 
when presenting the peptide p1049 (ALFGFFPVL) (Henderson et al., 1993).  So, 
p1058/Db and p1049/A2 both produce an agonistic response in AHIII.  Interestingly, it 
was found that when p1058 is bound and presented by A2 it becomes antagonistic.  
Experiments using fluorescently labeled p1058/A2 tetramer also suggested that the AHIII 
TCR bound p1058/A2 with lower affinity than p1049/A2 (Buslepp et al., 2001).  
However, this affinity has never been directly measured. 
 We utilized surface plasmon resonance (SPR) to determine the affinity and 
kinetics of AHIII TCR binding to A2 complexed with a panel of 24 variants of p1058 and 
p1049 including wild-type.  Based on the previous AHIII activation data (Buslepp et al., 
2001), we find a trend between T cell activation and TCR-pMHC affinity.  We show that 
the binding constants determined are not affected by the ability of A2 to bind the peptide 
variants.  Additionally, analysis of the determined crystal structures of p1058/A2 
(Buslepp et al., 2001) and AHIII TCR bound to p1049/A2 (Buslepp et al., 2003b) 
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revealed an unforeseen relationship between position 3 and position 5 of the peptides.  
Finally, our analysis suggests that the AHIII TCR must undergo a structural 
rearrangement, or must dock in an alternate manner in order to bind antagonistic 
p1058/A2. 
 
3.3 MATERIALS AND METHODS 
3.3.1 Protein Production and Purification 
Soluble AHIII12.2 TCR was produced as previously described in Chapter 2 
(Miller et al., 2007).  Briefly, the ectodomains of AHIII TCR α and β chains were 
expressed as inclusion bodies in E. coli.  Purified inclusion bodies, previously dissolved 
in 8M Urea, were rapidly injected into a folding buffer optimized for the AHIII TCR at a 
concentration of 50 µg/ml.  After incubation for 36 hours at 10 °C and extensive dialysis 
against 0.1 M Urea and 50 mM Tris, pH 8, the native TCR was purified and concentrated 
by DE52 anion exchange (Whatman, Florham Park, NJ) followed by gel filtration 
chromatography (Phenomenex, Torrance, CA) on HPLC.  Purified AHIII TCR for SPR 
experiments was concentrated to 200 µM and stored at -80 °C.  Soluble AHIII TCR was 
tested for proper folding and activity through an ELISA using HLA-A2 tetramer made 
from streptavidin conjugated to horseradish peroxidase (Leinco Technologies, St. Louis 
MO).  Typical yield for each 1 L in vitro fold is about 3-5 mg of active TCR.  The P14 
TCR (Tian et al., 2007) that was used as a negative control and reference in the surface 
plasmon resonance experiments was produced and purified identically to the AHIII TCR.  
Similarly, soluble HLA-A2 was produced as inclusion bodies in E. coli and folded 
in vitro (Garboczi et al., 1992; Miller et al., 2007).  Peptides p1049 (ALWGFFPVL) and 
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p1058 (FAPGFFPYL) and their variants were synthesized by both the UNC Peptide 
Synthesis Facility (Chapel Hill, NC), or by our collaborators in the laboratory of Dr. 
Ettore Appella at the NIH (Bethesda, MD).  Peptide, β2m, and heavy chain were then 
injected in that order into a folding buffer optimized for in vitro folding class I MHC at a 
concentration of 50 µg/ml.  After incubation for 36 hours at 10 °C the folded pMHC was 
concentrated in an Amicon ultrafiltration cell (Millipore, Billerica, MA) and purified 
using gel filtration chromatography (Phenomenex) on HPLC.  The purified pMHC were 
concentrated to approximately 10 mg/ml and stored at -80°C.  Typical yield for each 1 L 
in vitro fold is about 5 mg of pMHC.  Two to four folds of each pMHC variant were 
necessary to obtain the amount of protein needed for surface plasmon resonance 
experiments. 
3.3.2 Surface Plasmon Resonance Experiments 
The day of each surface plasmon resonance (SPR) experiment the frozen stocks of 
the pMHC being tested was removed from -80 °C and rerun over the gel filtration column 
to remove any aggregates from the freeze-thaw process.  These pMHC were then 
extensively buffer-swapped with HBS-EP buffer (GE Healthcare, Piscataway, NJ) and 
concentrated to the concentrations listed here: p1049(A1G)/A2, 80 µM; p1049(A1F)/A2, 
240 µM; p1049(L2A)/A2, 80 µM; p1049(W3F)/A2, 320 µM; p1049(W3L)/A2, 270 µM; 
p1049(W3P)/A2, 210 µM; p1049(G4A)/A2, 300 µM; p1049(F5V)/A2, 200 µM; 
p1049(F5A)/A2, 250 µM; p1049(F6V)/A2, 200 µM; p1049(F6A)/A2, 300 µM; 
p1049(P7A)/A2, 200 µM; p1049(V8Y)/A2, 200 µM; p1049(V8A)/A2, 80 µM; 
p1049(L9A)/A2, 250 µM; p1049(A1F/V8Y)/A2, 300 µM; p1058/A2, 300 µM; 
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p1058(P3L)/A2, 320 µM; p1058(F1A/P3W)/A2, 360 µM; p1058(P3W/Y8V), 340 µM.  
Two fold dilutions then resulted eight to nine concentrations for SPR. 
SPR experiments were carried out on a Biacore 2000 (GE Healthcare, Piscataway, 
NJ).  Approximately 2000-4000 resonance units (RU) of H57-597, anti-TCR Cβ antibody 
(eBioscience), were covalently bound to a Biacore CM5 sensor chip (GE Healthcare, 
Piscataway, NJ) using standard amine coupling.  Soluble AHIII12.2 TCR was then added 
to the Ab at a concentration of 800 nM to generate 600–700 RU of bound TCR.  Soluble 
pMHC was injected onto the surface at a flow rate of 50 µl/min in a 30 second pulse.  
TCR and MHC were removed from the surface with 0.1 M Glycine, pH 2, and the 
procedure was repeated until three curves were obtained for the different concentrations 
of pMHC.  Curves obtained at each concentration were subtracted from a reference 
surface that contained immobilized P14 TCR as a negative control.  The P14 TCR was 
loaded to generate the same ΔRU as the AHIII TCR.  Data were processed using 
Scrubber 2.0 software (Center for Biomolecular Interaction Analysis, University of 
Utah).  The suitability of the fit was measured based on χ2 values and the appearance of 
residuals.  In all cases, χ2 was below 2, residuals were small and random, and the 
experimental curves visually matched the predicted curves. The data from each two-fold 
pMHC dilution series from each experiment were processed and fit separately and the 
resulting binding constants were then averaged.  The mean values and their respective 
errors are presented in Table 1. 
3.3.3 Peptide-MHC Affinity Assay 
 Peptide-A2 binding constants were determined by measuring surface stability of 
A2 varying concentrations of peptide as previously described (Buslepp et al., 2001; 
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Kuhns et al., 1999).  Briefly, 2.0 x 105 T2 cells (ATCC #CRL-1992) were incubated 
overnight in AIM V serum-free media (Invitrogen) at 37 °C in 5% CO2 in the presence of 
100 nM soluble β2m and variant peptides at concentrations ranging from 0.5 µM – 20 
µM.  Cells incubated in AIM V with a peptide (KTFGPIYKR) that binds HLA-Aw68 
(Collins et al., 1999), but not HLA-A2 were used a negative control.  Cells were then 
stained with PE conjugated BB7.2 anti-A2 monoclonal antibody (BD Pharmingen).  Cells 
were analyzed by flow cytometry, and the mean fluorescence intensity (MFI) was 
determined using Summit software (Beckman Coulter).  Equilibrium binding curves were 
fit to the MFI data to determine an EC50 for each peptide using GraphPad Prism software 
(La Jolla, CA). 
 
3.4 RESULTS 
3.4.1 Affects of Altered Peptide Ligands on Binding Paramters 
 The amino acid sequences of p1049 (ALWGFFPVL) and p1058 (FAPGFFPYL) 
are identical from positions 4-7 and at position 9.  From the previously determined 
structure of the AHIII TCR bound to p1049/A2 (Buslepp et al., 2003b) we know that the 
majority of the peptide-TCR contacts occur in middle of the peptide, especially with F5 
and F6.  Yet, the T cell response to these two peptides is opposite: agonistic toward 
p1049 and antagonistic toward p1058 (Buslepp et al., 2001).  To help elucidate the 
different mechanisms of recognition between these two targets, we assessed the binding 
of the AHIII TCR to p1058/A2, p1049/A2, and variants of each peptide.  We employed 
surface plasmon resonance, which can determine both the affinity and the kinetics of the 
interaction in the same experiment.  Surface plasmon resonance kinetic and equilibrium 
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binding sensorgram data and the curve fits are shown in Figure 1.  The calculated binding 
constants are presented in Table 1. 
 SPR data had been previously collected on wild-type p1049/A2, determining a 
dissociation constant (Kd) of 9 µM and an off-rate (koff) of 0.27 s-1 (see Table 2.1) (Miller 
et al., 2007).  Mutations in the 1049 peptide all result in a weaker affinity except for one, 
V8A, where the increase in affinity can be attributed to an order of magnitude longer off-
rate, 0.024 s-1, which can be clearly seen in Figure 1.  Not surprisingly, mutations of F5 
and F6, which make van der Waals interactions with the CDR2 and CDR3 loops of the 
TCR, result in substantially weaker binding.  The two surprising peptide positions that 
are significantly impacted by mutation are position 1 and position 3, both of which make 
no direct contact to the TCR.  The A1F mutation decreases the affinity by over 200 µM, 
and ΔG by almost 2 kcal/mol.  A conservative mutation at position 3 of Trp to Phe results 
in a Kd of 101 µM, but any smaller side chain substitution (Leu, Val, or Pro) at position 3 
results in a Kd greater than 300 µM.  Mutations at position 8 also affect binding in some 
unexpected ways.  The valine at position 8 in p1049 points up toward the TCR, and 
makes a hydrophobic interaction with a Trp97 on the CDR3β loop.  As mentioned above 
the V8A mutation results in a higher affinity and a substantially longer off-rate.  The V8T 
substitution is well tolerated, but then V8Y likely causes steric problems because of its 
relative size and has a deleterious affect on the affinity.  Importantly, the mutations A1F,  
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p1049(L2A) 
p1049(A1F) 
p1049(W3P) 
p1049(F5V) 
p1049(V8A) 
240 µM 
80 µM 
200 µM 
210 µM 
80 µM 
100 
 
W3P, and V8Y individually have deleterious effects on AHIII binding to p1049/A2, and 
together essentially mutate p1049 into p1058.  In fact, energetically these mutations add 
up to the difference between p1049/A2 and p1058/A2.  Using the data in Table 1, the 
p1049(V8Y) 
p1049(A1F/V8Y) 
p1058 
Figure 1.  SPR sensorgram data and resulting kinetic and equilibrium curve-fits.  AHIII TCR 
was immobilized on sensor chip using an anti-Cβ antibody (H57).  Peptide/A2 at varying 
concentrations were then injected.  SPR data was processed using Scrubber 2.0.  Highest injected 
concentration is stated on equilibrium binding curve.  Few mutations like p1049(L2A) have little 
affect on equilibrium binding and kinetics compared to wild-type.  The increased half-life of 
p1049(V8A) can be clearly seen in the data.  Most mutations at positions 1, 3, and in the middle of 
the peptide (5 and 6) have a deleterious affect on binding affinity and increase the off-rate.  This is 
evident in the weak binding signal, the sharp drop after the injection, and the equilibrium binding 
curves that never reach an upper limit.  
 
 
 
 
 
300 µM 
300 µM 
200 µM 
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ΔΔG for A1F, W3P, and V8Y is 4.88 kcal/mol, while the ΔΔG for p1049 to p1058 is 4.33 
kcal/mol.   
Combining these mutations has a dramatic impact, as seen by the constants 
determined for p1058/A2.  The estimated affinity of 20 mM, according to the kinetically 
determined Kd, confirms previous tetramer binding experiments that the suggested AHIII  
 
Peptide Sequence 
Equil. Kd 
(µM) 
ΔG 
(kcal/mol) 
σ  
 ΔG 
kon 
(M-1s-1) 
σ  
 kon 
koff 
(s-1) 
σ  
 koff 
t1/2 
(s) 
p1049 ALWGFFPVL 9.0 -6.88  30000  0.270  2.57 
p1049(A1G) GLWGFFPVL 24.0 -6.30 0.04 30653 8766 0.710 0.17 0.98 
p1049(A1F) FLWGFFPVL 217.3 -5.00 0.06 20800 4689 4.647 0.38 0.15 
p1049(L2A) AAWGFFPVL 17.9 -6.47 0.03 39300 3100 0.707 0.02 0.98 
p1049(W3F) ALFGFFPVL 101.0 -5.45 0.10 14417 2766 1.440 0.08 0.48 
p1049(W3L) ALLGFFPVL 482.0 -4.53 0.12 5850 212 2.850 0.49 0.24 
p1049(W3P) ALPGFFPVL 324.0 -4.79 0.26 4839 228 1.580 0.59 0.44 
p1049(G4A) ALWAFFPVL 387.3 -4.66 0.13 8733 1955 3.367 0.38 0.21 
p1049(F5V) ALWGVFPVL 359.7 -4.75 0.30 2321 961 0.753 0.14 0.92 
p1049(F5A) ALWGAFPVL 698.0 -4.31 0.08 754 394 1.102 0.17 0.63 
p1049(F6V) ALWGFVPVL 221.0 -4.99 0.10 3847 1748 0.807 0.23 0.86 
p1049(F6A) ALWGFAPVL 363.7 -4.70 0.12 8186 2905 2.900 0.72 0.24 
p1049(P7A) ALWGFFAVL 58.4 -5.77 0.03 37307 13327 2.233 0.87 0.31 
p1049(V8Y) ALWGFFPYL 42.5 -5.97 0.10 36733 3450 1.587 0.43 0.44 
p1049(V8T) ALWGFFPTL 12.3 -6.70 0.05 32533 2804 0.400 0.02 1.73 
p1049(V8A) ALWGFFPAL 1.5 -7.97 0.09 29194 1795 0.024 0.00 28.88 
p1049(L9A) ALWGFFPVA 15.4 -6.56 0.06 39167 1935 0.603 0.05 1.15 
p1049(A1F/V8Y) FLWGFFPYL 950.0 -4.31 0.70 3593 4112 2.250 1.77 0.31 
          
p1058 FAPGFFPYL 20000 -2.55 0.82 206 244 1.700 0.53 0.41 
p1058(P3L) FALGFFPYL 800000 -0.11 0.02 5 1 4.150 1.06 0.17 
p1058(F1A/P3W) AAWGFFPYL 406 -4.64 0.16 3387 707 1.387 0.21 0.50 
p1058(P3W/Y8V) FAWGFFPVL 3550 -3.53 0.71 768 935 2.047 0.25 0.34 
 
Table 1.  TCR-pMHC Binding Constants Determined by Surface Plasmon Resonance 
Constants were determined by fitting kinetic and equilibrium binding data shown in Figure 1 using 
Scrubber 2.0 software.  Data from each series of peptide/A2 injections were processed and fit 
individually and then averaged to determine a mean value for Kd, ΔG, kon, and koff.  Free energy was 
calculated using ΔG = -RTln(Ka).  The standard deviation (σ) from each mean is listed.  Half-life is 
calculated as t1/2 = (ln2)/koff.  The calculated kinetic affinity was within 5% of the equilibrium affinity 
for almost all experiments.  Equilibrium affinities could not be determined for peptides p1058 and 
p1058(P3L), so kinetic Kd and ΔG is shown.  Wild-type p1049 values from data in Chapter 2. 
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TCR binding to p1058/A2 was much weaker than p1049/A2 (Buslepp et al., 2001).  
Mutations made that turn p1058 into p1049 improves the affinity, as seen by 
p1058(P3W/Y8V)/A2 and p1058(F1A/P3W)/A2.  The fact that the F1A/P3W  
mutation jumps to an affinity around 400 µM compared to P3W/Y8V, which stays above 
1 mM, suggests that tyrosine at position 8 is tolerated by AHIII better than phenylalanine 
at position 1.  This is further supported by the p1049 double mutant, A1F/V8Y, which 
has a calculated affinity of almost 1 mM.   
In general mutants with lowered affinities also displayed increased off-rates.  
Mutations F5V and F6V, however, have only a slight increase in off-rate considering the 
determined affinities are greater than 300 µM and 200 µM, respectively.  Similarly, 
mutants with decreased affinity also had slower on-rates, as shown by both p1049 and 
p1058 variants.  The increased time required to bind these altered peptide ligands might 
reflect some conformational change that must occur prior to TCR-pMHC binding.  
3.4.2 Peptide-MHC Binding  
 It is important to verify that the changes reflected in the binding constants 
determined by surface plasmon resonance (SPR) for all altered peptide ligands are due to 
differences in TCR-pMHC binding and not peptide-MHC binding.  Interpretation of the 
SPR data assumes that mutations in the peptide do not affect peptide-MHC binding.  To 
evaluate if the peptide mutations have any affect on peptide-MHC binding, we 
determined the peptide-MHC binding constants by measuring the pMHC complex 
stability on the surface of T2 cells.  T2 cells express high levels of surface class I HLA-
A2, yet are TAP deficient, which inhibits peptide-loading into the MHC while in the 
endoplasmic reticulum (Salter et al., 1985).  MHC without a peptide is very unstable and  
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(a) 
(b) 
Figure 2.  TCR-pMHC binding does not correlate with peptide binding to HLA-A2.  (a) A2 
expressing T2 cells were incubated overnight with peptide variants at various concentrations, and were 
stained with BB7.2 and analyzed flow cytometry.  A peptide that binds Aw68 but not A2 was used as a 
negative control.  (b) A scattergram of calculated EC50 for each peptide-A2 versus the determined 
AHIII-peptide/A2 affinities shows the lack of correlation (R2 = 0.025). 
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surface half-lives are very short.  By using T2 cells we can load peptide exogenously and 
study the stability of the peptide-A2 complex of any peptide.   
All peptides listed in Table 1 were incubated with T2 cells and surface peptide-A2 
levels were evaluated using flow cytometry.  The tighter the peptide-MHC interaction, 
the more stable surface A2 will be, and the resulting mean fluorescence intensity (MFI) 
will be higher.  Peptide titration curves are presented in Figure 2a.  An influenza peptide, 
np91(G3F) (KTFGPIYKR), that binds to the HLA-Aw68 MHC (Collins et al., 1999) but 
not A2, was used as a negative control and provides a MFI baseline of approximately 
200.  The weakest binding peptide was p1058.  This is not too surprising as two out of 
three MHC anchor residues for A2 (reviewed in section 1.2.2) are not ideal in p1058 (Ala 
at position 2 and Pro at position 3).  These two mutations in p1049 (L2A and W3P) also 
drastically affect p1049 binding to A2, bringing their MFIs close to those of p1058 
(Figure 2a). 
An EC50 for each peptide titration curve was determined by fitting the data to an 
equilibrium binding curve (data not shown).  The EC50 is effectively the peptide-MHC 
binding affinity.  The determined EC50 for each peptide was plotted against the TCR-
pMHC binding affinity values listed in Table 1 (Figure 2b).  With a resulting correlation 
coefficient of 0.025, we can confidently state that the binding constants determined by 
SPR for TCR-pMHC do not correlate with the ability of the peptide variants to bind to 
A2. 
3.4.3 Structural Prediction of AHIII TCR Docking on p1058/A2 
 So, why is AHIII TCR binding to these peptides so greatly affected by the peptide 
residues at positions 1, 3, and 8?  The AHIII TCR does not even contact the p1049 
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peptide at positions 1 and 3, and makes a single weak van der Waals contact with 
position 8 (Buslepp et al., 2003b).  While the co-crystal structure of AHIII-p1058/A2 is 
unknown, the apo structure of p1058/A2 has been determined (Buslepp et al., 2001).  We 
superimposed the p1058/A2 structure onto the complex structure of AHIII-p1049/A2  
(Buslepp et al., 2003b) (Figure 3) in attempt to explain the binding data we obtained in 
Table 1.  The structures were superimposed using the “align” feature in PyMol (DeLano, 
2002) restricting the alignment to the Cα of the peptide-binding cleft of the MHC. 
  Overall, the structure of the A2 MHC is identical (Figure 3a).  Even though the 
sequence of the peptides is different, primarily at the N and C termini, the peptide 
backbone orientation is virtually unchanged.  The only difference is seen within the side 
chains.  When we take a look at position 1 of the peptide in relation to the AHIII TCR, it 
becomes clear why the A1F mutation in p1049 (and F1 in p1058) is so deleterious 
(Figure 3b).  The Cε2 and Cζ atom of phenylalanine are less than 2.4 Å from the Cα and 
Cβ of Ser99 on the AHIII CDR3α, as well as Cζ being 2.1 Å from the backbone oxygen 
of Ser99.  The phenylalanine has no other rotamer options available due to the location of 
MHC residues, especially Trp167.  This suggests that the CDR3α loop must undergo 
some structural rearrangement to accommodate Phe at position 1.  However, this “new 
conformation” is not likely to be as energetically favorable, hence the decrease in 
affinity.   
 Figure 3c shows the C-terminal end of the peptides and in particular, position 8.  
A Tyr at position 8 in its current orientation would be too close for the CDR3β loop of 
AHIII to maintain the same position.  However, as shown by the binding data in Table 1,  
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 P1 
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Figure 3. (legend on next page) 
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this residue is more easily accommodated than Phe1.  This accommodation may occur 
through a slight movement of the CDR3β loop, the Trp97 on that loop, or perhaps a 
rotation about χ2 in Tyr8 itself to make a stacking interaction with Trp97.  Asp30 on the 
CDR2β loop is also positioned close enough to provide a hydrogen-bonding partner with 
the hydroxyl on Tyr8 with little rearrangement.  It is difficult to surmise any mechanism 
for the increased affinity and slower off-rate for the V8A mutation in p1049 based on the 
superimposition in Figure 3c. 
 Figure 3d helps demonstrate the critical role of F5 in p1049.  It is involved in a 
number of van der Waals interactions with both CDR3 α and β loops.  When the Trp in 
position 3 is removed either in p1058 (cyan) or p1049 mutants, the Phe at position 5 is 
recruited to fill the void, removing it from the TCR binding surface.  A bulky 
hydrophobic residue at position 3 is critical for peptide binding to A2.  Figures 3e and 3f 
clearly show the binding pocket filled by the Trp at position 3 in p1049 and how F5 
swings down into it with p1058.  This analysis suggests that a mutation placing a small 
side chain at position 3 simultaneously removes F5 from the TCR binding surface.  
Hence, the dramatic affects on binding data in Table 1 when position 3 is altered. 
Figure 3.  AHIII TCR cannot dock p1058/A2 in same manner as p1049/A2.  The previously 
determined structures of p1058/A2 (cyan) alone (1I7R) is superimposed onto AHIII - p1049/A2 
(magenta) complex (1LP9).  (a) A2 MHC forces both peptides into same backbone conformation, 
difference occur only in peptide side chains.  (b) Phe at position 1 (F1) of p1058 would clash with 
ΑΗΙΙΙ CDR3α (grey) if the TCR had the same conformation as when docked on p1049/A2.  Other 
rotamer positions for F1 are not available due to local A2 MHC structure including W167.  The 
CDR3α must change conformation or the TCR must dock differently.  (c) The AHIII TCR as it binds 
p1049/A2 clashes with Tyr (Y8) of p1058.  Y8 must take a different rotamer to avoid W97 of AHIII 
CDR3β (grey), or the TCR must bind in a different manner.  (d) Phe (F5) of p1049 is involved in 
numerous van der Waals interactions with AHIII TCR.  However, F5 of 1058 is forced to fill void left 
by removal of Trp at position 3, impeding interactions with the TCR.  (e) Surface of A2 (grey) with 
p1049 shows L2, W3, and L9 filling peptide-binding pockets.  F5 is available to interact with AHIII 
TCR.  (f) Surface of A2 with p1058 clearly shows how F5 side chain is necessary to fill pocket and can 
no longer engage TCR.  All figures were generated using PyMol (DeLano, 2002). 
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3.5 DISCUSSION 
We present here a large body of TCR-pMHC binding data, which is the 
biophysical half of a larger study including biological T cell responses to these p1049 and 
p1058 chimeras.  Previous work by Buslepp et al. suggested that mutations turning p1049 
into p1058 made the peptide less and less of an agonist until it became antagonistic 
(Buslepp et al., 2001).  That work included only a T cell lysis assay and an estimation of 
AHIII-peptide/A2 binding using pMHC tetramer.  Here we have directly measured the 
affinity and the kinetics of the AHIII TCR binding to an extended panel of p1049 and 
p1058 variants presented in A2 using surface plasmon resonance (SPR).  There seems to 
be a general correlation between low affinity binding and those peptides previously 
defined as antagonistic.  However, it is still unclear how the antagonism is manifest by 
signaling inside the cell. 
 Peptide binding to various MHC allotypes including HLA-A2 has been studied 
extensively (reviewed in section 1.2).  Each MHC allotype has unique binding pockets 
that prefer certain peptide side chains.  For peptides binding to A2 the primary anchor 
residues occur at P2 and P9, with secondary anchors at P1, P3, and P7.  P3 needs to be a 
large aromatic side chain to fill the large C-pocket in A2 (Falk et al., 1991; Ruppert et al., 
1993).  As we saw from our SPR experiments mutations at P1, P2, P3, P7, and P9 all had 
affects on AHIII-peptide/A2 binding.  To ensure that the change in binding constants 
were only due to the effect the mutation had on the AHIII TCR binding and not due to the 
peptide binding to HLA-A2, we evaluated the ability of each peptide variant to bind A2.  
We found that p1049 variants at P1, P7, and P9 had no effect on the peptide binding to 
A2.  Mutations at P2 and P3 were somewhat deleterious on peptide-A2 binding, but 
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binding of those mutants was still much stronger than the control peptide.  The mean 
fluorescence intensities at varying concentrations allowed us to determine an EC50 for 
each peptide.  Plotting these against the calculated AHIII-peptide/MHC affinities 
determined by SPR showed that there is no correlation between them.  Therefore, we are 
confident that our binding constants presented in Table 1 represent the effect of the 
mutations on the AHIII TCR binding. 
The crystal structure of p1058/A2 had been previously determined (Buslepp et al., 
2001) in an effort to explain the antagonistic effects of the 1058 peptide presented in A2.  
However, as this was before the co-crystal structure of AHIII-p1049/A2 (Buslepp et al., 
2003b) had been determined, it was difficult to interpret the consequences of changes 
seen in the p1058/A2 structure.  As part of this body of work, we superimposed the 
structure of p1058/A2 onto the complex of AHIII-p1049/A2, and were able to get a much 
clearer idea of the impact that p1058 and p1049 variants have on the AHIII TCR upon 
binding.  Peptide positions 1 and 3 in p1058 are particularly deleterious.  Phe at position 
1 cannot be accommodated by the AHIII TCR is its p1049/A2 conformation.  Altering 
the Trp at position 3 also has the unexpected consequence of a compensatory movement 
of the Phe at position 5 to fill the pocket, thus removing it from the TCR binding surface.  
F5 is critical, as it makes a number of hydrophobic contacts to the CDR3 loops of both 
the TCR alpha and beta chains.   
The only other structural study comparing a TCR docking on an agonist 
peptide/MHC versus two different antagonist peptide/MHC found no differences in the 
TCR between the two co-crystal structures in one, and a small change in the CDR3β loop 
of A6 in the other (Ding et al., 1999).  Our analysis presented above suggests that a 
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conformational change or alternate docking mode is required for AHIII binding to 
p1058/A2 and to some of the “p1058-like” p1049 variants.  However, we do not suggest 
that the conformational change has anything to do with T cell signaling, but more to do 
with CDR loop movements affecting binding.  The requirement for a conformational 
change is further supported by slower on-rates determined for these peptides.  A 
conformational change in the TCR required for binding has certainly been seen before for 
other TCR binding even their agonistic cognate peptide/MHC (Degano et al., 2000; 
Garcia et al., 1998; Kjer-Nielsen et al., 2003; Reiser et al., 2002), and movement has also 
been seen in the peptide itself (Tynan et al., 2007).  However, without determining the 
co-crystal structure of AHIII-p1058/A2, it is impossible to be certain where the 
conformational change occurs.   
The molecular events occurring upon substitution at position 8 of the peptides is 
also very interesting, and unfortunately not much information can be gleaned from the 
superimposed structures above.  Exactly how does the V8A mutation in p1049 make the 
TCR-pMHC interaction so stable?  As a continuation of this project, attempts at co-
crystallization of the AHIII TCR bound to p1049(V8A)/A2 are underway.  As this 
complex has a higher affinity and longer half-life than any other AHIII-p1409/A2 
interaction measured, we are confident that we will be able to co-crystallize these 
molecules and determined the structure using molecular replacement.  Aside from the 
crystal structure, isothermal titration calorimetry (ITC) will be used to evaluate changes 
to the enthalpy and entropy of binding in AHIII-p1049(V8A)/A2.  We have previously 
used ITC to verify the loss of H-bonds upon the K66A mutation in A2 (see Chapter 2) 
(Miller et al., 2007).  Even without the co-crystal structure, changes in ΔH and ΔS 
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between the wild-type complex and the V8A mutant will provide energetic details about 
how the AHIII-p1049(V8A)/A2 interaction achieves such tight binding and slow off-rate.  
Performing ITC or SPR experiments at various temperatures allows for the determination 
of the change in heat capacity (ΔCp) upon binding, which has been used as a means to 
estimate conformational change taking place upon TCR-pMHC binding (Anikeeva et al., 
2003; Armstrong and Baker, 2007; Boulter et al., 2007; Ely et al., 2006; Garcia et al., 
2001; Krogsgaard et al., 2003; Lee et al., 2004; Mazza et al., 2007).  As there is still no 
crystal structure of the AHIII TCR alone, determining the ΔCp of AHIII binding to 
p1049/A2 and some p1049/A2 mutants including p1049(V8A) may provide more insight 
into the degree of conformational change that occurs. 
The results presented in this chapter may also suggest something interesting 
regarding how the CDR loops are involved in AHIII-p1049/A2 molecular recognition.  
Chapter 2 focused on mutations made in the TCR binding surface of the A2 MHC and 
their effect on the TCR.  While SPR data was presented for only three MHC mutants, 
data had been collected for an entire panel of MHC mutants.  The A2(K66A) mutant had 
the worst binding affinity to the AHIII TCR of any of the mutants.  We showed that the 
K66A mutation resulted in a conformational change in the CDR3α loop, eliminated a 
number of hydrogen bonds.  Yet, the determined TCR-pMHC dissociation constant (Kd) 
was still approximately 30 µM.  The data presented in this chapter involve mutations 
made in the peptides presented by A2.  All the mutations to peptide residues between 
position 3 and position 7 result in binding affinities worse than that of the K66A mutation 
in A2.  Any amino acid substitution at P3 through P6 results in a Kd of greater than 100 
µM.  This says that the contacts made between the AHIII TCR CDR3 loops and the 
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p1049 peptide are more critical than the contacts made to the A2 MHC.  While the entire 
pMHC surface is recognized by the CDR loops of TCR, the discriminatory power of the 
TCR between agonist and antagonist comes from the interaction of CDR3 loops with the 
peptide. 
As mentioned above, the work presented here will be combined with biological 
data looking at the T cell response to these same peptides presented in A2.  T cell 
proliferation, cytokine secretion, and T cell killing will all be evaluated and correlated 
with the binding constants presented here.  Importantly, the experiments involving these 
biological assays will done using AHIII T cells from the AHIII12.2 transgenic mouse 
recently generated by our collaborators in the laboratory of Dr. Ettore Appella at the NIH 
(Bethesda, MD).  This has the advantage of having naïve AHIII T cells, and being able to 
use them directly ex vivo for functional experiments, providing a better measure of what 
might be occurring in vivo.  Previous studies evaluating the biological outcome of AHIII 
T cells (Buslepp et al., 2003a; Buslepp et al., 2001; Loftus et al., 1997; Miller et al., 
2007) used immortalized AHIII T cell lines coming form the original AHIII12.2 clone 
discovered in 1987 (Bernhard et al., 1987).  These cells have been passaged for weeks, if 
not months at a time, continually being in vitro stimulated with irradiated splenocytes, 
and, of course, frozen and thawed.  While they have provided information in the past, it is 
ideal to start with naïve T cells directly from the mouse. 
This will be the most comprehensive analysis of TCR-pMHC binding and 
resultant T cell activation to date; over 20 different peptides evaluated using SPR and 
three separate aspects of T cell activation.  Based on previously published (Chapter 2) 
(Buslepp et al., 2001; Miller et al., 2007) and preliminary data, we expect to see CTL 
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killing with p1049 and its variants the correlate with affinity.  The antagonistic ability of 
p1058 should also increase as affinity decreases.  As antagonistic peptides have been 
shown to have a differential cytokine profile of decreased IL-2 production, but normal 
IFNγ secretion (Schwartz, 2003), we expect to see this profile for p1058.   Similarly, we 
expect no proliferation of AHIII T cells exposed to antagonist peptides.   
114 
3.6 REFERENCES 
Alam S. M., Travers P. J., Wung J. L., Nasholds W., Redpath S., Jameson S. C. and 
Gascoigne N. R. (1996) T-cell-receptor affinity and thymocyte positive selection. 
Nature 381, 616-20. 
 
Anikeeva N., Lebedeva T., Krogsgaard M., Tetin S. Y., Martinez-Hackert E., Kalams S. 
A., Davis M. M. and Sykulev Y. (2003) Distinct molecular mechanisms account 
for the specificity of two different T-cell receptors. Biochemistry 42, 4709-16. 
 
Armstrong K. M. and Baker B. M. (2007) A comprehensive calorimetric investigation of 
an entropically driven T cell receptor-peptide/major histocompatibility complex 
interaction. Biophys J 93, 597-609. 
 
Armstrong K. M., Insaidoo F. K. and Baker B. M. (2008) Thermodynamics of T-cell 
receptor-peptide/MHC interactions: progress and opportunities. J Mol Recognit 
21, 275-287. 
 
Baker B. M., Gagnon S. J., Biddison W. E. and Wiley D. C. (2000) Conversion of a T 
cell antagonist into an agonist by repairing a defect in the TCR/peptide/MHC 
interface: implications for TCR signaling. Immunity 13, 475-84. 
 
Bernhard E. J., Le A. X., Yannelli J. R., Holterman M. J., Hogan K. T., Parham P. and 
Engelhard V. H. (1987) The ability of cytotoxic T cells to recognize HLA-A2.1 or 
HLA-B7 antigens expressed on murine cells correlates with their epitope 
specificity. J Immunol 139, 3614-21. 
 
Bongrand P. and Malissen B. (1998) Quantitative aspects of T-cell recognition: from 
within the antigen-presenting cell to within the T cell. Bioessays 20, 412-22. 
 
Boulter J. M., Schmitz N., Sewell A. K., Godkin A. J., Bachmann M. F. and Gallimore A. 
M. (2007) Potent T cell agonism mediated by a very rapid TCR/pMHC 
interaction. Eur J Immunol 37, 798-806. 
 
Buslepp J., Kerry S. E., Loftus D., Frelinger J. A., Appella E. and Collins E. J. (2003a) 
High affinity xenoreactive TCR:MHC interaction recruits CD8 in absence of 
binding to MHC. J Immunol 170, 373-83. 
 
Buslepp J., Wang H., Biddison W. E., Appella E. and Collins E. J. (2003b) A correlation 
between TCR Valpha docking on MHC and CD8 dependence: implications for T 
cell selection. Immunity 19, 595-606. 
 
Buslepp J., Zhao R., Donnini D., Loftus D., Saad M., Appella E. and Collins E. J. (2001) 
T cell activity correlates with oligomeric peptide-major histocompatibility 
complex binding on T cell surface. J Biol Chem 276, 47320-8. 
115 
Chen Y. Z., Lai Z. F., Nishi K. and Nishimura Y. (1998) Modulation of calcium 
responses by altered peptide ligands in a human T cell clone. Eur J Immunol 28, 
3929-39. 
 
Collins E. J., Booth B. L., Jr. and Cerundolo V. (1999) Extensive alanine substitutions 
increase binding affinity of an influenza nucleoprotein peptide to HLA-Aw68 and 
do not abrogate peptide-specific CTL recognition. J Immunol 162, 331-7. 
 
Degano M., Garcia K. C., Apostolopoulos V., Rudolph M. G., Teyton L. and Wilson I. A. 
(2000) A functional hot spot for antigen recognition in a superagonist TCR/MHC 
complex. Immunity 12, 251-61. 
 
DeLano W. L. (2002) The PyMOL Molecular Graphics System. DeLano Scientific, San 
Carlos, CA, USA. 
 
Ding Y. H., Baker B. M., Garboczi D. N., Biddison W. E. and Wiley D. C. (1999) Four 
A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are 
nearly identical. Immunity 11, 45-56. 
 
Ely L. K., Beddoe T., Clements C. S., Matthews J. M., Purcell A. W., Kjer-Nielsen L., 
McCluskey J. and Rossjohn J. (2006) Disparate thermodynamics governing T cell 
receptor-MHC-I interactions implicate extrinsic factors in guiding MHC 
restriction. Proc Natl Acad Sci U S A 103, 6641-6. 
 
Falk K., Rotzschke O., Stevanovic S., Jung G. and Rammensee H. G. (1991) Allele-
specific motifs revealed by sequencing of self-peptides eluted from MHC 
molecules. Nature 351, 290-6. 
 
Garboczi D. N., Hung D. T. and Wiley D. C. (1992) HLA-A2-peptide complexes: 
refolding and crystallization of molecules expressed in Escherichia coli and 
complexed with single antigenic peptides. Proc Natl Acad Sci U S A 89, 3429-33. 
 
Garcia K. C., Degano M., Pease L. R., Huang M., Peterson P. A., Teyton L. and Wilson I. 
A. (1998) Structural basis of plasticity in T cell receptor recognition of a self 
peptide-MHC antigen. Science 279, 1166-72. 
 
Garcia K. C., Radu C. G., Ho J., Ober R. J. and Ward E. S. (2001) Kinetics and 
thermodynamics of T cell receptor- autoantigen interactions in murine 
experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 98, 6818-
23. 
 
Garcia-Peydro M., Paradela A., Albar J. P. and Castro J. A. (2000) Antagonism of direct 
alloreactivity of an HLA-B27-specific CTL clone by altered peptide ligands of its 
natural epitope. J Immunol 165, 5680-5. 
 
116 
Henderson R. A., Cox A. L., Sakaguchi K., Appella E., Shabanowitz J., Hunt D. F. and 
Engelhard V. H. (1993) Direct identification of an endogenous peptide recognized 
by multiple HLA-A2.1-specific cytotoxic T cells. Proc Natl Acad Sci U S A 90, 
10275-9. 
 
Holler P. D. and Kranz D. M. (2003) Quantitative analysis of the contribution of 
TCR/pepMHC affinity and CD8 to T cell activation. Immunity 18, 255-64. 
 
Kersh G. J., Kersh E. N., Fremont D. H. and Allen P. M. (1998) High- and low-potency 
ligands with similar affinities for the TCR: the importance of kinetics in TCR 
signaling. Immunity 9, 817-26. 
 
Kjer-Nielsen L., Clements C. S., Purcell A. W., Brooks A. G., Whisstock J. C., Burrows 
S. R., McCluskey J. and Rossjohn J. (2003) A structural basis for the selection of 
dominant alphabeta T cell receptors in antiviral immunity. Immunity 18, 53-64. 
 
Krogsgaard M., Prado N., Adams E. J., He X. L., Chow D. C., Wilson D. B., Garcia K. 
C. and Davis M. M. (2003) Evidence that structural rearrangements and/or 
flexibility during TCR binding can contribute to T cell activation. Mol Cell 12, 
1367-78. 
 
Kuhns J. J., Batalia M. A., Yan S. and Collins E. J. (1999) Poor binding of a HER-2/neu 
epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the 
peptide. J Biol Chem 274, 36422-7. 
 
Lanzavecchia A., Lezzi G. and Viola A. (1999) From TCR engagement to T cell 
activation: a kinetic view of T cell behavior. Cell 96, 1-4. 
 
Lau L. L., Jiang J. and Shen H. (2005) In vivo modulation of T cell responses and 
protective immunity by TCR antagonism during infection. J Immunol 174, 7970-
6. 
 
Lee J. K., Stewart-Jones G., Dong T., Harlos K., Di Gleria K., Dorrell L., Douek D. C., 
van der Merwe P. A., Jones E. Y. and McMichael A. J. (2004) T cell cross-
reactivity and conformational changes during TCR engagement. J Exp Med 200, 
1455-66. 
 
Loftus D. J., Chen Y., Covell D. G., Engelhard V. H. and Appella E. (1997) Differential 
contact of disparate class I/peptide complexes as the basis for epitope cross-
recognition by a single T cell receptor. J Immunol 158, 3651-8. 
 
Lyons D. S., Lieberman S. A., Hampl J., Boniface J. J., Chien Y., Berg L. J. and Davis 
M. M. (1996) A TCR binds to antagonist ligands with lower affinities and faster 
dissociation rates than to agonists. Immunity 5, 53-61. 
 
117 
Madrenas J. and Germain R. N. (1996) Variant TCR ligands: new insights into the 
molecular basis of antigen-dependent signal transduction and T-cell activation. 
Semin Immunol 8, 83-101. 
 
Matsui K., Boniface J. J., Steffner P., Reay P. A. and Davis M. M. (1994) Kinetics of T-
cell receptor binding to peptide/I-Ek complexes: correlation of the dissociation 
rate with T-cell responsiveness. Proc Natl Acad Sci U S A 91, 12862-6. 
 
Mazza C., Auphan-Anezin N., Gregoire C., Guimezanes A., Kellenberger C., Roussel A., 
Kearney A., van der Merwe P. A., Schmitt-Verhulst A. M. and Malissen B. 
(2007) How much can a T-cell antigen receptor adapt to structurally distinct 
antigenic peptides? EMBO J 26, 1972-83. 
 
McKeithan T. W. (1995) Kinetic proofreading in T-cell receptor signal transduction. 
Proc Natl Acad Sci U S A 92, 5042-6. 
 
Miller P. J., Pazy Y., Conti B., Riddle D., Appella E. and Collins E. J. (2007) Single 
MHC mutation eliminates enthalpy associated with T cell receptor binding. J Mol 
Biol 373, 315-27. 
 
Rabinowitz J. D., Beeson C., Lyons D. S., Davis M. M. and McConnell H. M. (1996) 
Kinetic discrimination in T-cell activation. Proc Natl Acad Sci U S A 93, 1401-5. 
 
Reis e Sousa C., Levine E. H. and Germain R. N. (1996) Partial signaling by CD8+ T 
cells in response to antagonist ligands. J Exp Med 184, 149-57. 
 
Reiser J. B., Gregoire C., Darnault C., Mosser T., Guimezanes A., Schmitt-Verhulst A. 
M., Fontecilla-Camps J. C., Mazza G., Malissen B. and Housset D. (2002) A T 
cell receptor CDR3beta loop undergoes conformational changes of unprecedented 
magnitude upon binding to a peptide/MHC class I complex. Immunity 16, 345-54. 
 
Rosette C., Werlen G., Daniels M. A., Holman P. O., Alam S. M., Travers P. J., 
Gascoigne N. R., Palmer E. and Jameson S. C. (2001) The impact of duration 
versus extent of TCR occupancy on T cell activation: a revision of the kinetic 
proofreading model. Immunity 15, 59-70. 
 
Rudolph M. G., Stanfield R. L. and Wilson I. A. (2006) How TCRs bind MHCs, 
peptides, and coreceptors. Annu Rev Immunol 24, 419-66. 
 
Ruppert J., Sidney J., Celis E., Kubo R. T., Grey H. M. and Sette A. (1993) Prominent 
role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. 
Cell 74, 929-37. 
 
Salter R. D., Howell D. N. and Cresswell P. (1985) Genes regulating HLA class I antigen 
expression in T-B lymphoblast hybrids. Immunogenetics 21, 235-46. 
 
118 
Schodin B. A., Tsomides T. J. and Kranz D. M. (1996) Correlation between the number 
of T cell receptors required for T cell activation and TCR-ligand affinity. 
Immunity 5, 137-46. 
 
Schwartz R. H. (2003) T cell anergy. Annu Rev Immunol 21, 305-34. 
 
Sloan-Lancaster J., Evavold B. D. and Allen P. M. (1993) Induction of T-cell anergy by 
altered T-cell-receptor ligand on live antigen-presenting cells. Nature 363, 156-9. 
 
Sykulev Y., Brunmark A., Jackson M., Cohen R. J., Peterson P. A. and Eisen H. N. 
(1994) Kinetics and affinity of reactions between an antigen-specific T cell 
receptor and peptide-MHC complexes. Immunity 1, 15-22. 
 
Sykulev Y., Vugmeyster Y., Brunmark A., Ploegh H. L. and Eisen H. N. (1998) Peptide 
antagonism and T cell receptor interactions with peptide-MHC complexes. 
Immunity 9, 475-83. 
 
Tian S., Maile R., Collins E. J. and Frelinger J. A. (2007) CD8+ T cell activation is 
governed by TCR-peptide/MHC affinity, not dissociation rate. J Immunol 179, 
2952-60. 
 
Tynan F. E., Reid H. H., Kjer-Nielsen L., Miles J. J., Wilce M. C., Kostenko L., Borg N. 
A., Williamson N. A., Beddoe T., Purcell A. W., Burrows S. R., McCluskey J. 
and Rossjohn J. (2007) A T cell receptor flattens a bulged antigenic peptide 
presented by a major histocompatibility complex class I molecule. Nat Immunol 
8, 268-76. 
 
Uhlin M., Masucci M. and Levitsky V. (2006) Is the activity of partially agonistic 
MHC:peptide ligands dependent on the quality of immunological help? Scand J 
Immunol 64, 581-7. 
 
Valitutti S., Muller S., Cella M., Padovan E. and Lanzavecchia A. (1995) Serial 
triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 
375, 148-51. 
 
Vukmanovic S., Neubert T. A. and Santori F. R. (2003) Could TCR antagonism explain 
associations between MHC genes and disease? Trends Mol Med 9, 139-46. 
 
 
 
 
 
 
CHAPTER 4 
 
Rapid Production of Soluble Recombinant TCR from 
 Singly Isolated T cells 
 
 
4.1 ABSTRACT 
 Cytotoxic T cell (CTL) response to self and non-self peptides presented in the 
context of the MHC molecule (pMHC) relies on the molecular recognition of those 
pMHC ligands by the T cell receptor (TCR).  After years of study it is still unclear 
exactly how the TCR can discriminate between self and non-self.  There are an estimated 
108 clonal T cells in the body, each with a unique TCR, but most of what we know about 
TCR-pMHC binding is based on the study of only two dozen T cell receptors.  The 
paucity of TCRs studied may be due to the fact that the task of isolating a T cell specific 
for a particular pMHC target, determing the DNA sequences of its αβTCR, and 
recombinantly expressing its TCR for in vitro study, is technically arduous and time 
consuming, taking months to years.  To be able to answer fundamental questions about 
TCR-pMHC recognition that still exist, and identify and produce TCR that could be used 
as potential therapeutics, the rate of TCR identification and production needs to increase.  
We present here a TCR production scheme that allows for the production of soluble, 
recombinant TCR from singly isolated T cells in less than two months. 
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4.2 INTRODUCTION 
Cytotoxic T lymphocytes (CTL), or CD8+ T cells, are a critical component of the 
adaptive immune response to infection.  They are required for the elimination of infected 
host cells, which are harboring virus or intracellular bacteria.  The critical step required 
for T cell activation is the recognition of peptides derived from these pathogens when 
presented by the Major Histocompatibility Complex (MHC) molecule.  Recognition of 
foreign peptide, or antigen, bound to MHC is achieved through the clonotypic T cell 
receptor (TCR).  Upon TCR recognition of a peptide bound to MHC (pMHC) cytotoxic T 
cells kill the antigen presenting cell, thereby eliminating the means for pathogen 
replication.  Recognition of pMHC by the TCR heterodimer is accomplished using the 
three complementarity determining region (CDR) loops from each chain.  The CDR1 and 
CDR2 loops are germ-line encoded within the variable gene segment of each TCRα and 
TCRβ chain.  The CDR3 loop of each chain is unique and arises through V(D)J 
recombination (Schatz and Spanopoulou, 2005; Spicuglia et al., 2006).  While 
recognition of the pMHC is carried out using all the CDR loops of each chain, generally 
the CDR3 makes more contacts with the bound peptide than CDR1 and CDR2 (Rudolph 
et al., 2006).   
Considering the immense number of T cells generated in the body and the 
subsequent unique clonal TCR on those T cells (estimated 108), relatively few clones 
have been isolated for study.  Only 23 unique TCR have been studied structurally 
(presented in Chapter 1).  All the models we have regarding TCR-pMHC engagement 
and subsequent T cell activation, or inactivation, rely in some way on these few 
structures.  Fundamental questions surrounding TCR-pMHC interactions still exist, such 
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as: how a TCR discriminates between a self and non-self pMHC ligand, whether 
conserved TCR-pMHC contacts exist, and why the TCR seems to dock all pMHC 
molecules in a canonical diagonal orientation.  To accurately answer these questions a 
greater number of structural studies involving new and disparate TCR are required.  
Clinically, isolation of a T cell clone specific for an antigenic peptide-MHC followed by 
rapid production and purification of that TCR is essential to realistically use recombinant 
TCR for diagnostic or therapeutic purposes (Abad et al., 2008; Johnson et al., 2006; Zhao 
et al., 2007).   
Traditionally, T cell clones are isolated using multiple rounds of limiting dilution 
followed by clonal expansion (Engelhard and Benjamin, 1982).  This techniques has two 
drawbacks: 1) it takes months and consumes lots of money for reagents, media, and cells 
for in vitro stimulation; 2) the population of T cells that actually survive and can grow 
under these conditions may not be a good representation of the original T cell population.  
Once the T cell of interest is selected to acceptable clonality, its αβTCR genes can be 
determined.  Then these genes must be placed into a suitable expression system, which is 
another major technically challenging, time consuming step.  Production in mammalian 
expression systems, are traditionally expensive and do not produce the quantities of 
protein necessary for biophysical and structural studies.  Expression in E. coli is generally 
easier and more cost effective, but soluble expression again usually does not produce 
gram quantities of protein.  Expressing proteins as inclusion bodies allows for gram 
quantities, but then in vitro folding conditions and subsequent purification steps still need 
to be worked out.  We, therefore, sought to design a system to rapidly go from mouse to 
recombinant TCR production for TCR-pMHC studies or clinical applications.   
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In order to make recombinant TCR we must first obtain the nucleotide sequence 
of the V, D (for β chain), and J gene segments, which encode the TCR α and β chains.  
Single cell reverse transcription polymerase chain reaction (RT-PCR) has been used 
previously to identify alpha and beta variable gene usage, as well as specific CDR loop 
sequences of TCR to analyze the repertoire present in specific diseases (Baker et al., 
2002; Wong et al., 2006; Wong et al., 2007).  Using single cell RT-PCR we developed a 
strategy to generate TCR variable gene segments that could be quickly subcloned into an 
E. coli expression vector. 
To obtain the large quantities of protein necessary for structural biology and many 
other biophysical analyses, many laboratories, including ours, employ in vitro folding of 
proteins produced as inclusion bodies in E. coli.  Inclusion bodies are aggregated, 
insoluble proteins commonly formed upon over-expression of recombinant proteins in E. 
coli.  Once isolated and purified these inclusion body proteins can be solublized and 
folded in vitro.  As every protein has a unique amino acid sequence and unique three 
dimensional surface characteristics, each protein may require a unique in vitro folding 
condition in order to “find” its native fold (reviewed in (Rudolph and Lilie, 1996). 
The methods presented here are the result of our goal to develop a streamlined 
protocol to isolate T cells specific for one particular pMHC, determine the DNA 
sequences of the TCR α and β chains from those T cells, and generate soluble TCR in 
vitro from those T cells to use for structural, biochemical, and biophysical study.  We 
used molecules on which we currently work as our models for assay development, 
specifically H-2Kb MHC and the AHIII12.2 TCR.  We describe a TCR production 
scheme involving single-cell sorting of T cells, amplification of the TCR variable 
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domains, recombinant expression of the TCR chains in E. coli, and a means of testing 
successful in vitro folding using a novel folding screen and a pMHC-tetramer based 
ELISA. 
 
4.3 MATERIALS AND METHODS 
4.3.1 Expression Optimization of H-2Kb and Tetramer Production 
 Peptide/MHC-tetramers are necessary to stain and sort pMHC specific T cells.  In 
order to sort H-2Kb (Kb) specific TCR in the future, it was essential that we had a stock of 
Kb MHC inclusion bodies ready for in vitro folding.  Initial expression of Kb heavy chain 
in BL21-RIL E. coli (Stratagene) was poor.  Analysis of the heavy chain nucleotide 
sequence revealed a number of codons that were not used in E. coli as well as possible 
high-energy hairpins in the resulting mRNA transcript.  We optimized the codon usage 
for E. coli expression, and rebuilt the gene using two oligos with overlapping sequence, 
which were spliced together using Klenow.  The forward Kb oligo has the sequence of  
5’-GAATTCAGGAGGAATTTAAAAATGGGTCCACACTCTCTGCGTTACTTCGTTACTGCTGTT-3’ and a 
reverse primer of 5’-AAGCAATGACGACAAAGAGCAGGCCCGGACCCACTCGGCGCAATGTAC 
CTTCAGCCGATG-3’ (Invitrogen).  This new segment consisting of the first 84 base-pairs of 
the gene was then spliced with the remaining portion of the Kb heavy chain using PCR.  
The final Kb heavy chain was then subcloned into the inducible pLM1 expression vector 
(Zhao et al., 1999).  To facilitate tetramer formation the Kb heavy chain contains a 3’ 
biotinylation sequence (GLNDIFEAQKIEWHE) recognized by BirA enzyme (Avidity, 
LLC).  Test expressions were performed and the best Kb heavy chain expressing clone 
was selected for scale-up.  Heavy chain and β2m were recombinantly expressed in E. coli 
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as inclusion bodies, purified, and folded in vitro as previously described in Chapter 2 
(Miller et al., 2007).  Peptides were provided by the University of North Carolina Peptide 
Synthesis Facility (Chapel Hill, NC).  Folded and purified Kb monomer was then 
biotinylated using BirA enzyme (Avidity, LLC) following the manufacturer’s protocol.  
Biotinylated pMHC can then be mixed with streptavidin conjugated with a variety of 
fluorophores or enzymes to create pMHC-tetramers for flow cytometry or ELISA.   
4.3.2 Isolation of T cells 
 Spleens and lymph nodes from mice were harvested and cells were kept separate 
thru sorting.  Ideally cells are sorted directly ex vivo.  In preparation for fluorescence-
activated cell sorted (FACS), splenocytes and lymphocytes were treated with Fc block 
(2.4G2 supernatant), stained using a cocktail of CD19-PE-Cy7, CD11b-PE-Cy7, CD11c-
PE-Cy7, NK1.1-PE-Cy7, CD4-PacOrange, and pMHC-tetramer-APC, followed by a PBS 
wash step.  Staining with this cocktail allowed for CD19+ (B cells), CD11b+, CD11c+ 
(Dendritic cells, macrophages, and other leukocytes), and NK1.1+ (NK cells) to be 
shuttled directly to waste.  CD4+ cells (helper T cells) were gated out as well.  Single T 
cells (pMHC-tetramer-positive, CD4-negative) were FACS sorted on a Dako MoFlo 
(Beckman Coulter) at the University of North Carolina Flow Cytometry Core Facility 
into 96 well PCR plates containing lysis buffer consisting of RT/PCR reaction mix 
(Invitrogen), PBS, nuclease-free water, 100 mM DTT, and RNAse OUT (Invitrogen).  
Plates were immediately covered with adhesive sealing foil (Research Products 
International) and stored at -80 °C. 
4.3.3 Single-cell PCR 
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TCR variable gene sequences were determined by methods previously described 
(Baker et al., 2002; Riddle et al., 2008; Wong et al., 2006; Wong et al., 2007) with the 
following changes.  To each of the 96 wells described above, a cocktail containing Cα 
and Cβ primers and Super Script II Reverse Transcriptase (Invitrogen) was added. All 
primers were purchased through Invitrogen.  The Reverse Transcription (RT) PCR 
reaction was carried out following the manufacturer’s protocol.  The resulting cDNA was 
divided into two new 96 well PCR plates for the external and nested PCR to obtain the 
sequence of the TCR α and β chain variable regions.  A panel of external and internal 
primers specific for all murine TCR α and β chain variable regions were used along with 
the Cα and Cβ primers and Taq polymerase.  Wells were inactivated with exonuclease I 
and shrimp alkaline phosphatase and then sequenced at the University of North Carolina 
Genome Analysis Facility (Chapel Hill, NC).   
Variable gene sequences obtained were then trimmed and aligned against a basic 
database of variable (V) genes, J segments, and constant domains for both α and β chain 
of the TCR using Sequencher 4.5 (Gene Codes Corp.).  These “cleaned” sequences were 
then analyzed using V-QUEST (Giudicelli et al., 2004) for complete V gene, D, and J 
segment identification.   
4.3.4 Cloning and Protein Expression 
Lymphocyte RNA was purchased from Sigma and cDNA was obtained using the 
Cα and Cβ internal primers.  This cDNA was used to obtain additional upstream variable 
region sequence not amplified by the primers described above.  Once the variable gene 
had been determined from sequencing, we designed a 5’ primer unique to the start of 
framework 1 of each TCR variable gene with a 5’ EcoRI restriction site added.  
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Additionally, the reverse-complement of the internal variable gene primers used above 
provided the 3’ primer necessary to acquire the remaining upstream sequence of each 
TCR variable gene.  The entire variable region was then spliced together and unique 
restriction sites were placed at the 5’ and 3’ ends.  In order to rapidly go from variable 
gene sequence and identification to expressed TCR α and β chains, TCR expression 
constructs were generated using the pLM1 expression vector.  The alpha and beta 
constant regions, which contained unique 5’ restriction sites, Sac II and SnaB I, 
respectively, were cloned into pLM1.  The 3’ end of the Cα and Cβ regions also encoded 
a streptavidin binding peptide (SBP) tag and a hexa-histidine (HIS) tag, respectively, to 
aid in TCR protein purification.  The TCR variable regions obtained from single-cell 
PCR could then be easily subcloned into the Cα or Cβ TCR-pLM1 constructs using 
EcoR I and Sac II or EcoR I and SnaB I, respectively.  The TCR alpha and beta chains 
were then expressed recombinantly in E. coli as inclusion bodies.  
As a means to test this expression system, the variable domains of the AHIII12.2 
(AHIII) TCR α and β chains were PCR amplified using primers that added the unique 
SacII and SnaBI sites, respectively.  These AHIII constructs in the pLM1 expression 
vector were then transformed into BL21-RIL cells (Stratagene).  AHIII TCR α and β 
chains were expressed as inclusion bodies in E. coli in a 5 liter fermenter vessel.  
Inclusion bodies were then cleaned and solublized in 8M Urea.  
4.3.5 TCR Folding Screen 
 A TCR folding screen was developed to determine the best in vitro folding 
conditions for any new TCR that we are able to isolate.  The folding “matrix” of 48 
different folding conditions is described in Table 1.  Using the AHIII TCR chains as our 
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model, a 1:1 (α:β) ratio of TCR chains were diluted into an injection buffer consisting of 
10 mM Tris, pH 8, 6M Guanidine HCl, and 0.2 mM DTT.  20 µL of this TCR mixture 
was distributed into the bottom of each well a 96 deep-well (2 mL/well) plate, resulting in 
50 µg of protein per well.   
 
To this, 1 mL of the folding buffer was added to the well and aspirated to mix the protein 
with the buffer.  The plate was incubated at 10 °C for 36 hours.  In order to rapidly 
dialyze all 96 wells, the wells were first diluted 1:2 with 10 mM Tris, pH 8.  Then 
1 2 3 4 5 6 7 8 9 10 11 12
Sucrose  -  -  +  +  -  -  +  +  -  -  +  +
PEG  -  -  -  +  +  +  -  -  -  +  +  +
Na:K  -  +  -  +  -  +  -  +  -  +  -  +
A/B GuHCl  -  -  -  -  -  -  +  +  +  +  +  +
Glutathione  -  -  -  +  +  +  -  -  -  +  +  +
CHAPS  -  -  -  -  -  -  -  -  -  -  -  - 
Arginine  -  -  -  -  -  -  +  +  +  +  +  +
pH  -  -  -  -  -  -  -  -  -  -  -  -
Sucrose  -  -  +  +  -  -  +  +  -  -  +  +
PEG  -  -  -  +  +  +  -  -  -  +  +  +
Na:K  -  +  -  +  -  +  -  +  -  +  -  +
C/D GuHCl  -  -  -  -  -  -  +  +  +  +  +  +
Glutathione  -  -  -  +  +  +  -  -  -  +  +  +
CHAPS  +  +  +  +  +  +  +  +  +  +  +  +
Arginine  -  -  -  -  -  -  +  +  +  +  +  +
pH  -  -  -  -  -  -  -  -  -  -  -  -
Sucrose  -  -  +  +  -  -  +  +  -  -  +  +
PEG  +  +  +  -  -  -  +  +  +  -  -  - 
Na:K  -  +  -  +  -  +  -  +  -  +  -  +
E/F GuHCl  +  +  +  +  +  +  +  -  -  -  -  -
Glutathione  -  -  -  +  +  +  -  -  -  +  +  +
CHAPS  -  -  -  -  -  -  -  -  -  -  -  - 
Arginine  -  -  -  -  -  -  +  +  +  +  +  +
pH  +  +  +  +  +  +  +  +  +  +  +  +
Sucrose  -  -  +  +  -  -  +  +  -  -  +  +
PEG  +  +  +  -  -  -  +  +  +  -  -  - 
Na:K  -  +  -  +  -  +  -  +  -  +  -  +
G/H GuHCl  +  +  +  +  +  +  -  -  -  -  -  -
Glutathione  -  -  -  +  +  +  -  -  -  +  +  +
CHAPS  +  +  +  +  +  +  +  +  +  +  +  +
Arginine  -  -  -  -  -  -  +  +  +  +  +  +
pH  +  +  +  +  +  +  +  +  +  +  +  +
Sucrose: (+) 0.4 M; (-) 0 M.  PEG: (+) 0.05% PEG 3350, (-) 0%.  Na:K: (+) 0.25 M 
NaCl, 0.01 M KCl; (-) 0 M NaCl, 0 M KCl.  GuHCl: (+) 0.5 M; (-) 0 M.  Glutathione: 
(+) 5 mM reduced, 0.5 mM oxidized; (-) 1 mM reduced, 0.1 mM oxidized.  CHAPS: (+) 
0.06%; (-) 0%.  Arginine: (+) 1 M; (-) 0.5 M.  pH: (+) 100 mM Tris, pH 8.6; (-) 100 
mM Tris, pH 8.2.  All conditions also contain 2mM EDTA and 0.01% sodium azide. 
Table 1.  TCR in vitro Folding Matrix 
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aliquots from all 96 wells were transferred to a 10 kDa cutoff 96 well filter plate (Pall 
Corporation).  Liquid was pulled through the plate using a vacuum plate manifold 
(Eppendorf).  A total volume of 600 µL from each folding condition was concentrated.  
The volume of each well was then brought up to 400 µL with 10 mM Tris, pH 8.  This 
dialysis step is necessary as the ELISA assay is inhibited by components in the folding 
buffers (data not shown). 
 To quickly determine if the condition resulted in correctly folded, active TCR, an 
ELISA using horseradish peroxidase conjugated pMHC-tetramer was employed.  Two 
dilutions, 1:2 and 1:50, of the samples from the filter plate were added to ELISA plates 
that had been previously incubated with anti-Cβ antibody, H57 (eBioscience).  The 
appropriate pMHC tetramer was then added, followed by ABTS single solution 
(Invitrogen), and colorimetric readout was quantified on a plate reader at 415 nm.  
Background was determined and subtracted using a pMHC tetramer formed with a non-
specific peptide. 
4.3.6 Folded TCR purification 
 Following identification of ideal TCR folding condition, folding was then scaled-
up to one liter.  TCR α and β chains were diluted into 20 mL of injection buffer described 
above, and rapidly diluted into one liter of folding buffer (as determined from the folding 
screen) for a total mass of approximately 50 mg of TCR.  Following an incubation period 
of 36 hours at 10 °C, the fold was then dialyzed against 10 liters of 100 mM Urea for 24 
hours, followed by another 24 hours of dialysis against 10 liters of 100 mM Urea and 10 
mM Tris, pH 8.  The dialyzed TCR fold was first batch purified and concentrated using 
DE52 ion exchange resin (Whatman).  The protein was eluted off the DE52 with 20 mL 
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of 2 M NaCL in 10 mM Tris, pH 8.  This was then further concentrated down to 2 mL 
using Amicon Ultra Centrifugal concentrators (Millipore).  This TCR concentrate was 
then purified using a Biosep SEC S3000 column (Phenomenex) on a Waters HPLC in 
250 µL injections.   
4.4 RESULTS 
4.4.1 Expression Optimization of H-2Kb  
 Both single cell FACS sorting and the ELISA in the TCR folding screen require 
pMHC-tetramer as a reagent.  Initial attempts to over-express Kb heavy chain as inclusion 
bodies were unsuccessful (Figure 1a).  We examined both the codon usage of our Kb gene 
and any possible RNA secondary structure as these often effect expression levels.  Codon 
usage of the Kb heavy chain was analyzed using the program “E. coli Codon Usage 
Analysis 2.0” (www.biology.ualberta.ca/pilgrim.hp/links/usage2.0c.html).  As shown in 
Figure 1b, eight of the first 25 codons were rarely used in E. coli.  Secondary RNA 
structure analysis using the GeneBee server (Brodsky L.I., 1992) predicted two high-
energy RNA hairpins early in the mRNA transcript, one of which started already at the 
third nucleotide (Figure 1c).  Based on these findings the first 28 codons of the Kb heavy 
chain were rebuilt with ideal E. coli expressing codons (Henaut, 1996), which also 
resulted in removing the high-energy RNA hairpins early in the transcript (Figures 1b and 
1c).  These changes in the gene resulted in abundant over-expression of the Kb heavy 
chain (Figure 1a).   Following inclusion body clean-up Kb heavy chain was folded in vitro 
with β2m and peptide.  HPLC purified Kb monomers were then biotinylated using the 
BirA enzyme (Avidity LLC).  
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4.4.2 T cell Isolation, RT-PCR, and TCR Sequencing 
 As proof of principle, single cell sorting of cytotoxic T cells from Lymphocytic 
Choriomeningitis Virus (LCMV) infected double konckout mice, CD8α-/- x MHC II-/- (II-
/8-) (Riddle et al., 2008), was performed.  Infection of mice with LCMV has been used 
extensively as a model system to study cytotoxic T cell response to viral infection.  
Before Codon Optimization After Codon Optimization 
b. 
c. 
a. 
Figure 1.  Codon optimization results in successful over-expression of H-2Kb heavy chain.  (a) 
IPTG induced test expressions of Kb heavy chain in pLM1 vector in BL21-Codon Plus cells run on 
SDS-PAGE gels show almost no expression of Kb with original murine codons.  After codon 
optimization, every colony picked over-expresses heavy chain.  (b) Codon analysis determines 8 of 
the first 25 codons in the original Kb gene are rarely used in E. coli, and are subsequently fixed.   
(c) A high energy RNA hairpin is predicted to start at the third nucleotide of the gene, and is gone 
following codon optimization. 
33 kDa 
33 kDa 
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LCMV infection in mice provides a number of dominant and subdominant epitopes 
presented in the context of murine class I MHC H-2Db (van der Most et al., 1998; van der 
Most et al., 1996).  RT-PCR reactions from individual T cells was performed, run on an 
agarose gel, and sequences were obtain for the TCR α and β chains (data not shown). 
4.4.3 Cloning and Expression of TCR 
In order to move quickly from sequence analysis of any TCR α and β chain to 
expression of protein, TCR expression constructs were created.  These TCR α or β 
specific pLM1 expression constructs already encoded the Cα and Cβ domains, as well as 
streptavidin binding peptide (SBP) and hexa-histidine (HIS) purification tags, 
respectively.  The variable domains of any TCR with the appropriate restriction sites can 
be quickly subcloned into these vectors and recombinant TCR chains can be expressed.  
The variable genes of the AHIII TCR were amplified and subcloned into these expression 
constructs, and AHIII TCR α and β chains were expressed as inclusion bodies in E. coli. 
 
 
 
 
 
 
 
 
 
 
Figure 2.  TCR expression vector.  TCR Cα and Cβ gene 
segments were cloned into pLM1 expression vector.  The 3’ 
regions of the Cα and Cβ domains contained unique restriction 
sites allowing for fast subcloning of TCR Vα and Vβ genes into 
plasmids. 
132 
4.4.4 TCR Folding Screen and ELISA 
 Solubilized inclusion bodies of TCR α and β chains then needed to be folded in 
vitro.  We developed a unique TCR folding screen to quickly identify each new TCR’s 
ideal folding conditions.  As each TCR has a unique amino acid sequence, it 
consequently has a unique surface chemistry, and prefers different conditions to fold 
optimally.  The screen matrix contains a random combination of reagents that have been 
used successfully to fold proteins in vitro (Armstrong et al., 1999; Chen and Gouaux, 
1997; Heiring and Muller, 2001), as well as reagents for specific considerations of TCR 
folding, i.e. reducing and oxidizing reagents for disulfide formation in the TCR Ig folds.  
Our TCR folding screen consists of 48 different conditions listed in Table 1.  48 
conditions allows for the sample TCR to be in the same condition twice on a 96 well 
plate, and be tested using the relevant pMHC tetramer and an irrelevant, negative control, 
pMHC tetramer.  
Proof-of-concept of the folding screen was tested using the AHIII TCR, which 
has been extensively characterized by our lab (Buslepp et al., 2003a; Buslepp et al., 
2003b; Buslepp et al., 2001; Miller et al., 2007; Zhao et al., 1999).  The plot in Figure 3a 
clearly shows that there are conditions in which the AHIII TCR folds well (E12 and G12) 
and others where it does not.  We then wanted to see if the conditions determined in the 
screen were any better than the existing in vitro folding conditions we had previously 
been using to fold AHIII TCR (Buslepp et al., 2003b; Miller et al., 2007).  We did a side- 
by-side one liter fold of the AHIII TCR using our original folding condition and the E12 
folding condition.  The E12 folding condition resulted in a cleaner fold (Figure 3b) and 
doubled our yield of natively folded, active AHIII TCR.   
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a. 
b. 
Figure 3.  Folding of AHIII TCR is improved as a result of folding screen.  (a) 
ELISA results from AHIII folding screen with p1049/A2 tetramer.  Non-specific 
MLL/A2 tetramer used as negative control.  Conditions E12 and G12 resulted in 
highest amount of functionally folded AHIII TCR.  (b) Chromatogram showing size-
exclusion purification of AHIII TCR following 1 liter in vitro fold.  58 kDa AHIII 
TCR comes out just before 10 minutes on SEC column.  Fold on the left was done 
with folding conditions traditionally used for AHIII TCR.  Fold on the right was done 
using E12 folding condition.  Total yield at the end of purification was doubled using 
E12 condition. 
Original 
Condition 
E12 
Condition 
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The functional activity of this AHIII TCR was confirmed using surface plasmon 
resonance (SPR).  All of the SPR experiments performed in Chapter 3 of this dissertation 
utilized AHIIII TCR generated using these new expression constructs and E12 folding 
conditions.  The TCR was clean, active, and bound its pMHC ligand. 
 
4.5 DISCUSSION 
 Further study of TCR recognition of pMHC, and the development of TCR 
mediated therapeutics in a realistic timeframe requires the rapid production of soluble 
TCR from T cells specific to a pMHC of interest.  We present here a means to quickly 
isolate single T cells directly ex vivo, amplify their TCR V genes, subclone those V genes 
into E. coli expression vectors, and rapidly identify the best TCR folding conditions.  We 
have already successfully used this screen to improve the folding yield of our AHIII 
TCR.  We are currently using this scheme to isolate and express TCRs from our double 
knockout mouse, CD8α-/- x MHC II-/- (Riddle et al., 2008). 
 Traditional clonal T cell isolation and identification is a long arduous processing 
taking weeks if not months.  Splenocytes or lymphocytes are removed from the mouse 
and must be cultured and in vitro stimulated using irradiated target cells.  The surviving T 
cells are plated out using limiting dilution in hopes to isolate a single clone per well.  
These are then again in vitro stimulated using irradiated target cells (Engelhard and 
Benjamin, 1982).  Most T cells are not happy and do not survive.  If they do survive and 
proliferate, then after weeks of culturing and hopeful clonal expansion, enough cells are 
present to verify lysis of specific pMHC targets using a cytolysis assay, and isolate RNA 
and perform RT-PCR to identify the αβTCR genes.   
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 Most of the T cell systems studied and the determined TCR-pMHC structures 
have originated from T cells that have been isolated in a traditional limiting dilution 
manner.  In addition to the time that it takes to finally characterize the TCR from these 
cells, we must ask ourselves an important question.  Are these immortalized T cells that 
survived weeks of abuse, truly good representatives of T cells as a whole?  Perhaps the 
affinities we have measured, kinetics we have determined, and TCR-pMHC docking 
orientations that we have seen are characteristic of these “super” T cells that were able to 
outlast all others in vitro, but not characteristic of most T cells.  A rapid method allowing 
isolation of T cells directly ex vivo, without weeks of culturing and in vitro stimulation, 
may permit the isolation and characterization of T cells with unique properties not yet 
seen.   
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CHAPTER 5 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
 
5.1 Introduction 
 
TCR discrimination between self and non-self pMHC is the critical event in 
determining whether or not the CTL will be activated and lyse the antigen presenting cell.  
T cell activation through the cognate pMHC generates an agonist T cell response, 
including clonal proliferation, cytokine production, and ultimately cytolysis.  Altered 
peptide ligands, generated through mutations of the peptide or MHC, can result in a range 
of T cell responses.  It remains unclear how the TCR recognition of these different 
pMHC surfaces translates into qualitatively different signals in the T cell.  The goal of 
my project was to dissect and investigate the interaction between TCR and pMHC to 
determine what mechanism(s) exists to differentiate between agonist, partial agonist, and 
antagonist ligands.  
The AHIII12.2 (AHIII) TCR recognizes and is activated by its cognate pMHC, 
p1049 in HLA-A2(A2), while activation is inhibited by the peptide p1058 when 
presented by A2.  Through mutation of residues in both the peptides and MHC, we 
present here further support for the affinity model of T cell triggering, that AHIII T cell 
activation correlates with TCR-pMHC binding affinity.  Interestingly, mutations in the 
peptide seem to be more deleterious to binding than mutations in the MHC.  Crystal 
structures of A2 mutants bound to the AHIII TCR were determined, and showed that the 
140 
K66A mutation in the MHC can influence the conformation of a TCR CDR3 loop, which 
is generally thought of as being restricted to peptide recognition.  Thermodynamic 
analysis of p1049/A2(K66A) binding confirmed that the loop movement results in a loss 
H-bonds.  Thermodynamic analysis of the AHIII TCR binding to wild-type p1049/A2 
determined that binding occurs through favorable enthalpy and favor entropy, which 
contradicts the favored thermodynamic TCR-pMHC binding model of an enthalpically 
driven and entropically apposed binding.  Finally, we present here a streamlined protocol 
to express and purify soluble TCR from singly isolated T cells directly ex vivo. 
5.2 Mutation in MHC Results in CDR3 Movement in TCR and Loss of Binding 
Enthalpy 
 
Based on the co-crystal structure of the AHIII TCR bound to p1049/A2 (Buslepp 
et al., 2003), we chose to mutate residues in A2 that either made contacts to the AHIII 
TCR or residues that had high sequence identity in HLA MHC allotypes.  The main goal 
of the project presented in Chapter 2 was to determine what is happening on the 
molecular level between the AHIII TCR and these mutated p1049/A2 molecules to better 
understand how TCR-pMHC molecular recognition occurs.  Using these MHC mutants 
we first measured the resulting T cell response in the form of cytolysis.  From the range 
of responses observed, three representative A2 mutants, T163A, W167A, and K66A, 
were selected for further study.  Binding constants and co-crystal structures of the AHIII 
TCR and the three mutants were determined.  K66 in wild-type p1049/A2 makes contacts 
with both peptide and TCR and had previously been identified as a critical residue for 
recognition in other TCRs (Baker et al., 2001; Baxter et al., 2004; Gagnon et al., 2005; 
Wang et al., 2002); however, the affect of K66A on a bound TCR has never been seen 
structurally.  The K66A mutation resulted in the lowest AHIII T cell response and the 
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lowest binding affinity.  These data along with the binding and activation data for the 
other A2 mutants, suggests that T cell response may correlate with affinity.  Importantly, 
the K66A mutation in A2 does not affect the conformation of the peptide.  The decrease 
in affinity for AHIII-p1049/A2(K66A) appears to be due to a loss in hydrogen bonds in 
the interface as a result of a conformational change in the TCR CDR3α loop.  The 
resolution to which the AHIII-p1049/A2(K66A) structure was determined was too low to 
confidently place residue side chains and H-bonds.  Therefore, isothermal titration 
calorimetry (ITC) was able to confirm the loss of hydrogen bonding by a measured loss 
in enthalpy (ΔH).  Our findings in Chapter 2 are inconsistent with the notion that the 
CDR1 and CDR2 loops of the TCR are responsible for MHC restriction, while the CDR3 
loops interact solely with the peptide.  Instead, we found a MHC mutation in the peptide 
binding cleft that does not change the conformation of the peptide, yet results in an 
altered conformation of a CDR3 loop.   
5.3 The AHIII TCR Binds Antagonist pMHC with Very Weak Affinity 
 
T cell activation is not binary, as a full range of T cell responses have been 
reported, which stem from the discriminatory ability of the TCR to recognize self from 
non-self pMHC ligands.  Variants of a fully activating peptide, or altered peptide ligands 
(APL), can produce this range of responses, including antagonism, whereby the T cell 
response is actually inhibited.  TCR engagement with antagonist pMHC complexes 
actually results in unique phosphorylation events with T cell activation signaling 
molecules inside the cell (Schwartz, 2003).  It remains unclear through which biophysical 
mechanism this altered signaling event occurs.  Previous work by our lab has suggested 
that the p1058 peptide, when presented by A2, acts as an antagonist peptide on the AHIII 
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T cell (Buslepp et al., 2001).  This p1058 peptide (FAPGFFPYL) differs from the agonist 
p1049 (ALWGFFPVL) peptide by only a few residues.  The goal of the project presented 
in Chapter 3 was to identify which TCR-pMHC binding parameter(s) is important for 
determining the difference between an agonist and antagonist pMHC.  A panel of over 20 
variants of p1049 and p1058 presented in A2 was used in surface plasmon resonance 
experiments to determine binding constants to the AHIII TCR.  The data presented here 
suggest that the antagonism of p1058 correlates with a very weak binding affinity and 
this weak binding is due to the inability of the AHIII TCR to bind p1058/A2 without 
undergoing a conformational change.  These data also suggest that mutations made on the 
surface of the MHC molecule are better tolerated by the TCR than mutations in the 
peptide.   
5.4 Improved Expression, Folding, and Purification of TCR 
There are an estimate 108 clonal T cells in the body, each with a unique TCR, but 
most of what we know about TCR-pMHC binding is based on the study of only two 
dozen T cell receptors (reviewed Chapter 1).  Traditionally the task of isolating a T cell 
specific for a particular pMHC target, identifying the DNA sequences of its αβTCR, and 
recombinantly expressing these TCR, has been incredible arduous and can take years.  To 
be able to answer fundamental questions about TCR-pMHC recognition that still exist, 
and identify and produce TCR that could be used as potential therapeutics, the rate of 
TCR identification and production needs to increase.  During my time here working on 
the projects presented in Chapter 2 and 3, I was able to develop methods to improve the 
TCR isolation, folding, and purification.  The work in Chapter 4 presents a TCR 
production scheme that can go from infection of mice to purified, soluble, recombinant 
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TCR in less than two months.  All of the AHIII TCR used for SPR studies in Chapter 3 
was generated following this new protocol.  This TCR production scheme is currently 
being employed on a project involving a double knockout mouse generated by our lab 
(Riddle et al., 2008) to isolate T cells and generate soluble TCR for biophysical and 
structural studies.  
5.5 Contributions to the Understanding of TCR-pMHC Molecular Recognition 
Although exceptions exist, the two-step binding model (Wu et al., 2002) is 
favored to depict TCR-pMHC molecular recognition.  As the name implies, this model 
describes the TCR-pMHC binding event in two discrete steps.  First, the CDR1 and 
CDR2 loops of the TCR make contact with the α helices of the MHC, followed by the 
CDR3 loops contacting the peptide after finding the right conformation.  The data 
presented in Chapter 2 is inconsistent with this model.  The K66A mutation in the α helix 
of the MHC induces a conformational change in the CDR3 loop of AHIII TCR.  This 
finding and data from other sources (Davis-Harrison et al., 2007; Kjer-Nielsen et al., 
2003) suggest that the pMHC should be thought of as one surface that the TCR 
recognizes using all of its CDR loops; peptide and MHC should not be thought of as two 
separate pieces.  
Between the work presented in Chapter 2 and 3, we have mutated a full spectrum 
of residues on the pMHC surface, which contact the TCR.  Combining this large data set, 
the data suggest something interesting regarding how the CDR loops are involved in 
AHIII-p1049/A2 molecular recognition.  Chapter 2 focused on mutations made in the 
TCR binding surface of the A2 MHC and their effect on the TCR.  While SPR data was 
presented for only three MHC mutants, data had been collected for an entire panel of A2 
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mutants.  The A2(K66A) mutant had the worst binding affinity to the AHIII TCR 
compared with any of the other A2 mutants.  We showed that the K66A mutation resulted 
in a conformational change in the CDR3α loop, eliminated a number of hydrogen bonds.  
Yet, the determined TCR-pMHC dissociation constant (Kd) was still approximately 30 
µM.  All of the mutations presented in Chapter 3 take place in the peptides presented by 
A2.  All the mutations to peptide residues between position 3 and position 7 result in 
binding affinities worse than that of the K66A mutation in A2.  Any amino acid 
substitution at P3 through P6 results in a Kd of greater than 100 µM.  This says that the 
contacts made between the AHIII TCR CDR3 loops and the p1049 peptide are more 
critical than the contacts made to the A2 MHC.  While the entire pMHC surface is 
recognized by the CDR loops of TCR, the discriminatory power of the TCR between 
agonist and antagonist comes from the interaction of CDR3 loops with the peptide. 
When we set out to analyze the energetics of AHIII-p1049/A2 binding using ITC, 
few thermodynamic experiments had been performed and it was generally accepted that 
TCR-pMHC binding was enthalpically driven and entropically unfavorable (Anikeeva et 
al., 2003; Boniface et al., 1999; Garcia et al., 2001; Krogsgaard et al., 2003; Lee et al., 
2004; Willcox et al., 1999).  These results were satisfying considering polar interactions 
should provide the specificity seen with TCR-pMHC recognition, compared to relying on 
van der Waals contacts.  In addition, entropically unfavorable binding seems to correlate 
well with the idea that flexible CDR loops are being constricted upon TCR-pMHC 
binding.  Our thermodynamic data presented in Chapter 2 show that this is enthalpically 
driven TCR-pMHC binding model is not generalizable to all TCR-pMHC.  The AHIII 
TCR binds to p1049/A2 with a small enthalpic contribution and is entropically favorable.  
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As we prepared our manuscript for publication, other groups began reporting similar data 
proving entropically favorable, and sometimes entropically driven, TCR-pMHC binding 
does occur (Colf et al., 2007; Davis-Harrison et al., 2005; Ely et al., 2006).  
Finally, the AHIII TCR and its recognition of p1049/A2 brings into question the 
concept that H-bonds and enthalpically driven binding drive high specificity interactions.  
As mentioned above our thermodynamic data and data of others have shown that TCR-
pMHC binding can be achieved with little or no enthalpic contribution.  Additionally, as 
seen by our SPR data in Chapter 3, the critical residues for AHIII-p1049/A2 binding 
recognition are positions 5 and position 6 in the p1049 peptide, which are hydrophobic 
phenylalanine residues at both positions.  Only 21 H-bonds occur in the AHIII-p1049/A2 
interface (Buslepp et al., 2003), and the recently determined structure of 2C-QL9/Ld 
(Colf et al., 2007) reveals an interface with less than 10 hydrogen bonds.  What does this 
say about specificity?  If there are no hydrogen bonds determining specificity, the only 
way the TCR can be sure to only recognize the foreign complex must be complementarity 
of fit.  Not surprisingly perhaps, AHIII-p1049/A2 (Buslepp et al., 2003) and 2C-QL9/Ld 
(Colf et al., 2007) have the greatest complementarity of fit of all TCR-pMHC structures 
determined to date.  Perhaps we should be more careful ruling out the importance of van 
der Waals contacts in conferring specificity. 
5.6 Future Experiments 
 
While I have completed a large body of work over the last five years, by no 
means is this dissertation an exhaustive analysis of TCR-pMHC interactions.  The Collins 
lab will continue to probe the AHIII T cell system and is in the process of expressing new 
TCR from other model systems to look at fundamental questions like whether conserved 
146 
TCR-pMHC contacts exist and why the TCR seems to dock all pMHC molecules in a 
canonical diagonal orientation. 
Specifically, the biophysical data presented in Chapter 3 will be combined with a 
full spectrum of biological assays on AHIII T cells including cytolysis, proliferation, and 
cytokine secretion, as a means to evaluate any correlation between TCR-pMHC 
recognition and T cell activation.  This will be the most comprehensive analysis of TCR-
pMHC binding and resultant T cell activation to date; over 20 different peptides 
evaluated using SPR and three separate aspects of T cell activation.  Based on previously 
published (Chapter 2) (Buslepp et al., 2001; Miller et al., 2007) and preliminary data, we 
expect to see CTL killing with p1049 and its variants to correlate with affinity.  The 
antagonistic ability of p1058 should also increase as affinity decreases.  As antagonistic 
peptides have been shown to have a differential cytokine profile of decreased IL-2 
production, but normal IFNγ secretion (Schwartz, 2003), we expect to see this profile for 
p1058.   Similarly, we expect no proliferation of AHIII T cells exposed to antagonist 
peptides.   
Also from Chapter 3, the enormous decrease in the off-rate measured for the 
p1049(V8A) mutant using SPR cannot be explained through analysis of the existing co-
crystal structure of AHIII-p1049/A2 (Buslepp et al., 2003).  We are already in the process 
of screening for crystal conditions in the hopes of determining the co-crystal structure of 
the AHIII TCR bound to p1049(V8A)/A2.  We feel confident this will be successful as 
other mutant structures presented in Chapter 2 were crystallized with AHIII, and the V8A 
mutation actually results in a higher affinity and long half-life, theoretically increasing 
the chances of the complex to crystallize. Aside from the crystal structure, isothermal 
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titration calorimetry (ITC) will be used to evaluate changes to the enthalpy and entropy of 
binding in AHIII-p1049(V8A)/A2.  Changes in ΔH and ΔS between the wild-type 
complex and the V8A mutant will provide energetic details about how the AHIII-
p1049(V8A)/A2 interaction achieves such tight binding and slow off-rate. 
Finally, the T cell isolation scheme and TCR folding screen will be utilized 
heavily in the future here in the Collins lab.  Our lab recently generated a double 
knockout mouse, without class II MHC and CD8 (Riddle et al., 2008), to determine the 
effect of not having the CD8 coreceptor present during thymic selection (reviewed in 
Chapter 1).  This mouse has functional cytotoxic T cells and attempts are underway using 
the isolation scheme and TCR folding screen to isolate TCR for biophysical and 
structural studies. 
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